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Abstract 
The discovery of phosphatidylinositol-phosphates (PIPn) within cell membranes, in the 
early 1950’s, ignited the interest in their biological roles, and soon after scientific 
evidence proposed their tight association with processes involving cell signaling, cell 
adhesion, polarization and migration, as well as membrane trafficking and oncogenesis. 
PRL-3, an oncogenic phosphatase, has been recently shown to adopt 
phosphatidylinositol (4,5) bisphosphate (PI(4,5)P2) as a natural substrate, through 
which it orchestrates several hallmarks of cancer, culminating in metastasis. Therefore, 
the PIPn-metabolizing enzyme PRL-3 became of great interest in biomedical research. 
To understand the binding mechanisms of PI(4,5)P2 with PRL-3, the development of 
synthetic approaches to synthesize analogues of this natural product is paramount. 
 
The goal of this work was to develop an approach to synthesize PI(4,5)P2 mimetics with 
alkylation(s) on the inositol ring. The newly established synthetic route was first tested 
with the chiral 6-O-methoxy PI(4,5)P2, after many arising synthetic challenges were 
overcome. The chemical literature is abundant with PI(4,5)P2 analogues bearing 
thiophosphate groups, different lipid tail composition, and novel functional groups, but 
none with direct changes to the hydroxyl groups on the inositol ring have been reported 
so far. Within the resulting collection of novel, inositol-modified analogues, some 
showed significant biological activity with PRL-3, compared to the lipid tail-modified 
analogues and the one containing the natural PI(4,5)P2 head group, which were also 
synthesized as part of this work. These active analogues were specific to PRL-3 as they 
did not show major activity with other PI(4,5)P2 –metabolizing enzymes.  
 
In parallel, in silico shape similarity screening methods were applied using PI(4,5)P2 as a 
template, to look for specific PRL-3-active small molecule inhibitors. This led to an 
active compound, which stresses the potential of prediction tools in finding inhibitors 
for challenging targets. 
 
Future applications of the synthesized PI(4,5)P2 analogues can be numerous: 
investigating the binding requirements of specific PIPn- metabolizing phosphatases,  
understanding the biology of specific PIPn, designing ligands through in silico and 
synthetic methods to modulate their interaction, and probing their usefulness in the 
treatment of diseases.  
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Zusammenfassung 
Die Entdeckung der Phosphatidylinositol-Phosphate (PIPn) in Zellmembranen in den 
frühen 50er Jahren entfachte das Interesse an ihren biologischen Rollen. Kurz darauf 
wurden ihre engen Verbindungen mit Prozessen, wie beispielsweise Signaltransduktion, 
Zelladhäsion, Polarisation und Migration, sowie Membrantransport und Onkogenese, 
belegt. PRL-3, eine onkogene Phosphatase, dephosphoryliert Phosphatidylinositol 
(4,5)bisphosphat (PI(4,5)P2), wodurch es mehrere Prozesse von Krebs orchestriert, die 
in Metastasen münden. Daher ist das PIPn-metabolisierende Enzym PRL-3 von großem 
Interesse in der biomedizinischen Forschung. Um die Bindungsmechanismen von 
PI(4,5)P2 mit PRL-3 zu verstehen, ist die Entwicklung von synthetischen Ansätzen zur 
Synthese von Analoga dieses Naturstoffes von größter Bedeutung. 
Das Ziel dieser Arbeit war, einen Ansatz zur Synthese von PI(4,5)P2-Mimetika mit 
Alkylierung(en) am Inositolring zu entwickeln. Der neu etablierte Syntheseweg wurde 
zuerst mit dem chiralen 6-O-Methoxy-PI(4,5)P2 getestet, nachdem viele der 
auftretenden synthetischen Herausforderungen überwunden waren. Die chemische 
Literatur ist reich an PI(4,5)P2-Analoga, die Thiophosphatgruppen, verschiedene 
Lipidschwanzzusammensetzungen und neue funktionelle Gruppen tragen, aber bisher 
wurden keine mit direkten Änderungen der Hydroxylgruppen am Inositolring 
hergestellt. Innerhalb der resultierenden Sammlung von neuen, am Inositolring 
modifizierten Analoga zeigten einige signifikant erhöhte biologische Aktivität mit PRL-3 
verglichen mit den lipidschwanzmodifizierten Analoga und demjenigen, das die 
natürliche PI(4,5)P2-Kopfgruppe enthielt. Diese wurden auch als Teil dieser Arbeit 
synthetisiert. Diese aktiven Analoga waren spezifisch für PRL-3, da sie keine oder wenig 
Aktivität mit anderen PI(4,5)P2-metabolisierenden Enzymen zeigten. 
Parallel dazu wurden in-silico-Struktur-Ähnlichkeits-Screening-Verfahren angewendet, 
wobei die Kopfgruppe von PI(4,5)P2 als Templat verwendet wurde, um nach 
spezifischen PRL-3-aktiven kleinen Molekülen als Inhibitoren zu suchen. Dies führte zu 
einer aktiven Verbindung. Dies untermauert das Potenzial von Vorhersagewerkzeugen 
bei der Suche nach Inhibitoren für anspruchsvolle Zielproteine. 
Zukünftig mögliche Anwendungen der synthetisierten PI(4,5)P2-Analoga sind vielfältig, 
wie beispielsweise zur Untersuchung von Bindungsanforderungen spezifischer PIPn-
metabolisierender Phosphatasen, zum Verständnis der Biologie spezifischer PIPn, zum 
Design von Liganden durch in silico und synthetische Methoden zur Modulation ihrer 
Wechselwirkungen, und zur Untersuchung ihrer Nützlichkeit bei der Behandlung von 
Krankheiten. 
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Chapter 1. Introduction 
 
1.1. Phosphorylation and dephosphorylation 
 
In Eukaryotes, one of the most common mechanisms by which gene product formation is 
tightly regulated is reversible phosphorylation. In fact, the reversible phosphorylation of 
proteins and other cellular molecules, such as the phosphatidylinositol phosphates 
(PIPn)1 allows cells to adapt to environmental changes.  
The abovementioned process is carried out by the coordinated action of protein kinases 
and protein phosphatases: kinases catalyze phosphate transfer from ATP molecules to 
functional groups of proteins (serine, threonine and tyrosine side chains) and non-
protein substrates to be modified, thus leading to conformational changes eventually 
activating a cellular response; while phosphatases revert these covalent modifications by 
hydrolyzing the respective phosphate moieties on protein and non-protein substrates 2–
4. Constituting 2-4% of the genes in a typical eukaryotic genome5,6, kinases and 
phosphatases equally stand as the architects of universal and crucial processes which are 
tightly regulated in cells in order to guarantee physiological balance, but are also 
implicated in numerous disease mechanisms upon their deregulation 7.  
1.1.1. Phosphatase families 
 
While strong advancement has been achieved, our understanding of phosphatases still 
lags behind that of kinases for many reasons8, including their high evolutionary diversity 
and complexity based on different ancestors (i.e., evolutionary unrelated) compared to 
the evolution of kinases based on a common ancestor 5,9,10. In fact, protein phosphatases 
evolved into mechanistically and structurally distinct superfamilies. There exists an 
extensive detailed perspective on these proteins in the literature9,11,12. 
 
Traditionally, these proteins have been grouped according to their substrate specificity 
and distinct catalytic mechanisms into the protein serine/threonine phosphatases 
(PSTPs) and the protein tyrosine phosphatases (PTPs). These broad and common classes 
were further classified into “superfamilies”7,13. However, newer structure-sequenced 
based classification methods differ from the traditional view. Phosphatases are now 
grouped into their evolutionary related families, and while many of the old relationships 
still exist, new ones have been identified12,14. Phosphatases within these families largely 
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have similar substrate specificity, however, this is not true for all members of all 
families12,14.  
 
The CC114/Family 19,12 superfamily, traditionally called the class 1 protein tyrosine 
phosphatase (PTP) family, is of special interest to this work. This superfamily is defined 
by its catalytic signature Cx5R, and well known for its diversity in domain structure and 
substrate preference. This family consists of non-transmembrane PTPs and receptor-like 
PTPs, which are both largely pTyr-specific, as well as the dual-specificity phosphatases 
(DSPs or DUSPs), which show diverse substrate specificity dephosphorylating not only 
pTyr containing proteins but also pSer/Thr, carbohydrates, mRNA, and, most importantly 
for this work, PIPn. Newer classifications also added some other PIPn-phosphatases to 
this family1,15. 
 
Despite their low abundance, PIPn control a multitude of central cellular processes, like 
signal transduction, intracellular membrane trafficking, cytoskeleton remodeling, nuclear 
events, control of cell growth and survival, and others (see chapter 1.3)16. Among the PTP 
superfamily, the phosphatases which dephosphorylate PIPn fall into four primary 
families: the Sac1 domain containing phosphatase, PTENs, myotubularins, and 4-
phosphatase15. In addition, one receptor-type tyrosine-protein phosphatase (PTPRQ)17 
and phosphatase of regenerating liver-3 (PRL-3)18,19, which is the major subject of this 
work, were shown to dephosphorylate PIPn.  
 
1.1.2. The phosphatases of the regenerating liver (PRLs) 
 
The phosphatases of the regenerating liver (PRLs) belong to the DUSP family of 
phosphatases (described above), and comprise three members: PRL-1, -2 and -3. This 
family is unique in many ways: first, the members do not share much sequence similarity 
with other phosphatases, but they share 76-87% similarity amongst each other. In fact, 
the closest related PTPs to the PRLs are the DUSPs Cdc14 and PTEN20,21. Second, the PRLs 
contain unique structural characteristics: they are the only ones amongst the PTPs to 
possess a CAAX box (where C is cysteine, A an aliphatic amino acid, and X any amino acid) 
at the C-terminus, which presents a prenylation motif that serves for localization to 
cellular membranes22. In addition, the PRLs contain a C-terminal polybasic stretch, which 
aids in membrane attachment through ionic interaction with negatively charged lipids23. 
Also, the PRLs show unusually shallow and hydrophobic active site characteristics, which 
makes them stand out from other phosphatases20.  
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Nevertheless, the PRLs are known to follow the general PTP mechanism, taking into 
account that it is equipped with the conserved CX5R motif of the active site p-loop, with 
the catalytic cysteine and arginine residue, and the invariant aspartic acid of the WPD-
loop as general acid/base24. These structural elements, conserved around the active site, 
are common to PTPs: presented as a thiolate anion, the very acidic catalytic cysteine acts 
as a strong nucleophile, which attacks the phosphate moiety of a substrate25. This 
represents the first step of the dephosphorylation reaction, and is assisted by the 
conserved aspartic acid in the neighboring loop, which donates a proton to the 
dephosphorylated substrate. Then, and as the second step of the catalysis, the aspartate 
residue, now acting as a base, helps with the hydrolysis of the covalent intermediate by a 
water molecule, releasing inorganic phosphate and the original state enzyme (Figure 
1)7,24. The conserved arginine in the P-loop is important for the stabilization of the 
phosphoryl-cysteine transition state26. The conserved WPD-loop aspartate in the PRLs 
however, as opposed to other PTPs, is not important as the general acid/base (mentioned 
above) in the dephosphorylation of phosphoinositides, demonstrating an alternative 
reaction mechanism27. 
 
 
 
Figure 1 Common catalytic mechanism of the PTPs. The figure is adapted from Tautz et al28. 
 
1.1.3. PRL-3: a phosphatase critical for cell deregulation 
 
In addition to being involved in cell growth, proliferation, and invasion29,30, the functional 
role of PRL-3 in disease implications, and particularly in cancer metastasis is by now well 
established. For instance, PRL‑3 is consistently highly expressed in metastatic colorectal 
tumors compared with non-metastatic tumors and the normal colorectal epithelia31. In 
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addition, consolidated work has denoted that PRL-3 could actually operate as a biomarker 
for poor prognosis in gastric cancer, ovarian cancer, breast cancer, and colon cancer32–34. 
It is not surprising that the DUSP PRL-3 would pose as a promising therapeutic target. 
Throughout various cancer cell lines in culture and in mouse models, PRL-3 was 
functionally characterized, either by overexpression or knockdown approaches which 
indicated that it promotes cell migration in vitro, and metastatic invasion in vivo20,35. PRL-
3 has been further associated with even more hallmarks of cancer such as tumor 
angiogenesis36, epithelial-to-mesenchymal transition (EMT)37, and metastatic events in 
various tumor environments34–36.  
 
It is important to note the cellular localization of PRL-3 as a context for the 
abovementioned functions and disease implications: due to its C-terminal prenylation 
motif and the preceding polybasic stretch, PRL-3 localizes to the plasma membrane and 
early endosomes38. Because of its farnesylation potential, PRL-3 was shown to further 
shuttle between the nucleus and the cytosol, sometimes localizing in the endoplasmic 
reticulum35. Farnesylation was therefore suggested to conceal the nuclear localization 
signal (NLS) of the polybasic stretch, retaining the proteins bound to membranes39. These 
findings proposed that PRL-3 play a role in the plasma membrane, early endosomes and 
at the Golgi40. 
 
Such observations ignite the interest of what substrates PRL-3 binds to, and what kind of 
effectors it is linked with. Interestingly, potential, direct substrates/modulators of PRL-3 
remain elusive today, despite the slowly growing literature of target identification: in fact, 
some potential targets for membrane-bound (active) PRL-3 have been suggested, after 
high-throughput phospho-proteomic or proteomic analyses, revealing chiefly proteins 
which either shape or control the cytoskeleton, such as ezrin41, stathmin42, keratin 843, 
cadherin CDH22, NHERF144, and most recently, integrin β122. Intriguingly, most of these 
binding partners seem mainly of nuclear localization and nuclear-related functions, with 
so far unidentified connection to PRL-3 mechanisms of action20. In addition to the 
abovementioned strategies for identification or PRL-3 targets, if one regards its structural 
information as another platform for investigation, PRL-3 has been shown to have very 
dynamic protein rearrangement, highlighted by an open/free conformation with active 
site components pointing at different directions, according to NMR studies45,46. This is also 
one of the representative reasons for which structures of PRL-3 with physiological ligands 
do not exist to date: because of the highly flexible nature of the phosphatase, a 
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physiological state has not been apprehended just yet, which poses many obstacles for 
studying this enzyme’s structure-activity relationship.  
Nevertheless, PRL-3 was assigned one specific enzymatic substrate: phosphatidylinositol 
4,5 bisphosphate (PI(4,5)P2)18,19.  
 
1.1.4. PI(4,5)P2, a special substrate for PRL-3 
 
The identification of signaling pathways involving PRL-3 is key to uncovering its roles in 
cancer progression. PRL-3, as opposed to PRL-1 and -2, dephosphorylates PI(4,5)P2 in 
vitro, making this substrate an individual one for PRL-3 among the PRL phosphatase 
family18,19. Our group showed recently that PRL-3 dephosphorylates PI(4,5)P2 in cells 
(unpublished), which is also an unpublished observation by another group19.This 
substrate could relate to the many phenotypes known for PRL-3. For instance, certain 
PIPs such as PI(3,4,5)P3 and PI(3,4)P2, and especially the depletion of PI(4,5)P2 have been 
designated as being involved in promoting cell motility, such a role being important in 
cancer47. Since it is a small molecule substrate, PI(4,5)P2 can act as a rational starting point 
for structure-activity relationship studies and inhibitor design.  
 
1.2. Modulating PRL-3 activity: a challenging search  
 
Small molecule modulators (activators or inhibitors) offer a way to detect cellular 
processes in which phosphatases are involved. This is a powerful complementary method 
to the genetic methods, because the usage of tool compounds focuses on acutely 
modulating enzymatic activity, which offers advantages such as handling simplicity, 
speed, and tunability. Particularly, small molecule inhibitors can eventually be used as 
lead compounds for drug discovery and are required for target validation48–50. 
Unfortunately, the small molecule PRL-inhibitors reported so far are either unselective 
relative to other phosphatases or among the PRL family, or they simply have been tested 
for only one of the PRLs and mostly exclusively in vitro51,52. One analog has been recently 
developed using in silico and biochemical screening assays53, but is still not selective 
among the PRLs, in addition to its only moderate potency. There is, therefore, an unmet 
need for a specific inhibitor for PRL-3, and taking its natural substrate (PI(4,5)P2) as a 
starting point is the most promising approach to fill this need due to it being a selective 
substrate within the PRL family.  
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1.2.1. Computational aid in the search of an inhibitor 
 
To further build the search for an adequate small molecule, which could help study the 
mechanisms in which PRL-3 are involved, computational screening methods, which 
increase the chances of finding good tool compounds, were also examined.  This had 
inspired the work of Hoeger et. al53, who have relied on a novel computational method for 
molecular shape comparison, to screen for molecules which were similar in shape to a 
known, but unselective, PRL-3 inhibitor thienopyridone52. This technique, termed 
Ultrafast Shape Recognition (USR)54, consists of probing online molecular databases for 
compounds that most closely resemble the shape of a given query (template) molecule. 
In this respect, it is an elegant alternative to other computational methods like docking, 
whereby the screened molecule, aligned to a macromolecular biological target (e.g., a 
protein), is simulated to provide an estimate of binding energy, thus the likelihood of 
being bioactive55. Docking has worked with a series of proteins with known crystal 
structure, but this was not the case for PRL-3, which crystal structure still needs to be 
better understood, despite the recent work on crystallizing it with binding partners56. In 
the Hoeger et. al53 study, the query molecule was thienopyridone, the most potent cell-
active inhibitor identified to date, with a reported IC50 of 173 nM for PRL-1, 277nM for 
PRL-2 and 128 nM for PRL-3. Thus, biochemical screening of hits generated by the in silico 
screen afforded a micromolar inhibitor that could be further optimized by a basic SAR 
study53. 
 
1.2.2. Virtual screening tools using natural substrates 
 
In such computational methods, nevertheless, the abovementioned chemical 
template/query does not only have to be an inhibitor of a target protein, but could also be 
a known ligand, such as a natural substrate, or a patented compound57. This means that 
one could theoretically use the information provided by biochemical studies for the 
validation of a natural substrate in studying a target protein. Here, for instance, the 
valuable information of selective dephosphorylation of PI(4,5)P2 by PRL-3 (amongst the 
PRL family), sets this phosphoinositide as an interesting starting point for computational 
prediction means, in order to learn more on binding mechanisms.  
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1.3. PIPn: substantial molecules in cell signaling  
 
Phosphatidylinositol-phosphates (PIPn) belong to the large group of phosphorylated 
inositol compounds, amongst the two other members comprising the inositol 
polyphosphates (InsPs) and the diphosphoinositol polyphosphates (PP-InsPs). These 
compounds represent critical biomolecules, which order a hefty directory of important 
biological processes. Being an extremely diverse family of biosynthetically distinct 
signaling molecules, these compounds exist, at all times, with numerous combinations of 
phosphorylation patterns, resulting in an intricate network of correlative signaling blocks 
that regulate different cellular events58.  The inositol family comprises nine possible 
1,2,3,4,5,6-cyclohexanehexol isomers, these being the myo-, cis-, epi-, allo-, muco-, neo-, L-
chiro, D-chiro, and scyllo-inositols. While these regioisomers are proven to exist in some 
natural systems59, the most prominent family member is myo-inositol, as it represents the 
main unit for the abovementioned abundant biologically active molecules. myo-inositol is 
a meso-cylohexane hexol (achiral) with five hydroxyl groups in the equatorial position 
and one in the axial. The carbon with the lone axial hydroxyl group is labelled with C2 (all 
the other hydroxyl groups being in equatorial positions, Figure 2). The recognized 
convention is to label the anti-clockwise counting with the prefix “D”, which is currently 
being used for all biologically relevant compounds.  
 
The PIPn are molecules with a lipophilic tail and a polar head group in form of an inositol 
ring that can be phosphorylated in the 3, 4 or 5 position (Figure 2).  
The lipid tail consists of a glycerol backbone with two acyl carbon chains that are linked 
via a phosphodiester to C-1 of the inositol ring. Most common in animals is the 
arachidonic acid in sn-2- and stearic acid in sn-1-position on the glycerol backbone. The 
myo-inositol motif acts as the core scaffold for the head group of these 
glycerophospholipids. The PIPn family comprises seven isomers that are phosphorylated 
at different positions.  
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Figure 2 Phosphatidylinositol (PI) with 1-stearyl-2-arachidonoyl-glycerol-backbone. Example of a cellular-
membrane PIPn: the structure of the phosphatidylinositol composition contains a polar head group and a 
lipophilic tail. 
As can be seen in Figure 3, these family members contain every combination of  
phosphate groups at the 3-, 4- and 5- positions on the head group: therefore, each member 
can contain three (PI(3,4,5)P3), two (PI(4,5)P2, PI(3,4)P2 and PI(3,5)P2), or one (PI(3)P, 
PI(4)P, or PI(5)P) phosphate group(s) on the head group, in addition to the common 
phosphodiester.  
 
 
 
Figure 3 Structures of phosphatidylinositol (PI) and the seven phosphatidylinositol polyphosphates (PIPn) as 
found in nature. 
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What differentiates PIPn from the rest of the group of phosphorylated inositol molecules 
is that these phospholipids are anchored in cellular membranes, displaying the inositol 
head group on the (inner) membrane surface. This is key to understanding the 
localization requirements and implications of PIPn–proteins interactions, which convey 
various processes in cell signalling. In fact, specific PIPn, at specific locations, recruit 
different cytosolic proteins, which are, in turn, tangled in various structural functions 
and/or signal transduction.  
 
Moreover, in addition to the specific recognition of these lipids by various protein 
domains, the sophistication of their signalling system also relies on the well-established 
participation of approximately a hundred isoforms of kinases and phosphatases in their 
concerted production and inactivation. These protein-lipid binding events, which are 
often reversible associations, result in regulating crucial processes in cell signalling, by 
affecting both protein function and subcellular localization60. They can in fact control 
protein function either by promoting direct modification of the protein itself upon 
binding, or by ushering the interaction of this now membrane-bound protein with other 
binding partners, also localized at the cellular membrane surface60. Adding to that the 
abovementioned structure-function diversity of PIPn, these molecules can direct proteins 
to distinct locations within the cell, depending on where the target lipid is present61. A key 
example for this thesis is the localization of PRL-3 to the plasma membrane, where its 
target lipid/substrate is PI(4,5)P2 (see section 1.1.3.). 
 
1.3.1. Biological significance of PIPn  
 
It is not surprising, therefore, that PIPn would be involved in intracellular signalling 
mechanisms which are known to play a vital role in essential cellular functions such as 
vesicle trafficking, apoptosis, cell proliferation and metabolism62–64. Thus, defects in 
binding and lipid compositions result in onset of serious regulatory diseases like chronic 
inflammation, autoimmunity, allergy, cancer, atherosclerosis, hypertension, heart 
hypertrophy, metabolic and degenerative diseases, among others65–68. The amount of PI 
in membranes is 4 % and the other phosphorylated PIPn amount all together to 
approximately 1%69. 
To appreciate the crucial role of PIPn in cellular homeostasis, one needs to recognise that 
signalling activities often arise through the activation of protein function upon binding to 
the cellular membrane: once the attached effector protein is activated, it can then detach 
(reversible associations, see above) and transduce that harnessed material throughout 
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the entire cell by traversing to diverse sites in solubilized form. This underlines the 
serious nature of lipid conversion balance, which needs to be tightly regulated to avoid 
abnormal interactions, quantities of lipid substrates, and spatial-temporal availability. 
This equilibrium takes place via the rigorous actions of kinases and phosphatases, a 
considerable amount of which genes could be mutated in various cancers58. An abridged 
scheme is shown in Figure 4. These enzymes, by continuously producing a vast directory 
of soluble inositol polyphosphates and membrane polyphosphoinositide lipids, represent 
key players in signalling cascades. For example, phosphoinositide 3-kinase (PI3K), 
regulated by cell-surface receptors, leads to the formation of PI(3,4,5)P3, in turn a 
signalling lipid which modulates cell growth, proliferation and motility70. Most notably, 
PIPn are involved in inflammation, cancer and metabolic syndromes, as part of the lipid 
signalling dysregulation context71.  
 
The metabolism in which the PIPn are implicated is therefore quite complex and broad, 
whereby the continuous synthesis and interconversion of phosphorylated myo-inositol 
species takes place in the context of a myriad kinase and phosphatase enzyme linkage. 
The metabolic pathways in which the PIPn are associated have been the subject of 
extensive reviews, and the reader is referred to some of those for detailed mechanisms72–
75.  
 
The capacity of the PIPn-protein interactome can therefore unravel as very complex and 
broad, the molecular detail of which relies on binding modules with conserved sequences, 
which target specific PIPn isomers. This association network has been the focus of many 
reviews in the last two decades60,69,76–81. Many of these binding domains have been 
recognized, and examples include the pleckstrin homology (PH), phox homology (PX), 
Fab1, YOTB, Vac1 and EEA1 (FYVE), epsin N-terminal homology (ENTH), AP180 N-
terminal homology (ANTH), band 4.1 ezrin radixin moiesin homology (FERM), Tubby, and 
b-propellers that bind phosphoinositides (PROP- PIN) domains58.  
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Figure 4 Metabolism and biosynthesis of PIPn. Phosphatases are in blue, kinases in red. The question mark 
stands for unknown enzymes. DAG, diacylglycerin and Ins(1,4,5)P3, Inositol(1,4,5)-triphosphate are second 
messengers; INPP5E, inositol polyphosphate 5-phosphatase; MTM, myotubularin; OCRL, Inositol 
polyphosphate 5-phosphatase; PIKfyve, phosphoinositide kinase containing fyve Zn-finger motive; PTEN, 
phosphatase and tensin homolog deleted on chromosome 10; PIS, phosphatidylinositol synthase; PIC, 
phospholipase C; Sac ,suppressor of actin domain containing phosphatase, SYNJ, Synaptojanin; SHIP, SH2 
domain containing inositol phosphatase. 
Such domains could be present in several different proteins, and PH domains are a typical 
example for that: in fact, sequence homology searches have connected more than 250 PH 
domain-containing proteins in humans69. But not all PH domains interact productively 
with PIPn. This is one proof that binding modules actually vary amongst proteins, even 
those carrying the same module(s). These variations take ground in three important 
nuances: specificity, structural requirements, and binding localization60. This also 
explains why some proteins bind with high affinity towards a particular phospholipid 
(FYVE domains generally target PI(3)P for instance), while others appear to be more 
promiscuous (PH domains were shown to target different PIPn isomers69).  
 
In addition, binding modules amongst this network are not universal: binding can be 
principally driven by electrostatic attraction to the myo-inositol head group, with no 
requirement of the membrane milieu (such as PH domain of PLCδ to PI(4,5)P282), but for 
other domains/proteins (such as FYVE8583 and PX8684 domains), the membrane context 
is essential for binding to occur. This subtle difference is important, as it can be the 
consequence of a contact between the hydrophobic sequence of a certain protein and the 
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hydrophobic membrane core, thereby delivering a major input to the driving force for 
association. PRL-3 is a prominent and relevant example for this, as it requires the lipids 
to actually bind PI(4,5)P2 itself19 (which can bind PLCδ without the presence of a lipid 
bilayer), further illuminating the intricacy that should be interpreted to better apprehend 
binding at the molecular level.  
 
PI(4,5)P2 is actually a known substrate for the different phosphoinositide-specific 
phospholipase C (PLC) enzymes, thereby being the precursor of Ins(1,4,5)P3 and DAG 
(diacylglycerol)59. It is also the substrate of the type I PI 3-kinases which produces 
PI(3,4,5)P3. The significance of this lies in the fact that protein kinase C (PKC) docks, 
through its C1 PI effector proteins Ras-GRPs domain, onto DAG, while Ins(1,4,5)P3 
stimulates the release of Ca2+ ions from the endoplasmic reticulum (ER). The plasma-
membrane-localized PI(4,5)P2 represents a principal player in Ca2+ phosphoinositide-
dependent signalling, by serving as the substrate for two potent receptor-regulated 
signal-generating enzymes66. Although its overall level does not considerably rise in 
stimulated cells, confined increases in PI(4,5)P2 concentrations are likely to occur and 
recently, more and more supporting information suggests that this PIP even acts as a 
signaling molecule on its own: it can, for instance, influence actin cytoskeleton 
organization through interactions with actin-binding proteins85.  
 
The above-mentioned tightly controlled and dynamic network of phosphoinositide 
signalling is a reason for the metabolic instability and relatively low concentrations of 
PIPs, which pose as factors contributing to the incapacity to isolate useful amounts of 
these compounds in pure form for biological studies. For this reason, amongst many 
others, the chemical synthesis of PIPs and derivatives started as early as almost five 
decades ago, and remains, today, an attractive endeavour. 
 
1.3.2. Chemical approaches to synthesize PIPn and analogues  
 
After the continuous discovery of the essential biological roles of InsPs, PP-InsPs and PIPn 
in cell signaling, developing synthetic approaches to study them rose. In fact, the inability 
to isolate practically useful amounts of PIPn compounds from cells has led to a need of 
efficient syntheses, and the literature is wide-ranging and large since 197086. First 
syntheses of myo-inositol 1,4,5-trisphosphate were reported in 1986 by Ozaki et. al87 and 
these have been trailed by noteworthy synthetic progress to the extent that all of the 
problems inherent to inositol phosphate synthesis have now been principally overcome88.  
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These problems are preeminent for the area of phospholipid synthesis, and can be 
summarized in three main synthetic facets: first, the synthesis of a suitable selectively 
protected inositol derivative, which would expose free hydroxyl groups at desired 
positions; second, a phosphorylation in an proficient manner, with a reagent carrying a 
suitable phosphate-protecting groups (this has been, for instance a major challenge for 
compounds with vicinal diols, where cyclic phosphate formation was a chief undesired 
side reaction89); and third, deprotection while avoiding migration of phosphate 
substituents to adjacent free hydroxyl functions.  An additional necessity arose amongst 
this stage: the resolution of appropriate synthetic intermediates, allowing the preparation 
of optically pure inositol phosphates. This was unraveled by the use of chiral starting 
materials90. Consequently, establishing routes with selective protecting groups91, 
different phosphorylation strategies92–96 (Figure 5) and optical resolution of the 
enantiomers87,97,98 with reagents such as (S)-(+)-O-acetyl-mandelic acid, (R)-(+)-1-
phenyl-ethyl isocyanate, (R)-(+)-camphor dimethyl acetal, or L-menthyl chloroformate 
was completed.  
 
 
 
Figure 5 Phosphorylating and phosphitylating agents. A) Mono-functional PV and PIII reagents that were used 
for phosphorylation of vicinal diols. B) Bi-functional PIII reagents used for the phosphodiester link to attach 
the diacylglycerol backbones in PIPn. 
 
Nevertheless, the complex nature of inositol phosphate metabolism is providing ever-
growing new targets for synthesis: this interest further gave rise to the synthesis of 
modified inositol phosphates with novel biological properties. The synthesis of unnatural 
InsPs and PIPn analogues for structure-activity studies of proteins58,99,100 as affinity 
probes for pulldown of effectors and metabolic studies has then become a major 
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discipline: a prodigious amount of reviews up to 2010 have covered the preparation of 
biologically important myo-inositol derivatives58,101–109. These include myo-inositol 
1,4,5,6-tetrakisphosphate, myo-inositol pentakisphosphate and hexakisphosphate 
derivatives, diphosphoinositol phosphate derivatives, D-1,5- and D-3,5-
diphosphoinositol 1,2,4,6-tetrakisphosphate InsP8, diphosphoinositol analogues, 
replacement of the 5-Phosphate of Ins(1,4,5)P3 with bioisosteres, inositol phosphate 
ligands that uncovered the capture site of PPIP5K2, photoactivated myo-inositol lipid 
derivatives, solid phase synthesis of myo-inositol DiC8-phospholipids, 
plasmanylinositols, and biphenyl phosphate derivatives (examples of each mentioned 
derivative are shown in Figure 6).  
 
All of this demands the mastering of all three synthesis aspects mentioned above, 
particularly the synthesis of protected inositol derivatives, which require careful 
selection of a starting material (the inositol head group). The synthesis of PIPs starts by 
the synthesis of protected inositol derivatives. These can use the following as starting 
materials: myo-inositol, chiral starting materials such as naturally occurring inositol-like 
molecules (Galactinol, L-Quebrachitol, D-Pinitol or (-)-Quinninc acid), or other starting 
materials such as benzene-derivatives like meso-diol89. 
 
Due to the ready commercial availability of pure myo-inositol however, most syntheses 
have used the parent cyclitol as a starting material. In fact, the symmetry which comes 
with this material makes it easy to design numerous synthetic route from one starting 
material89. One of the most common and classic methods of manipulation of this starting 
material is shown in Scheme 1 (A): the reaction of this starting material with 
cyclohexanone or more efficiently with a cyclohexanone precursor such as l-
ethoxycyclohexene, in the presence of an acid catalyst gives a mixture of three bisacetals 
which may be separated by crystallization and chromatography. Each of these bisacetals 
gives the monoacetal on mild hydrolysis of the less stable transacetal. Due to the 
conformational constraints imposed on the inositol ring by the bisacetal groups, each of 
the free hydroxyl groups and may be selectively manipulated under suitable conditions, 
providing access to a series of inositol derivatives having five hydroxyl groups 
differentially protected. Another classic manipulation uses orthoformate as a strategy 
(Scheme 1, B). In this strategy, the orthoformate offers a derivative in which positions 1, 
3, and 5 can be simultaneously protected. The normal axial/equatorial relationship of the 
remaining free hydroxyl groups is reversed. The spatial juxtaposition of the axial hydroxyl 
groups allows highly selective alkylations to be performed at these positions110.  
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Figure 6 Examples of biologically important myo-inositol derivatives. Adapted from Potter et. al (2016)111. 
The categories of the derivatives are written in blue, the example molecule in black. 
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Scheme 1 A) Reaction of cyclohexanone precursors with myo-inositol to form three isomeric bisacetals, which 
can be selectively cleaved to yield a monoacetal. B) Orthoformate, on which the 1, 3, and 5 OH groups are 
protected simultaneously. 
 
More details on the general synthetic considerations and synthetic strategies for the 
design of such compounds can be found in the extensive literature compiled by both the 
Billington and Potter groups88,89,112. In general, reviews of the chemical synthesis of 
phosphoinositides emphasize methods to be able to control regioselectivity and to obtain 
chiral intermediates, predominantly by the separation of diastereoisomeric derivatives 
with chiral auxiliaries, or by starting from the chiral group.  
 
Of interest to this thesis work, the synthesis of PIPn analogues bears other challenging 
issues: not only the choice of selective protective groups, but also the corresponding 
conditions required for their global deprotection. In addition, final purification of such 
targets is achieved on the fully protected lipid precursor since it is very hard to fractionate 
the deprotected lipid from any related contaminants. Therefore, it is important that the 
global deprotection causes no degradation of the final lipid, and that protective group and 
reagent debris are easily separated from the product. These are the kind of challenges 
confronted and overcome when designing analogues of PI(4,5)P2. Moreover, and during 
successive hydroxyl groups deprotection and/or any additional purification, excesses of 
acidity/basicity which could initiate acid- or base-catalyzed migration and/or hydrolysis 
should also be circumvented, and some decompositions during such handlings were 
actually reported; for instance, the de-acylation of the glyceride moiety113. 
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Figure 7 IPn and PIPn analogues. A) Thiophosphonate analogues; B) Membrane permeable PIPn. C) and D) 
PIPn with phosphonate groups; E) Deoxygenated I(1,4,5)P3 in 3-position; F) PI(3,4,5)P3 functionalized onto 
an affinity matrix. 
Alterations of both the inositol-phosphate head group and the lipid tail were undertaken 
by groups like Potter et al.102 van Boom and coworkers96, Bruzik et al91,114 and Prestwich 
and his group115. Their work contributed to the successful design of metabolically stable 
thiophosphates, phosphonates, deoxygenated inositols116 and their PIPn with varied 
length of the individual acyl chains in the lipid tail (Figure 7). Such analogues find their 
use in many applications. For example, for intracellular applications, the need for 
membrane-permeable molecules arose. Due to the high polarity of the inositol head 
group, concealing agents like propionyloxymethyl and acetyloxymethyl were proposed 
with success by Schultz et al.117 and Tsien and coworkers118 to make the molecules 
membrane-permeable (Figure 7B). Another application example is affinity matrices, 
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whereby PIPn would be attached to a solid support in order to identify selective and 
competitive binding proteins.  
 
Though many diverse analogues were advanced so far, there is still a missing number of 
analogues in the rather modest existing phosphatidylinositol-phosphate library119. There 
are a number of PIPn, with some alterations to the composition and the length (and the 
nature/structure) of the lipid tails as well as to the phosphate groups, but none so far that 
have direct alterations at the inositol ring, at least not PI(4,5)P2. Evolving these tools for 
biological elucidation of protein structures and mechanisms is a constant effort in 
progress. In fact, and so far, only a few structure activity relationship (SAR) studies were 
done with PIPn analogues, to meet the needs for the development of PIPn analogue-based 
inhibitors. This is because chemical modifications of the inositol head group can be very 
challenging and arduous, due to multiple synthetic steps that often require tough 
purifications. Here, to conduct investigations if molecules based on by PI(4,5)P2 could be 
used for the development of a selective PRL-3-inhibitor, it was sought to devise a practical 
synthetic route to derivatives of this phosphoinositide.  
 
In the light of what has been said, it is evident that both current and future works of 
bioorganic, medicinal, and eventually computational chemists would support efforts 
directed towards the molecular understanding of, and the pharmacological intervention 
in, the phosphoinositide signalling system.  
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Chapter 2. Aim of this work 
 
The general aim of this thesis work was to conduct structure-activity relationship studies 
with PIP-metabolizing proteins, by synthesizing a PIPn analogues library. This would help 
to understand PIP-binding requirements for specific proteins. Specifically, this was 
completed by synthesizing a library of phosphatidylinositol-4, 5-bisphosphates PI(4,5)P2 
analogues (Figure 8), and characterizing their biological activity with PRL-3. Considering 
the structure of PI(4,5)P2, there are three possible areas of the molecule which could be 
modified for this purpose: I) the lipid tail, II) the inositol ring and III) the phosphates. In 
this thesis, the focus was put on the modification of the inositol ring by blocking the free 
hydroxyl-groups 2, 3 and 6 with alkyl groups, as this has not been done before, and on the 
modification of the lipid tails to understand the requirements regarding the nature of the 
alkyl chains for binding. Inventing and developing the synthetic route for one of the 
analogues, the 6-O-methoxy PI(4,5)P2, and then expanding that route toward synthesis of 
a whole library of molecules was envisioned as the synthetic strategy.  
 
After the successful synthesis of analogues their biological activity was aimed to be tested 
not only against PRL-3, but also against three other known PI(4,5)P2-metabolizing 
phosphatases, to answer if selectivity targeting these enzymes can be achieved using the 
common substrate as a basis for ligand development.  
 
 
 
Figure 8 PI(4,5)P2 from a medicinal chemistry viewpoint: the different sites of chemical modification are the 
lipid chains (red), the inositol ring (blue), and the phosphate groups (green). 
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Chapter 3. Results and Discussion 
 
3.1. Total Organic Synthesis of PI(4,5)P2 analogues 
3.1.1. First Considerations for the Synthetic Approach 
 
Considering the structure of the target molecule, a convergent synthetic strategy was 
deemed the most functional approach. In fact, it was first thought to follow the solid phase 
synthesis procedure of PIPn synthesis, established by the Koehn group in 2012120. In this 
strategy, PIPn analogues and derivatives would be synthesized in a combinatorial fashion, 
building on only four inositol building blocks to synthesize the seven phosphorylation 
patterns, which was made possible by a novel selective benzylidene acetal ring opening 
on a solid support120 (Figure 9).  
For that, a suggested solid phase synthesis for the preparation of methylated PI(4,5)P2 
molecules, shown in Figure 10, was considered. Although this strategy sets a basis for the 
modification of the inositol head group in a conjunctional mode, it was unsuccessful (not 
described here in detail), mainly for two reasons: 1) the lability of the compounds, which 
makes it hard to use stringent alkylating conditions on the ring after the 
phosphatidylinositol has been fully synthesized, and 2) the steric hindrance of the inositol 
ring in the fully synthesized PIP, making it even harder to alkylate effectively at desired 
positions. After unsuccessful previous trials (including different methylation strategies 
such as the usage of methyl iodide, dimethyl sulfate, sodium hydride, silver oxide, and 
trimethylsilyldiazomethane), it was deemed better to apply the modifications of the 
inositol ring on a precursor molecule before putting it up on solid phase and to then 
resume the phosphoinositide synthesis. This would be a better route, but only for one 
alkylated PIP, which is the one alkylated on the 6-OH group, as the remaining 2 OH groups 
(positions 2 and 3) would be sequestered by the benzylidene acetal protecting group and 
solid phase support linker, throughout the whole synthesis of the PIP (Figure 9). This 
would make alkylation at positions 2 and 3 of the inositol ring impossible until the end of 
the synthesis (i.e., cleavage of the benzylidene linker), which means it would have to be 
alkylated after the full labile and sterically hindered PIP had been synthesized. Therefore, 
it was thought that synthesizing the whole PI(4,5)P2 modified analogues in solution 
would be the most equitable approach for this work.  
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Figure 9 Outline of the solid phase strategy for soluble PIPn analogues and derivatives. NB: Adapted from 
Koehn et al. (2012)120. The encircled analogue is the analogue of interest for this work. 
 
 
Figure 10 Outline of the solid phase strategy for the preparation of PI(4,5)P2 analogues. Adapted from the 
Koehn research group [unpublished data]. 
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3.1.2. Solution synthesis of the alkylated inositol ring precursors  
Fortunately, the protective group strategy used the abovementioned solid phase 
synthesis strategy was a compatible and sound method to apply in solution phase 
synthesis of those PIPs. Nevertheless, each step in the total solution synthesis of these 
molecules required optimization and careful monitoring to aim for the best results and 
yields.  
Three synthetic routes were designed for the monoalkylated, dialkylated and trialkylated 
analogues, respectively, for each of the methylated and the ethylated PI(4,5)P2 (Schemes 
2-5). In total, 6 target molecules (as alkylated precursors) were originally planned to be 
synthesized. The overall schemes of the differently alkylated final PI(4,5)P2 analogues are 
shown below, followed by a comprehensive discussion on the total synthesis steps.    
a. Synthesis plan for monoalkylated inositol precursors 
Two monomethylated analogues, the 6-O-methylated and the 6-O-ethylated, were 
planned to be synthesized using the racemic starting material first, in order to establish a 
suitable synthetic route, and were tested for activity against PRL- 3. After successful 
establishment of this route with the racemic starting material, this synthetic route 
(Scheme 2) was then applied for the synthesis of the more expensive chiral analogues.  
 
Scheme 2 Monoalkylation reaction pathway of 6-O-methylated/ethylated PI(4,5)P2. Compounds 2 and 3 have 
been made according to prior synthesis establishment120. 
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b. Synthesis plan for trialkylated inositol precursors 
The 2,3,6-O-trimethylated PI(4,5)P2 (protected, compound 27) was also planned to be 
synthesized. Following deprotection of compound 27 it was planned to obtain the sodium 
salt form (28’) and free-acid form (28) of the final trialkylated compounds. The synthetic 
route is shown in Scheme 3.  
 
Scheme 3 Trialkylation reaction pathway of 2,3,6-O-methylated PI(4,5)P2 
. 
c. Synthesis plan for dialkylated inositol precursors 
Dialkylation of inositols can be used to generate several different combinations of 
regioisomers, each of which requires developing an additional protecting group strategy. 
For example, Scheme 4 shows a strategy for the synthesis of 3,6-O-methyl analogues 
utilizing the allyl protecting group, which can be removed in the final step. The dialkylated 
compounds 20 and 23 were thus planned to be synthesized.  
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Scheme 4 Dialkylation reaction pathway of 3,6-O-methylated PI(4,5)P2. 
 
Another dialkylated analogue was considered to be synthesized, this time dialkylated at 
the 2- and 3-O positions, instead of the 3- and 6-O positions. The synthetic route is shown 
in Scheme 5.  
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Scheme 5 Dialkylation reaction pathway of 2,3-O-methylated PI(4,5)P2. 
3.1.2.1. Synthesis of the starting material 
The solution synthesis of the analogues always started with the building block 1, available 
in the research group and purchased from Sichem®. A D-myo-inositol ring protected at 
positions 2 and 3 with a cyclohexylidene ketal group, this starting material allows 
reactions at the four remaining hydroxyl groups. The synthesis of the starting material 
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for mono-alkylation and trialkylation of the inositol ring was achieved in two or three 
steps, respectively.  The protective group strategy has been established by Bruzik and 
coworkers91,114, and used by the research group for the abovementioned solid phase 
strategy. First, 2,3-cyclohexyl ketal-protected inositol was selectively protected at the 1-
OH position by introduction of the TBDPS group. After several repeats of this reaction 
considering the amount of precursors and analogues which had to be produced, it was 
finally optimized to yield the highest yield so far (66%) within the research group. The 
reaction was achieved by dissolving 1 and imidazole (2.25 eq) in dry pyridine, cooling the 
reaction solution down to -10°C before adding TBDPSCl (1.5 eq), then letting the 
reaction warm up to rt, stirring overnight. The product 2 was purified by automated 
column chromatography (Biotage®, see chapter 5), which afforded better yields than 
those achieved using classical glass column chromatography. Automated flash 
chromatography was used for the rest of this thesis work, unless when dealing with labile 
compounds like P(III)-compounds (see further sections). Analysis of the compound was 
carried out by 1H- and 13C-NMR and MS. Compound 2 was then selectively protected by 
O-benzoylation of positions 4 and 5 (Scheme 2), by dissolving in chloroform and pyridine 
(1:1) and cooling down the reaction solution to -40°C. A solution of benzoyl chloride 
(BzCl) was added dropwise and after the reaction mixture was slowly warmed to rt, an 
aqueous work-up was conducted and the crude product was purified by column 
chromatography. After reaction optimization regarding equivalents, time and purification 
techniques, 3 was isolated with a slightly higher yield of 93 % compared to the data found 
in literature (90 %)91.The identity of this compound and confirmation of the correct 
regioisomer was confirmed by 2D-NMR studies (COSY, HSQC and HMBC, Figure 11). 
 
 
Figure 11 Constructed diagram of 3 after extensive structure elucidation using COSY, HSQC and HMBC. 
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Inositol 3 was the starting material for the monoalkylation reaction. For a possible 
dialkylation and trialkylation reaction, the cyclohexylidene protecting group had to be 
removed first. This was first attempted using the conditions used for the solid phase 
organic synthesis work, whereby the cyclohexylidene ketal would be cleaved to free the 
2,3-OH groups for further protection with the benzylidene linker120. The conditions 
entailed using 75% formic acid in MeOH, but this led to only 30 % yield, in addition to 
the formation of side products, which might be due to the long reaction time (48 
hours). Also, the solubility of the reactant in MeOH was unsatisfactory, and it would 
have been possible that the prolonged exposure to the basicity of this solvent has 
prompted the Benzoyl groups to react (fall off or migrate). Cleaving the 
cyclohexylidene group with TFA114 was a very quick reaction with a better yield. But 
it also had to be optimized. The fastest and most efficient reaction was achieved by 
dissolving compound 3 in DCM and 200-300 μL water, then adding the TFA-solution 
(final ratio of TFA to DCM 1:1), and stirring the reaction mixture at rt. The reaction 
progress was monitored with TLC and after completion (in less than 15 minutes), the 
reaction solution was diluted with Toluene (3 times the existing volume) before the 
evaporating under reduced pressure. After purification by column chromatography 
the product was isolated with a yield of 86%. The synthesized product was analyzed 
by 1H- and 13C-NMR and MS. An additional problem had to be overcome in this type of 
reaction: comparing the reaction control TLC which showed total conversion to 21 
with the TLC of the crude material shows a reformation of the product during the 
work up. This suggested a possible mechanism: the warm water bath in the rotary 
evaporator was facilitating a reattachment of the cyclohexylidene to the starting 
material. To overcome this, a 200 to 300 μL of ethylene glycol were added to the 
reaction mixture prior to evaporation, in order to scavenge the cleavage product 
cyclohexanone, thereby preventing it from interacting with the diol again (Scheme 6).  
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Scheme 6 Cyclohexylidene cleavage and scavenging with TFA and Ethylene Glycol, respectively. 
The ketone group of cyclohexanone is a good electrophile, and could be made it an even 
better electrophile if protonated. Ethylene glycol has 2 hydroxyl groups, which are both 
good nucleophiles. Since these two hydroxyl groups are in the same molecule, if they both 
react with 1 other molecule (an electrophile) this would form a 5-membered ring (cyclic 
molecule). This is a big driving force for cyclic acetalization reactions, and ethylene glycol 
is very often used to form stable cyclic acetals. In fact, the free diol in the deprotected 
inositol ring also has the capacity for acetalization, but in a less flexible manner. Taking 
that with the fact that it is less abundant in the reaction, ethylene glycol would react first, 
and faster. In the 1H- NMR, peaks corresponding to the protons of the free hydroxyl 
groups are clearly visible between 2.50 and 3.00 ppm (Figure 12) before the 
purification of 21. 
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Figure 12 1H NMR of compound 21. 
For synthesis of lipid tail modified analogues in solution, the same starting material and 
protective group strategy was used, in addition to a MEM protecting group at position 6 
of the ring, to ensure no OH-free group except the 1-OH, which would serve for 
attachment of the lipid tail phosphoramidite analogues (coupling reaction, see section 
3.1.4.). The reaction is shown in Scheme 7. To achieve this, compound 3 was dissolved in 
chloroform under Argon atmosphere, before DIPEA (14 eq) was added at rt, followed by 
MEM chloride (MEMCl, 9.8 eq). The reaction was heated under reflux to 58°C and left 
stirring overnight. Monitoring the reaction by UPLCMS showed the presence of the 
product, with full conversion, and with no signs of multiple regioisomers (only one peak, 
Figure 13). After working up the reaction with NaCO3 and EtOAc extraction, the product 
could be isolated with a 66% yield, which could be due to the steric hindrance around the 
6-OH by the benzoyl groups on one side and the TBDPS bulky group on the other side, 
thereby curtailing the reaction from going towards completion.   
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Scheme 7 MEM protection of the 6-OH on the protected inositol ring. 
 
 
 
Figure 13 UPLCMS of the reaction control of compound 29 (10 hours after reaction start).  
 
3.1.2.2. Alkylation of the inositol ring 
This procedure was at the heart of the challenges that were met during this work. It was 
initially thought that the alkylation step, which succeeds the two previous selective 
protection steps (previous section), would be simply and efficiently achieved, but it was 
not. 
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Scheme 8 Methylation of the 5-OH on the inositol ring upon usage of NaH and MeI. The cyclohexylidene ketal 
was cleaved for clearer structure elucidation upon 2D NMR. 
The alkylation of the hydroxyl group in the 6 O-position on the inositol ring was very 
difficult to achieve, due to the steric hindrance of a bulky TBDPS group and a benzoyl 
group on the neighboring ring positions. This necessitated the usage of rich 
methylation agents, and strong bases for activation. Therefore, a variety of alkylating 
reagents with different bases were tried under a myriad of conditions (Table 1). These 
preliminary experiments indicated that the benzoyl protecting groups on the inositol 
ring were prone to migration. Following optimization of the solvent (Table 1) and 
reaction duration, conditions were found which gave a reasonable yield of a mono-
methylated inositol. To confirm the identity of this fully-protected compound, 
thorough structure elucidation by NMR was carried out, after cleavage of the 
cyclohexylidene ketal PG to prevent noisy signals. Unfortunately, the compound was 
found to be the wrong regioisomer (compounds 4 and 5, Scheme 8). Migration of the 
5-O-benzoyl group to the 6-O position was found to have occurred, and methylation 
of the more stable 5-oxyanion had occurred. This is indicated in Figure 15, a 
reconstructed diagram based on the COSY spectrum in Figure 14.  
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Table 1 Bases and Solvents screened for methylation reaction, using MeI, in similar temperature conditions, 
equivalents of base, and time. MeI: Methyl Iodide; PG: Protective Group; DMF: Dimethyl Formamide, DME: 
Dimethoxyethane; ACN: Acetonitrile ; THF: Tetrahydrofuran ; DMSO: dimethyl sulfoxide. 
Base Solvent Reaction Status 
NaH DMF PG migration, low rate 
Dioxane PG migration, low rate 
DME High product rate, wrong 
regioisomer 
Ag2O ACN PG migration, very low rate 
Cs2CO3 DMF No reaction 
THF PG migration, no reaction 
DMSO PG migration, very low rate 
Li2CO3 DMF PG migration, no reaction 
Na2CO3 DMF PG migration, no reaction 
K2CO3 DMF PG migration, no reaction 
DIPEA DMF PG migration, very low rate 
DBU DMF PG migration, no reaction 
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Figure 14 1H, 1H COSY spectrum of compound 5. 
 
Figure 15 Constructed diagram of compound 5 after extensive structure elucidation using COSY, HSQC and 
HMBC. Protons are shown in red font, carbons in black. 
A new protecting group strategy was designed involving replacement of the labile 
benzoyl groups by more stable benzyl groups. For this, the Dudley benzylation 
reaction was carried out121. Unfortunately, it was found that the TBDPS group was 
also prone to migration upon exposure to the strong bases used in Williamson ether 
synthesis (Scheme8, Figure 16).  
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Scheme 8 Attempt to use benzyl groups as PG instead of benzoyl groups. a) conditions: 2-benzyloxy-1-
methylpyridinium triflate (4eq), MgO (4 eq), PhCF3, 83°C, 1day. 
 
Protection of compound 1 at the 1-OH position with monomethoxytrityl (MMT) instead 
of the bulky TBDPS group was also carried out, but the reaction was not selective (at least 
2 regioisomers and one di-substituted inositol ring were formed), and never went to 
completion, so this attempt was soon aborted.  
As a breakthrough in this synthesis, the methylation reaction on the 6-O position was 
finally achieved using a mild methylation reaction which employs a Meerwein’s salt 
derivative, called trimethyl oxonium tetrafluoroborate, and proton sponge, known to 
Figure 16 UPLCMS result of the benzylation reaction after one day: peak 6 depicted on the ELSD is actually a 
multitude of peaks at similar retention times, containing the same TBDPS-protected, dibenzylated 
compound mass, which indicates the presence of different regioisomers. 
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be a mild base but a strong nucleophile, which could overcome the hurdle of 
protecting group migration (Scheme 9). This procedure was inspired from the work 
of Paterson and Coster, who achieved the total synthesis of the potent cytotoxic 
macrolide, altohyrtin A (spongistatin 1)122. Since this reaction was successful, it was 
thought to make use of it further to protect the free hydroxyl groups of PI(4,5)P2 with 
a group other than methyl, hence expand the library: the most direct and available 
one was the ethyl (Meerwein’s salt as a reagent). This led to the design of a series of 
methylated and ethylated precursors were envisioned to be synthesized according to 
the planned synthetic routes shown in the previous section’s schemes (above).  
 
Scheme 9 Successful methylation of the 6-OH of compound 3. 
The reactant, dissolved in DCM, was cooled to 0°C before adding the proton sponge 
and the corresponding Meerwein salt derivative. The suspension was slowly warmed 
to room temperature and stirred for 48 hours. After filtration of the reaction mixture, 
the solvent of the supernatant was evaporated and the crude product was purified by 
column chromatography. 6 could be isolated in a yield of 99 % and 13 with 80 %. Both 
compounds were analyzed by 1H- NMR, 13C- NMR (Figures 18 and 19), COSY (Figure 
17), HMBC, HSQC and HR-MS. 
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Different discussion section: 
The reaction of the ethyl group seems to be more hindered than with the smaller 
methyl moiety. In the 1H - NMR of 6, the methyl group is clearly distinguishable with 
a singlet at ca. 3.5 ppm (Figure 18). Comparing the 1H - NMR of 6 and 13 (Figure 19) 
one can see that the proton in the 6-O position on the ring is shifted to the deep fields 
even further in the spectrum of 13 than in 6. 
Figure 17 COSY spectrum of compound 6. 
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Figure 18 1H- NMR of 6 measured in CDCl3. 
 
Figure 19 1H- NMR of 13 measured in CDCl3. 
* 
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For the di- and trialkylation of 21 the application of the Meerwein salts as reagent was 
successful as well. Both products were formed in a one-pot reaction (Scheme 10). 
However, there was a considerable difference between the di- and tri-alkylation 
yields, and also a difference between methylation and ethylation multi-alkylation 
yields. 
After solving 21 in DCM and cooling the solution to 0°C, the respective Meerwein salt 
was added together with the proton sponge, and the solution was slowly brought to 
room temperature. After the reaction was finished, which was determined by TLC 
monitoring, and which took up to 6 days depending on the reaction, the reaction 
mixture was filtered, and the crude product purified by column chromatography. The 
methylation yielded 44% of 20 and 19% of 19. The ethylating reaction produced 45% 
of 23 and only 15 % of 22.  
 
 
Scheme 10 Synthesis of di-and trialkylated myo-inositols. 
The structural elucidation of every compound was conducted with 1H- NMR, 13C-NMR and 
HR-MS and COSY analysis confirmed the unsubstituted hydroxyl group in position 2 in 
case of compounds 20 and 23. Both reactions were done using a very large excess of 
reagents (alkylating agent and base). These conditions were chosen because of the 
sterically hindered 6- position, but also because the hydroxyl group on the axial 2-
position is the least reactive in the ring.  
The ethylating reaction was probably slower than the methylation reaction due to the 
bigger bulk of the ethyl group, as was already observed in the mono-ethylation. The 
dialkylated compounds 20 and 23 were isolated in a much higher yield than the 
triakylated ones. This could be linked to the steric hindrance due to the neighboring 
TBDPS group for the axial hydroxyl group, as well as the relative inactivity of that group. 
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The respective yields were possible to increase by letting the reaction run as long as the 
monoalkylation. But the total yields of both reactions were significantly lower compared 
to the formation of 6 and 13.  
In other words, the major difficulty encountered in this synthesis was that trimethylation 
or triethylation using the oxonium salt never proceeded to completion, even when large 
excesses of alkylating reagent were used. There were always two products to separate 
(the dialkylated intermediate product and the trialkylated desired product). This 
separation was difficult due to the similarity in properties of the compounds.  In order to 
obtain sufficient amounts of the successfully synthesized trimethylated PI(4,5)P2, this 
was overcome by the multiple methylation reactions of both starting material and 
dimethylated minor product of previous trimethylation reactions. This was repeated 
many times, to try to utilize as much of the undesired dialkylated products as possible as 
starting materials for further methylation. The reactions took up to 7 days to achieve at 
least 50% conversion, and many solubility experiments were tried on the oxonium salts 
beforehand to achieve optimization. In the case of the triethylated derivative the 
alkylation reaction was so slow and with such poor conversion that it was decided to 
deprioritize this compound. For the total separation of the di- and trialkylated 
compounds, as well as from other impurities, two column chromatographic separations 
were sometimes necessary which naturally led to some loss of product. In the 2D-COSY 
NMR spectra of 19 and 20, the peaks for the respective methoxy groups (marked with *) 
are clearly visible (Figures 20 and 21). 
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Figure 20 Section of 2D-COSY spectrum of compound 19 measured in CDCl3 with annotated myo-inositol ring 
protons. 
There is also a clear shift to the higher field of the proton signal of the hydrogen at the 
2 position of the inositol ring discernable when comparing their respective spectra. 
This further supports the assumption that the hydroxyl group in the axial position is 
the last one to react in the multialkylation reactions. This can also be confirmed in the 
1H- NMR spectra from 22 and 23 (Figures 22 and 23). The methyl part of the ethoxy 
group can be seen in their distinctive triplet form while the methylene group signals 
are less distinguishable. The dialkylated compounds 20 and 23 were thus planned to be 
taken further down the PI(4,5)P2 analogue synthesis. However, the steric hindrance of the 
TBDPS protecting group made further alkylation at the 2-O position difficult under non-
forcing conditions. Unfortunately, attempts to introduce the allyl protecting group in the 
2-O position were not successful, presumably also due to steric reasons. This route was 
put on hold for future revisit, and the 3,6-O-dialkylated PI(4,5)P2 was not fully 
synthesized as part of this thesis work.  
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Figure 21 Section of 2D-COSY spectrum of compound 20 measured in CDCl3 with annotated myo-inositol ring 
protons. 
Yet another dialkylated analogue was considered to be synthesized, this time dialkylated 
at the 2- and 3-O positions, instead of the 3- and 6-O positions. The synthetic route is 
shown in Scheme 5. This was made possible with availability of the starting material (9), 
previously used for solid phase synthesis in the Köhn lab120 (Figure 9). This compound is 
protected at the 6-O position by a MEM group, allowing for alkylation at the 2- and 3- O 
positions selectively, after cleaving the benzylidene linker. Methylation was chosen over 
ethylation in this case, for obvious feasibility reasons (see above). The cleavage of the 
benzylidene linker was successfully achieved, after using ethylene glycol as a scavenger 
to prevent it from reforming upon removal of acid. The methylation at the 2- and 3-O 
positions of the ring was successful too, following an established procedure as part of this 
thesis. Unfortunately, the MEM group was lost (partially) during the methylation reaction 
(scheme 5, second step). This could be overcome by re-protecting with a MEM group and 
carrying on the synthetic route as in Scheme 5. The 2,3-O-dimethylated inositol should 
provide an additional building block for the PI(4,5)P2 analogues library. Due to time 
constraints, the 2,3-O-dimethylated PI(4,5)P2 analogue was, however, not synthesized as 
part of this work.  
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Figure 22 1H- NMR of compound 22 measured in CDCl3. 
 
 
Figure 23 1H- NMR of compound 23 measured in CDCl3. 
* 
* 
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3.1.2.3. Debenzoylation 
The deprotection of the hydroxyl groups of the 4 and 5 position of the inositol ring was 
carried out following the procedures of Bruzik et al.91 and Vanek and coworkers123 
(Scheme 11). 
 
Scheme 11 General debenzoylation reaction. 
The starting material was dissolved in the solvent and the solution cooled to 0°C before 
NaOMe dissolved in MeOH was added. The reaction was slowly warmed to room 
temperature and monitored by TLC. After complete conversion, the reaction solution was 
neutralized and worked up. The crude product was purified by column chromatography. 
Product 8 could be isolated in 74% yield and the conversion of 13 to 14 gave a yield of 
99%. The discrepancy in the yields might be due to two independent reasons: 1) the 
bulkiness of the ethyl group which might push the reaction to go faster, and hence, more 
efficiently, and 2) the extent of the dry conditions. The structural confirmation of 
compounds 8 and 14 were both conducted with 1H- NMR, 13C- NMR and HR- MS. Since the 
first debenzoylation reaction was performed on compound 6, it was used as a reference 
for optimization. Hence, the first time this reaction was conducted, NaOMe was used in 
a catalytic amount, and MeOH was used both as solvent and to regenerate the reactive 
species. But compared to the reaction by Bruzik and coworkers91,  which was also 
later applied for the formation of 8, and in which the reagent was used in an equimolar 
amount (instead of catalytic), the reaction time is considerably longer and the yield is 
slightly lower. This is why it was opted to use the latter technique for the 
debenzoylation of all the analogues precursors (both the inositol-ring modified and 
the lipid tail modified), since it seemed that the best and quickest route to 
debenzoylate these hydroxyl positions in solution is by using NaOMe as a reagent, not 
as a catalyst. 
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In the 1H- NMR, the shift of the proton signal assigned to the hydrogen on 4 and 5 position 
to the higher field has clearly shifted for both compounds compared to their respective 
starting materials (Figures 24 and 25). The peaks for the free hydroxyl groups were no 
longer visible in either spectrum in approximately the same area, after addition of D2O to 
the NMR samples. This was a method to prove that the Hydroxyl groups were now free. 
The 13C NMR spectra of the compounds also confirm the loss of the carbonyl compounds 
in the 170 ppm area (Appendix), in addition to less signal in the proton NMR at 7-8 ppm.   
 
Figure 24 1H- NMR of 8 measured in CDCl3. 
* 
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Figure 25 1H- NMR of 14 measured in CDCl3. 
 
3.1.2.4. Phosphorylation 
For the addition of the phosphate groups to the inositol ring, a procedure developed by 
Fraser- Reid et al.124 utilizing the monofunctional phosphine was used (Scheme 12).  
 
Scheme 12 General phosphorylation synthesis of alkylated myo-inositols. 
* 
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After dissolving the respective starting material in solvent, 1H-tetrazole, then the 
phosphoramidite were added dropwise and the solution stirred until no starting material 
remained. Then the reaction mixture was cooled to -40°C and the phosphite groups were 
oxidized with mCPBA to give the protected phosphate groups. After warming the solution 
to room temperature, the reaction mixture was quenched and subjected to an aqueous 
work up. After purification of the products with column chromatography, 9 was isolated 
in a yield of 99% and 15 with 67%. The apparent difference in yield is thought to be 
mostly due to the steric hindrance of the ethoxy group, which is bulkier than the methoxy 
group, and with which the reaction was never pushed to completion. Therefore, changes 
in reaction conditions (equivalents of reagents and time) had to be closely investigated 
before obtaining the documented yield. Below is an explanation of the reaction 
conditions, which were optimized prior to the best (abovementioned) conditions.   
 
The same phosphorylation method was applied for the trialkylated inositol ring after 
sufficient amount of the starting debenzoylated material was successfully obtained. The 
phosphorylation reactions were optimized according to three variables: the type of 
activator, the type of solvent, and the type of oxidation method. As can be seen in Table 2, 
the best activator was 1H-tetrazole, though extreme caution had to be considered as the 
use of an accidentally non-dry reagent solution had led to the total loss of product before 
oxidation. 2,5 Dicyanoimidazole, which has been used as an activator for phosphorylation 
in solid phase synthesis of PIPs120, was not as good as 1H-tetrazole, at least in solution 
synthesis. The best solvent was DCM, not acetonitrile, nor chloroform, nor a mixture of 
either, and the best and cleanest oxidation method was the one using mCPBA (meta-
Chloroperoxybenzoic  acid) instead of peracetic acid (used in the solid phase 
synthesis120). In fact, the little amount of product that was formed in the reaction was not 
possible to isolate because a lot of side products formed during this kind of oxidation. 
Oxidation with peracetic acid lead to the formation of many side products that hinder 
the isolation of the product and oxidation on air is a very slow and indefinite 
technique. 
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Table 2 Phosphorylation reaction optimization. 
Reaction Activator Solvent (dry) Time stirred 
before 
oxidation (h) 
Oxidation 
method 
Yield 
1 2,5 
Dicyanoimidazole 
DCM:AcCN 2 Peracetic acid 50% 
2 1H-tetrazole DCM:AcCN 2.5 mcpba 74% 
3 1H-tetrazole CHCl3 2 mcpba 82% 
4 1H-tetrazole DCM 2 mcpba 99% 
 
For TLC monitoring of products and impurities during these first part of these reactions 
(i.e., before oxidation), a solution was devised to be able to run the P(III) compounds on 
silica without possible hydrolysis or oxidation, as these compounds are highly labile. For 
that, the TLC plate was treated with trimethylamine (TEA) fumes in a small TLC chamber 
prior to its use. The base TEA helped neutralize the acidic environment on the TLC plate, 
which contributed to the migration of the reaction components on the plate without 
decomposition. With that, one could tell if the presence of any additional spot(s) other 
than the desired product on the TLC were actual impurities. Overall, impurities in the 
optimized phosphorylating reactions were increasingly insignificant after final 
purification on silica columns, as can be seen in the 31P NMR of products 9 and 15 in 
Figures 26 and 27, respectively. The structural elucidation of all the phosphorylated 
compounds was done by 1H- NMR, 13C- NMR, 31P- NMR and HR- MS. 
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Figure 26 31P- NMR of 9 measured in CDCl3 with only a minor impurity (*). 
 
Figure 27 31P- NMR of 15 measured in CDCl3 with only a minor impurity (*). 
* 
* 
* 
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3.1.2.5. TBDPS deprotection  
For the deprotection of the 1-hydroxyl group on the inositol ring by cleaving the TBDPS 
group, an adapted method by Bruzik et al91,  developed for the synthesis of PIPn, was 
applied (Scheme 13). 
 
Scheme 13 General TBDPS deprotection reaction. 
The respective starting materials were dissolved in THF and the solutions cooled to 0°C 
before TBAF was added. After warming the solution to room temperature and monitoring 
the reaction by TLC, the reaction was quenched, aqueously worked up and purified with 
column chromatography (see Chapter 5 for more details).  
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Table 3 TBDPS deprotection optimization. *As part of the same solution synthesis outline, the native PI(4,5)P2 
substrate was also synthesized, but that included protecting at the 6-OH with a MEM group.  
R-group Reagent Amount 
(eq) 
Time (hr) Temperature Solvent Yield (%) 
Me TASF 2.5  2.5 rt DMF 34 
Me TBAF (solid) 2.5 2 rt THF 47 
Me TBAF (1M in 
THF) 
2.5 2.5 rt THF 57 
Me TBAF (1M in 
THF) 
2 3 0°C  rt THF 80 
Me TBAF (1M in 
THF) 
1.9 2.5 0°C  rt THF 69 
Et TBAF (1M in 
THF) 
1.9 2 0°C  rt THF 73 
Et TBAF (1M in 
THF) 
1.8 2.5 0°C  rt THF 47 
MEM* TBAF (1M in 
THF) 
1.8 2.5 0°C  rt THF 82 
 
In the optimized reaction, the amount of 10 yielded to 80% and of 16, a yield of 73% could 
be isolated. Analyzed were both compounds by 1H- NMR, 13C- NMR, 31P- NMR and HR- MS.  
After testing different solvents, it was determined that THF is the best solvent for the 
reaction and for monitoring thereof. The first two trials were directed with solid TASF 
and solid TBAF as reagents. Using TASF as reagent and DMF as solvent was inspired by 
the solid phase synthesis of such phosphoinositides120, but it was soon shown to work 
much less efficiently in solution synthesis. Due to the hygroscopic nature of such reagents, 
the weighing and transport between scale and flask lends itself for the reagent to draw 
water from air which decreases the reactivity of the compound and leads to the necessity 
of using a higher amount. To avoid this problem a change to 1M-TBAF solution in THF 
was made. A variety of equivalents were tested from 1.7 to 2. The main results can be 
found in Table 3.  
During the monitoring of the reaction with TLC it was apparent that more side product 
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was formed while increasing the amount of the reagent gradually. Using less reactant to 
avoid side product formation and letting the reaction run longer while monitoring the 
reaction with TLC led also to a decrease in yield. Reasons for this observation could be 
linked to the increase of side product, the longer the reaction mixture was stirred, as well 
as the lack of total conversion of the reaction. To avoid the increase of side product while 
using a higher amount of TBAF-solution, the reaction mixture was cooled to 0°C before 
the reagent was added. Surprisingly, the bigger the R group, the better the yield. This 
could be due to the bulkiness of the group, which pushes the leaving group to leave faster, 
but it is just an assumption. In the 31P- NMR, it is apparent that the synthesized products 
can be isolated in 100% purity (Figures 28 and 29).  
 
Figure 28 31P- NMR of compound 10 measured in CDCl3. 
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Figure 29 31P- NMR of compound 16 measured in CDCl3. 
 
3.1.3. Solution synthesis of the diverse lipid tails 
Part of the overall total organic synthesis of PI(4,5)P2 analogues involved synthesizing the 
lipid tail phosphoramidite prior to its attachment to the 1-O position of all the analogues.  
The DiC8 lipid tail was successfully synthesized according to the synthetic route shown 
in Scheme 14. This is a previously established synthesis, used as part of the PIP solid 
phase synthesis120.  
The diisopropyl-O-benzyl phosphoramidite (51) was also synthesized using a different 
technique, involving bulb-to-bulb distillation. This afforded a large amount of reagent, 
which was used for further lipid tail synthesis, as well as three other lipid tail analogues: 
the di-carbamate, the di-adamantane, and the phenylpropanol chains (Schemes 15 and 
16). These phosphoramidites were again synthesized and optimized following the 
technique used in Scheme 14 (see chapter 5 for more details about the procedures). 
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Scheme 14 Synthesis of phosphine 51 and the phosphoramidite 47. 
 
 
Scheme 15 Synthesis of phosphoramidite 38. 
 
The di-carbamate lipid chains were chosen to study the difference in analogue activity 
when the ester bonds of the lipid chains are replaced by the more stable carbamate bonds. 
The di-adamantane lipid chains were chosen based on a study by Gregory and coworkers 
125, who synthesized phosphatidylinositol phosphate analogues containing adamantyl 
carboxylic ester groups, in place of the natural lipid side chains. These were shown to be 
significantly more soluble in water than other lipid chain analogues, and to not form large 
aggregates such as liposomes or micelles. These adamantyl analogues were also shown 
to bind to known phosphoinositide-binding proteins with similar affinities to native 
ligands125, such as FYVE domains and others. The phenylpropanol lipid tail was selected 
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to be a simplified version of the hydrophobic lipid tail, to check for how significant large 
lipid tails are for binding. This reasoning was from a medicinal chemistry point of view 
aiming to design a potential inhibitor. The pathways of the lipid tails synthesis are shown 
in Schemes 14-16. 
 
Scheme 16 Reaction pathways of the synthesis of the Di-adamantane and Di-carbamate glycerol lipid chains 
phosphoramidites 44 and 41, respectively. 
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3.1.4. Synthesis of PI(4,5)P2 analogues  
The final steps in the solution phase synthesis of the analogues were: a) coupling of the 
separately synthesized phosphoramidite(s) with the free hydroxyl group on position 1 of 
the inositol precursors (in this case, compounds 10, 16, 26 and 32), b) deprotection the 
full molecule to yield the free acid and c) salt formation using a salt exchange resin.  
The DiC8 chains (compound 47) were coupled to compounds 10, 16 and 26 to strictly 
account for inositol modifications in the SAR studies. For the lipid tail attachment, the 
phosphorylation reaction method by Fraser-Reid and coworkers124 was adapted for 
this purpose (Scheme 17), and applied for all the coupling reactions.  
3.1.4.1. Lipid tail attachment  
In DCM dissolved, the respective starting material was cooled to 0°C before the diC8 lipid 
tail phosphoramidite 47 and 1H-Tetrazole were added. After warming to rt and stirring 
until full conversion is achieved the reaction mixture was cooled to -40°C and oxidation 
with mCPBA was carried out. After the work up, the crude product was purified using 
column chromatography. 11 was isolated with a yield of 70%, the conversion of 16 to 17 
led to a yield of 54%, and the conversion of 26 to 27 led to a yield of 76%. Structural 
elucidation was carried out by 1H- NMR, 13C- NMR, 31P-NMR and HR -MS. Using the same 
reaction method for the attachment of the diC8 phosphoramidite that was used for the 
phosphorylation led to the formation of the desired products.  
Comparing the synthesis of the three products, it was obvious that the reaction is a lot 
slower for the ethylated precursor as seen before in the bisphosphorylation and TBDPS 
cleaving reactions. The ethoxy group seems to hinder the reaction sterically through its 
size. Furthermore, it was not possible to achieve full conversion of the starting material 
by stirring longer and increasing the amount of the reagents. A solution to this might be 
to increase the amount of 1H-Tetrazole to ensure the full activation of the 
phosphoramidite. Coupling with the trimethylated inositol precursor achieved the best 
yields, since both the cyclohexylidene ketal and the ethoxy groups around the 1-OH were 
substituted by smaller, methoxy groups.   
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Scheme 17 Lipid tail attachment reaction to the three inositol precursors 10, 16 and 26. 
 
In the 1H-NMR of 11 the signal for the methoxyl group is split into a doublet for which 
both peaks integrate to 1.5 protons (Figure 30, marked with a “*”), which could be 
explained by the nuclear overhauser effect (NOE). In this case, the spin-spin coupling does 
not ensue through bonds, but through space. The protons of the methoxy group could 
hence be interacting with the protons of the benzyl protecting group in the 
phosphodiester, and the benzyl groups on the 5-phosphate, generating this effect. It might 
also be possible that through the bulky protecting groups the rotation around the single 
bond is inhibited and the environments on both sides of the methoxy group are dissimilar, 
thereby generating two separate signals. 
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Figure 30 1H NMR of compound 11 measured in CDCl3. 
The other lipid tail analogues phosphoramidites (Section 3.1.3, compounds 38, 41 and 
44) were coupled to the unmodified inositol ring precursor (protected with a MEM group 
at the 6-OH), to strictly account for lipid tail variances during SAR studies. Since no 
changes to the inositol ring had to be made for these steps, it was envisaged to synthesize 
the lipid tail modified PI(4,5)P2 analogues using the solid phase strategy developed by the 
lab126, provided that the total synthesis would be similar, except for the use of different 
lipid tails in the second last step of the synthesis.  
With the help of Dr. Sven Stadlbauer, a former postdoctoral fellow in the Köhn group, the 
solid-phase synthesis of the phenylpropanol lipid tail PI(4,5)P2 analogue was achieved, 
albeit with very low yields and amounts. The synthesis of the di-carbamate and di-
adamantane lipid tail PI(4,5)P2 analogues was, however, not successful using the solid-
phase methodology, especially for the latter. Re-synthesis of the di-carbamate PI(4,5)P2 
analogue was repeated at larger scales using solid phase synthesis, which required the 
need of excess valuable reagents. It is believed that the di-adamantane PI(4,5)P2 analogue 
was not successful because of the bulkiness of the adamantane molecules, which could 
hinder its passage through the resin mesh for coupling. It was therefore decided to 
* 
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synthesize it using solution phase synthesis. Thus the di-adamantane glycerol 
phosphoramidite was resynthesized and purified as described already. The reaction steps 
are shown in Scheme 18, and show the selective MEM protection at the 6-O position after 
TBDPS and Benzoyl protection. Cleaving the TBDPS protecting group would leave the 
most reactive 1-OH free (32) for coupling to the phosphoramidite containing the lipid 
tails, a very fast organic reaction in solution. 
 
Scheme 18 Solution synthesis of the lipid modified PI(4,5)P2 analogues. The last reaction step, which involves 
the overall deprotection of 33 and 35, is described in section 3.1.4.2. 
 
Using this solution-phase route, three lipid tail modified analogues would be synthesized 
and the route compared to the reported solid phase syntheses, according to practicality. 
 
71 
This shows the importance of versatility in methods for achieving the most desired 
results.  
 
3.1.4.2. Global deprotection 
The deprotection of all attached protecting groups with TMSBr was conducted after the 
method of Köhn et al126 (Scheme 19). The starting material dissolved in THF was cooled 
to 0°C, before TMSBr was added. After stirring for 1h, the solvent and the unreacted 
TMSBr were evaporated under reduced pressure and the precipitate dissolved in MeOH. 
This had first been attempted by evaporating on the rotary evaporator under inert 
conditions, but that resulted in total loss of the product. After evaporating under reduced 
pressure, the reaction mixture was stirred for another hour in MeOH and then evaporated 
(again, under reduced pressure), to yield the final product. The reactions with all 
compounds gave a quantitative yield. The compounds were analyzed by 1H- NMR, 13C- 
NMR, 31P- NMR and HR- MS. After optimization of the deprotection strategy, in the 1H-
NMR spectra of the final compounds, it was obvious that the reaction was clean and 
proceeded without formation of side products, which makes a purification 
unnecessary. Usually, salt-exchange reactions would add a purification step to the 
final compounds, but salt exchange reactions were avoided for the analogues 
synthesized as part of this work (see section 3.1.4.3.) An example of a free-acid final 
product is shown in Figure 31, for the analysis of compound 12. 
 
Scheme 19 Global deprotection reaction for compounds 12, 18 and 52. 
 
 
72 
 
Figure 31 1H NMR of compound 12 measured in MeOH 
 
For the deprotection of the trimethylated analogue, TMSBr was avoided, not only to avoid 
possible degradation of the very valuable compound 27 during the synthesis with a harsh 
reagent, but also because the only PGs to deprotect were benzyl groups, and for this, a lot 
of other cleaner methods were possible. The chosen method for deprotection of 27 was 
hydrogenation in glacial acetic acid, as this method would afford the clean product after 
freeze drying the solvent once the reaction is done (Scheme 20). The compounds were 
analyzed by 1H- NMR, 13C- NMR, 31P- NMR and HR- MS.  
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Scheme 20 Deprotection of compound 27, yielding the final compound 28 as a free acid. 
For the deprotection of the other lipid tail modified compounds (33 and 35), TMSBr was 
not sufficient for full deprotection, and an additional step involving the use of TFA had to 
be done to get rid of the cyclohexylidene ketal (See Chapter 5, Section 5.2.3). 
3.1.4.3. Salt exchange of the final compounds 
The conversion of the final compounds (free acids) to the sodium salts by ion exchange 
(Na form) was planned as the final step of the synthetic strategy, as was done in other 
works, including that of Koehn et. al99,100,120. This step, which would be considered as a 
purification step, counters every lost proton during deprotection steps: purification by 
ion exchange is used to remove contaminating acids, alkali metals, salts or mixtures from 
non-ionized or slightly ionized organic or in-organic substances. Salt exchange using the 
Dowex® cation-exchange media resin had already been used for such compounds126. The 
ion exchange technology is a good means to remove or exchange contaminants present in 
low concentrations.  
In the case of the synthesized free acid final compounds however, this step was not 
proven proficient, for a couple of reasons, the first being the running time until the resin 
is exhausted, which can be long (up to 48 hours). This could subsequently create a basic 
environment, which could lead to loss of esters or migration.  Another reason is that any 
contaminant that is not ionised cannot be removed by ion exchange, which could explain 
the amount of remaining impurities after salt exchange. Figures 32 and 33 show the 
proton and phosphorus NMR spectra of compound 12 before and after salt exchange, 
respectively.  
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Figure 32 31P (below) and 1H (above) NMR spectra of compound 12 before ion exchange. 
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Figure 33 31P (below) and 1H (above) NMR spectra of compound 12 after ion exchange. The impurities are 
marked with a “*”. 
The salt exchange step was thus an aborted step for the analogues. To make sure that this 
would not pose a problem for biochemical assays, as the non-ion exchanged analogues 
are more acidic, optimization of the assays using free acids instead of salts was done (see 
Section 3.2.). 
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3.2. Biochemical evaluation of the PI(4,5)P2 analogues 
In order to assess if the modified PI(4,5)P2-based compounds would be substrates of PRL-
3, they were tested in a biochemical phosphatase assay. To investigate the hypothesis that 
introducing modifications could lead to selective recognition of the compounds, other 
PI(4,5)P2-phosphatases were included in this study. 
3.2.1. Activity assays with PRL-3 against PI(4,5)P2 analogues 
The six successfully synthesized and characterized PI(4,5)P2 analogues (Figure 34) were 
available for testing, and were assayed for biological activity with PRL-3 using the 
commercially available Enzcheck assay19, in addition to the original chiral PI(4,5)P2-diC8 
substrate as control (compound 52, also synthesized in solution as part of this thesis 
work, see section 5.2.). The phosphatase activity of WT PRL-3 PI(4,5)P2-based substrates 
was then analyzed. The phosphatase concentration was chosen to be in the low micro 
molar range, and thus quite high, because of the reported low activity of PRL-3 in vitro25, 
and for the same reason, a high substrate concentration range was selected (25-250 μM). 
These conditions match previously reported ones18,19,120. 
 
 
Figure 34 Structures of the PI(4,5)P2 original substrate (52) and its 6 analogues (12, 18, 28, 34, 36 and 50). 
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The release of phosphate was monitored continuously over time. Each analogue was 
assayed at 5 different concentrations, twice in triplicates. The enzyme concentration was 
constant in all experiments, and so was the assay protocol (see Chapter 5). To account for 
possible changes in acidity of the well contents upon addition of the free-acid analogues, 
two control experiments were conducted prior to the assays to make sure that the free 
acid analogue (or substrate), would not perturb the pH of the reaction. First, a direct 
comparison between the salt form and the free acid form of the synthesized substrate was 
conducted using the assay, which showed similar results in phosphate release. Second, 
pH measurements before and after adding the free acid in the reaction wells showed that 
the acidity of the analogues did not change the pH; thus they were deemed compatible for 
the consequent experiments. 
The release of phosphate from soluble PIP substrates carrying modifications either on the 
inositol ring (compounds 12, 18 and 28) or on the lipid chains (compounds 34, 36 and 
50) by WT PRL-3 was continuously measured over 2 hours using the EnzChek assay. The 
dephosphorylation signal intensity was used to compare the substrate preferences of 
PRL-3 against the whole range of PI(4,5)P2 analogues. The resulting substrate preference 
profiles are shown in Figures 35 and 36. The respective absorbance curve of each 
analogue, at different concentrations, is shown in Figure 35 (A-F). The initial velocities 
were then calculated from the slope of the linear part of the ensuing reaction, to generate 
the bar diagrams in Figure 36. These bar graphs allow quantitative analysis on the activity 
of the active analogues, and their significance with reference to the control (in % values). 
For compounds 36 and 50, it was not possible to calculate the respective velocities as 
there was no slope that allowed this: the compounds were simply not active, and are not 
part of Figure 36.  
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Figure 35 The dephosphorylation activity of PRL-3 toward the PI(4,5)P2 analogues, at 5 different 
concentrations (25, 50, 100, 200 and 250 μM). The slopes are shown until 1500-3000 seconds of 
measurements because of the signal variation observed after that time point in all assays, which could either 
be due to the precipitation of the protein or the interaction of the analogues with the photoactive component 
in the assay. A) Absorbance measurements of compound 28: the signal intensity at 100, 200, and 250 μM of 
this compound is higher than that of the natural substrate at 250 μM. B) Absorbance measurements of 
compound 18: the signal intensity at 200 and 250 μM of this compound is higher than that of the natural 
substrate at 250 μM. C) Absorbance measurements of compound 34: the signal intensity at 200 μM is 
comparable to that of the control, and that of 250 μM is higher than that of the control (at 250 μM). D) 
Absorbance measurements of compound 12: although somewhat active, the signal intensity at 100 and 250 
μM of this compound, is lower than that of the natural substrate. E) and F), Absorbance measurements of 
compounds 36 and 50, respectively: those compounds were not active against PRL-3. Graphs are shown 
without error bars for clarity: the lower the signal intensity, the higher the relative error in the assay18,19,120, 
leading to error bars that would mask other curves. An error was accounted for in Figure 36, where the slopes 
were quantified.  
Before ongoing with the discussion on the analogues’ biological activity, it is imperative 
to note that the assay appeared to give a strong variability with PRL-3 as a phosphatase. 
This is because PRL-3 does not follow a Michaelis-Menten trend, and because it shows 
only low enzymatic activity18. This is why PI(4,5)P2 and its analogues’ titration profiles 
reveal non-Michaelis−Menten kinetics, with sigmoidal curve shapes (Figure 35 - curves). 
Otherwise, such kinetics are not a general feature of the assay format, and the same kind 
of assay was actually used for the assessment of three other phosphatases which follow 
classical Michaelis−Menten profiles (see section 3.2.2.). Other studies have also used this 
assay for classical Michaelis-Menten protein profiles127. A plausible reason for this could 
be the fact that PRL-3 is prone to oligomerize128, and non-Michaelis−Menten behavior is 
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characteristic for oligomerizing enzymes129, not to mention that phosphoinositides also 
have a propensity to oligomerize, making the issue less simple to tackle. Particularly with 
the analogues, the readout was noisy and poor, and the figure (curve) got unstable after 
a certain time point of measurement (1500 to 3000 seconds).  
From what can be appreciated in Figures 35 and 36, the trialkylated analogue (28) shows 
the highest activity, which leads to reason that the more hydrophobic the inositol ring, 
the better the interaction, taking into consideration that the active site of PRL-3 is 
unusually shallow and hydrophobic, as opposed to other PTPs20. In fact, the 6-O-ethylated 
analogue (18) follows as second best, rather than the 6-O-methylated analogue (12) 
which suggests that the bulkier the group blocking the inositol’s 6-OH, the better the 
interaction. However, more data should be generated on this, as the assay did not perform 
consistently with this analogue (18). In fact, two concentrations (25 and 50 μM) had to be 
excluded from the bar graphs for that compound, because the generated values were 
neither reproducible nor analyzable in the context of the rest of the data. Compound 12, 
which has the least structural changes compared to the parent compound, showed the 
fewest changes compared to the control.  
 
These results can be taken as a first stage towards understanding the specificity of PRL-3 
in terms of catalytic reaction with its substrates. This can be supported by the fact that 
the three other analogues, which are only modified at the lipid tail part of the molecule 
(34, 36 and 50) did not show significant activity compared with the inositol-modified 
ones (12, 18 and 28) (Figure 35). Actually, only compound 34 was active amongst the 
three lipid tail modified analogues. This analogue, bearing a double chain of adamantanes 
instead of the unsaturated diC8 chains, appears to be slightly more active than the control. 
The analogues bearing carbamate and phenylpropanol chains were not active at all. This 
shows, first of all, that the diC8 chains are important for binding to PRL-3, as reported 
previously120, and, second, that complete aberration of a double chain (as in 50) or 
replacement of the esters (as in 36) by a different atom did not show any improvement 
for interaction. However, it is not entirely clear why PRL-3 lacks phosphatase activity 
against compound 36 in this assay, given the similarity to the control compound. This 
might reflect that the nature of the lipid connection to the glycerol is of importance 
regarding the binding affinity of the compounds toward PRL-3. 
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Thus, the inositol modified analogues show increased activity compared to both the 
control substrate and the lipid-modified substrates with PRL-3. Therefore, these 
compounds can be the basis for prolific structure activity relationship studies with PRL-
3. 
 
3.2.2. Activity assays with other phosphatases against PI(4,5)P2 analogues 
 
As stated earlier, phosphoinositide metabolism is tightly regulated by a set of specific 
kinases responsible for synthesis of phosphoinositides, and phosphatases that temporally 
and spatially catalyze phosphoinositide dephosphorylation16. Of these phosphatases, 
those, apart from PRL-3, that are known to dephosphorylate PI(4,5)P2 were of specific 
interest for this study, as they would potentially hold an activity against the synthesized 
PI(4,5)P2 analogues.  
Figure 36 Results of the compounds activity towards PRL-3. PRL-3 (6 µM) was incubated with analogues at 
different concentrations and the assay conducted at 25 °C. Data are shown as mean ± SD. Statistics: *** p<0.0002; 
**** p<0.0001; ns – not significant. A) Compound 28 results. Tukey’s multiple comparison test: ns: Control 250 
μM vs 250 μM. B) compound 18 results: Tukey’s multiple comparison test: ns: 100uM vs 250uM; 200uM vs 
250uM; 250uM vs Control 250uM. Concentrations of 25 and 50μM were omitted because the data was not 
analyzable because it was too noisy. C) Compound 34 results: Tukey’s multiple comparison test: ns: 25uM vs 
50uM; 25uM vs 100uM; 25uM vs 200uM; 25uM vs Control 250uM; 50uM vs 100uM; 50uM vs 200uM; 50uM vs 
Control 250uM; 100uM vs 200uM; 100uM vs Control 250uM; 200uM vs 250uM; 200uM vs Control 250uM. D) 
Compound 12 results: Tukey’s multiple comparison test: only the displayed relationship is significant, all others 
are not. 
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Using the DEPOD database12, a literature review on PI(4,5)P2 dephosphorylating 
phosphatases was conducted, with careful consideration of the type of activity assays 
used in the studies, and the availability of a recombinant protein to test in in vitro activity 
assays. Three phosphatases, that represent different families and are commercially 
available as recombinant proteins, were chosen and purchased for assaying the analogues 
in activity assays. These phosphatases are INPP5E, which belongs to the large family of 
the 5-phosphatases that cleave the 5 position phosphate of several inositol phosphates 
and lipids including PI(4,5)P2130; OCRL, another inositol 5-phosphatase whose preferred 
substrate is PI(4,5)P2, and that has been shown to promote biogenesis of membrane-
trafficking intermediates through binding to this substrate131; and lastly, the SYNJ1 
(Synaptojanin 1) phosphatase, which has recently been shown to modulate membrane 
curvature through degradation of its substrate PI(4,5)P2132. The phosphatases were 
assayed like PRL-3 with the Enzchek assay19, against the control phosphoinositide 
PI(4,5)P2 and the synthesized analogues of it. An optimization of the activity assay was to 
be executed beforehand, as these proteins’ activities had not been measured with this 
specific assay type to our knowledge.  
The results of these assays, shown in Figure 37, provided substantial information on the 
specificity of the four phosphatases not only against PI(4,5)P2 itself, but also against the 
different PI(4,5)P2 analogues.  As can be seen from Figure 37, the compounds that show 
significant activity towards the three PI(4,5)P2–metabolizing phosphatases are the lipid-
modified PI(4,5)P2 analogues 34 and 36. Compound 50 did not show significant activity 
with any of the phosphatases, further corroborating that the double lipid chain is 
important for binding of the substrate. Similar to PRL-3, OCRL is also weakly active in 
vitro. Interestingly, the inositol ring-modified analogues did not show any activity with 
SYNJ1 and INPP5E.  This underlines the specificity of the inositol ring alkylated PI(4,5)P2 
analogues towards PRL-3, based on the hydrophobicity of its active site.  
SYNJ1 and INPP5E are known to possess a basic region near their active site. Besides the 
5-phosphatase domain, SYNJ1 bears an N-terminal Sac1 domain, which was later found 
to be a member of a new family of PI phosphatases133. The large C-terminal portion in 
SYNJ1 is a divergent proline-rich region (PRD), which contains a string of peptide motifs 
that mediate binding with a variety of endocytic proteins such as amphiphysin134. 
Furthermore, biochemical characterization showed that the 5 phosphatase domain 
dephosphorylates PI(4,5)P2 at the 5-position of the inositol ring15. INPP5E was also 
shown to have a PRD region preceding the inositol polyphosphate phosphatase catalytic 
domain, making the catalytic active site’s milieu largely basic135, which could explain why 
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it could not accommodate the hydrophobic analogues in its catalytic pocket.  On the other 
hand, OCRL does present a hydrophobic patch and a sequence motif defining the binding 
of the aliphatic moiety of the substrates to it. 
 
 
Figure 37 Activity of the 6 analogues with three different PI(4,5)P2-metabolizing phosphatases, with respect 
to the parent substrate (control) PI(4,5)P2. 
 
The PH domain of OCRL actually lacks the basic PI(4,5)P2 binding pocket present in the 
PH domain of PLCδ for instance136. One could then argue that this is why it might 
accommodate a hydrophobic analog like the inositol-modified PIP analogues. Still, these 
analogues show no significant activity with OCRL as opposed to the activity they show 
with PRL-3, and can thus still pose as specific substrates to the latter.  
In addition, the analogues which actually show activity with SYNJ1, INPP5E and OCRL 
show no significant activity with PRL-3, further underlining that the main element of 
specificity would be the alkylated, increasingly hydrophobic inositol ring. Thus, these 
analogues could act as interesting tool compounds which could be further modified, 
leading to further understanding of the specific mechanisms for substrate recognition of 
PRL-3 to eventually create a selective inhibitor from the gained knowledge.  
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3.3. Virtual screening tools to aid inhibitor search using PI(4,5)P2 
 
During this thesis work, an alternative approach for designing PRL-3 probes and 
eventually inhibitors was explored, using the PI(4,5)P2 molecule as a starting point for 
virtual screening of similar molecules. The Ultrafast Shape Recognition (USR) method54, 
which can identify similarly shaped compounds within the largest molecular databases 
was applied to the PI(4,5)P2 head-group in collaboration with Pedro Ballester, a former 
colleague from the EBI (Hinxton, UK), and the Chemical Biology Core Facility (EMBL, 
Heidelberg). Only the head-group of the template molecule was chosen and used because, 
firstly, the full molecule was too big for the computational system, and secondly, the 
phosphoinositide head is the part involved in enzymatic activity with the phosphatase 
(contains the cleavable phosphate group). 
 
3.3.1. USR screening based on PI(4,5)P2, data filtering, clustering and drug 
design 
 
A set of screened compounds whose USR score30 was high (>0.8), was obtained. A second 
screen was made, and further filtering, clustering and analysis were done to make a 
rational choice on which molecules can be sourced or synthesized for testing PRL- 3’s 
activity by biochemical screening. After obtaining a list of hits from a USR run, and with 
the help of Dr. Ulrike Uhrig from the Chemical Biology Core facility (EMBL, Heidelberg), 
483 compounds were exported as structures from the ZINC database, and duplicates 
(same compound, different vendor) were removed, which left us with 216 compounds. 
The assignment into families based on 2D similarities resulted in 42 clusters and 35 
singletons. Using computational chemistry methods (see chapter 5.1) to make a selection 
of the “best” representative of a cluster, a series of compounds were selected for synthesis 
and biochemical activity screening.  
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Figure 38 Overlay Sstructure of one of the identified hits from the USR run (compound in blue) with the 
original PI(4,5)P2 head group (compound in yellow). 
 
Figure 38 shows an example of a hit, which closely resembles the given lead molecule 
(PI(4,5)P2 head-group in this case). In addition, since it is known that the lipid tails are 
crucial for binding to PRL-3 in the original molecule120 (see chapter 3.2), the synthesis of 
these hits was planned to include attachment of the diC8 lipid chains before testing them 
on PRL-3. This necessitated devising a synthetic route for each of the finally selected 
target molecules. The potential target molecules are depicted in Figure 39. 
Although the screening was carried out using a database of commercially available 
compounds, it turned out that all the potent compounds found were only theoretically 
commercially available and thus required custom synthesis from the vendor. This was 
found to be prohibitively expensive. Unfortunately, many of the compounds imposed a 
tough or impossible synthetic challenge. Nevertheless, two target molecules were 
identified (Figure 39) to be synthesized. 
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Figure 39 Target compounds from the results of the PI(4,5)P2 similarity screening study. The areas shown in 
blue depict the location of the lipid tail attachment based on structural overlay. The crossed out molecules 
correspond to ruled out targets due to the synthetic challenges.  
 
3.3.2. Synthesis of a potential target molecule from the similarity screen 
 
With the collaboration of the Chemical Biology Core Facility at EMBL, Heidelberg, two 
target molecules were planned to be synthesized (Chapter 5.2.5). These were deemed to 
be the best hits according to computational overlay experiments done by Dr. Ulrike Uhrig 
(Figure 39, compound 61 and 62). Dr. Mascha Jaekel successfully synthesized and 
characterized the molecules in Figure 40. Compound 61 was synthetically more difficult, 
and gave the hydantoin (70, Figure 40-C, Chapter 5.2.5) as major side product. The 
successfully synthesized molecule 62 (Figure 40-A), in addition to its protected precursor 
molecule 69 and the major side product 70 of the other target (Figure 40-C) were tested 
in inhibition assays (DiFMUP)137 against PRL-3.  
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Figure 40 Synthesized molecules based on the USR screen, which were tested using inhibition assays against 
PRL-3 (chapter 3.3.3). A) Successfully synthesized target molecule. B) Precursor of A; with the carboxylic acid 
protected with a Bn group marked in red. C) Side product of the second target molecule (Chapter 5.2.5).  
 
3.3.3. Inhibition assays with the synthesized targets 
The abovementioned molecules were investigated for inhibition using 6,8-difluoro-4-
methylumbelliferyl phosphate (DiFMUP) as a PRL-3 substrate53 Judith Weyershaeuser, a 
PhD student in the Koehn group, performed the inhibition assays. The results of the 
inhibition assays are shown in Figure 41.  
Excitingly, the first compound, 62, which was the one successfully synthesized as an 
analogue of the hit in cluster 4 (Figures 39 and 40) showed inhibitory activity of PRL-3,  
 
albeit with high concentrations (compound concentrations of 600 µM and 300 µM 
showed full inhibition of PRL-3), with an IC50 of 185 uM. The two other compounds 69 
and 70 were not biologically active, and did not show any inhibition of PRL-3. The 
interesting observation here was the activity difference between compound 62 and its 
benzyl ester 69, showing that the negative charges of the carboxylic acid are required for 
activity. As an outlook, it would be interesting to conduct structural overlay studies, to 
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account whether this carboxylic acid overlaps with the 5-or 4-phosphate group, helping 
to understand if this entity binds similarly to PRL-3 as the phosphate in the PI(4,5)P2 
substrate.  
 
Obviously, more SAR studies should be undertaken on such a compound, if it is even 
reasonable to consider it as an “optimizable” lead given the high IC50. Nevertheless, in 
spite of the challenges regarding the synthesis of the compounds, the synthesis of only 
one hit molecule gave a molecule that inhibits PRL-3, which is a remarkable result and 
demonstrates the feasibility of this approach. The inhibitor has no structural similarity 
with any previously published inhibitors27. In addition, this inhibitor can pose as 
interesting analog for more lead design ideas for generating further PI(4,5)P2 
analogues/inhibitors; and it can potentially offer new valuable information for new 
templates in shape similarity in silico assays. Additionally, 62 could be overlayed, in future 
experiments, with the natural substrate to draw information on binding, by, for instance, 
identify which phosphate is implicated in the enzymatic reaction.  
Figure 41 Results of the DiFMUP assay with the three synthesized compounds. The compound is A), B) and 
C) belong to compounds 62, 69 and 70, respectively. A) compound 62, depicted in Figure 40-A, shows 
inhibition of PRL-3 activity with a mean IC50 value of 185 µM ± 22. B) and C) each show the inhibition 
measurement for compounds 69 (Figure 40-B) and compound 70 (Figure 40-C), with no inhibition of PRL-
3. 
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Chapter 4. Conclusion and Outlook 
 
4.1. Total synthesis of novel PI(4,5)P2 analogues 
 
In this work, I have successfully established the synthetic route for the analogues 12, 18, 
28, 34, 36 and 50, which are modified PI(4,5)P2 analogues, bearing chemical 
modifications either on the inositol ring or on the lipid tail moiety. Inferring the reasons 
for issues and solving the bottlenecks in the solution synthesis, particularly the selective 
alkylations on the free, less reactive OH groups of the inositol ring, was resolved 
satisfactorily. Furthermore, the route which was tested with the synthesis of 12 validated 
the synthetic approach that was established with the rest of the compounds.  
 
The overall consideration of the established synthetic routes shows that the developed 
approach for the different reaction steps can be used to synthesize more and varied 
modified compounds in the pursuit of enlarging the existing library of PI(4,5)P2 
analogues. Moreover, these synthetic pathways can set the basis for differently modified 
analogues, such as analogues bearing modifications at the phosphate group moiety. Such 
modifications can be sulfurization instead of oxidation of the phosphate groups, inserting 
methylene phosphonates as phosphate analogues, or replacing the phosphate groups by 
cyclic compounds which could mimic the electronegative environment (examples include 
tetronic acids and carboxylic acids). The larger the library of such analogues, the easier it 
would be to combine various modifications in order to design the best potent probe 
(inhibitor/modulator).  
 
Furthermore, I applied the solid phase strategy developed by my group in order to 
synthesize analogues bearing lipid tail modifications, which illuminates the possibility of 
using different synthetic strategies depending on the alteration nature of the compound. 
This offers back-up solutions to synthetic challenges whenever a compound proves to be 
challenging to synthesize.  
 
As an outlook, these compounds could be employed to broaden the understanding of 
conditions for binding behavior of PI(4,5)P2-binding and metabolizing proteins in the cell, 
thereby providing information about their efficacy in the treatment of diseases. 
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4.2. Biochemical application of unnatural PIP analogues as phosphatase 
substrates 
 
Effectively, the six analogues synthesized as part of this work were used for SAR studies 
with PRL-3, helping to understand the structure activity relationships between PRL-3, a 
metastasis promoting phosphatase, and its recently discovered natural substrate 
PI(4,5)P2. The inositol-modified analogues have shown significant biological activity with 
PRL-3, compared to the lipid tail-modified analogues and the control PI(4,5)P2-diC8 
compound. The most active compound was the trialkylated PI(4,5)P2 28, where all the 
free hydroxyl groups were blocked, underlying the importance of the hydrophobicity 
required for better binding at PRL-3’s remarkably hydrophobic active site. The 
phosphatase activity assays would still need to be optimized with such analogues 
nevertheless, as the combination of low-activity phosphatase, labile compounds and 
kinetics other than Michaelis-Menten makes it hard to extract very clear results.  
 
In addition, the same analogues were used for SAR studies with three other PI(4,5)P2–
metabolizing phosphatases: SYNJ1, OCRL and INPP5E, aiming at deciphering the 
differences in activity of the analogues towards different phosphatases, which share the 
same natural substrate. Interestingly, the analogues that showed increased activity with 
PRL-3 did not show any significant activity with the other phosphatases, and those that 
proved to be poor substrates for PRL-3 turned out to have more significant activity with 
the other phosphatases. This sets the grounds for specificity of the inositol-ring modified 
PI(4,5)P2 analogues toward PRL-3, as the other phosphatases can accommodate more 
hydrophilic substrates due to their generally basic catalytic active site (particularly SYNJ1 
and INPP5E). The results show that these analogues, beyond being valuable tools for 
studying the activity of a specific target, can also act as specific modulators to clarify 
activity variance amongst diverse targets.  
 
4.3. Computational power: a potential for inhibitor quest 
 
The interest in developing inhibitors for oncogenic phosphatases such as PRL-3 was a 
stimulating complement in the context of this project’s chemistry, and since 
computational methods were already accessible for screening small molecules which 
could mimic a known substrate or inhibitor, I thought of using the natural substrate as a 
template to search for similar small molecules which could help add more information to 
PRL-3’s SAR studies. Using PI(4,5)P2 as a query molecule in such computational software 
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was not an easy task though because of its relatively big structure. Still, the method was 
used on the head group by our collaborators (Pedro Ballester and the CBCF), which was 
known to be the direct interactor with PRL-3’s active site, and generated a list of hits, from 
which a target molecule was successfully synthesized, bearing the diC8 lipid chains as a 
required moiety for binding. This final molecule was shown to inhibit PRL-3, albeit with 
high concentrations. This was surprisingly positive, as it could support the scientific 
reasoning behind employing a computational-experimental system as such.  
 
In summary, this sets the ground for imminent exciting approaches that can combine 
predictive computational tools, total organic synthesis of natural products analogues, and 
medicinal chemistry-oriented SAR techniques to decipher, in the most effective way, the 
intricate mechanisms of oncogenic phosphatases, potentially making them “druggable” 
despite the challenges.  
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Chapter 5. Experimental  
5.1. General: chemicals and methods 
 
All the chemicals and anhydrous solvents used were obtained from commercial suppliers 
(Sigma-Aldrich, VWR, Acros Organics). The chiral starting material D-2,3-cyclohexylidene 
myo-inositol was purchased from SiChem GmbH, Bremen, Germany. The Wang resin 
(200-400 mesh, 0.88 mmol/g) was obtained from Bachem. The resin intermediates were 
dried properly on high vaccum before subjecting to the subsequent reactions.  
 
1H, 13C and 31P nuclear magnetic Resonance (NMR) spectra were recorded on a 400 MHz 
Bruker Avance DPX. Chemical shifts (δ) are measured in ppm and coupling constants (J) 
are given in Hz. (1H and 13C chemical shifts were referenced to the solvent peaks (7.26 and 
77.0 ppm for CDCl3, 4.84 and 49.05 for CD3OD). Splitting patterns are designated as 
follows: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, brs = broad singlet, 
dd = doublet of doublet and dt = doublet of triplet. 13C and 31P spectra were broadband 
hydrogen decoupled. For 1H-assignment COSY and HMQC spectra were recorded. 
Assignment abbreviations for chemical groups: Ph = phenyl, cy = cyclohexylidene, myo = 
myo-inositol, MEM = methoxyethoxymethyl. 
 
HPLC analysis and purifications were carried out on a Shimadzu High Performance Liquid 
Chromatograph/Mass Spectrometer LCMS-2010EV with a UV/Vis Photodiode array 
detector SPD-M20A Prominence. For the analytical and semipreparative injections the 
solvent delivery module LC-20AD was used. And for the preparative injections the LC 
pump unit LC-8A was used. The analytical column was a Macherey Nagel C18 EC 250/4.0 
NUCLEODUR 100-5 C18 ec. For semipreparative separations the column was a Macherey 
Nagel C18 VP 250/10 NUCLEODUR 110-5 C18 ec and for preparative separations a 
Macherey Nagel C18 VP 250/21 NUCLEODUR 100-5 C18 ec column was used. Mass 
spectra (ESI) were recorded using a Waters Micromass ZQ mass spectrometer.  
 
High resolution mass spectra were recorded using a MaXis II Q-Tof mass spectrometer 
(Bruker Daltonics) and at the University of Heidelberg with a Bruker ApexQe hybrid 9.4 
T FT-ICR. Masses are given as m/z (% intensity).  
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ESI+-MS spectra were measured with an Agilent Infinity 1290 UPLC-MS System. An 
Acquity UPLC BEH C18 column (1.7μm; 2.1x50mm) was used at 40°C with an injected 
volume of 3 μL, a flow rate of 1mL/min and a runtime of 3 min. The solvents used were 
A.) water plus 0.1% TFA and B.) MeCN with 0.1% TFA. 
 
The MS method used was single quadrupole electrospray ionization. 
HR-MS spectra were measured on a Bruker ICR Apex-Qe with the following method: ESI 
pos HPmix 200-1800. 
 
Optical rotations values were measured at the sodium D-line in a 10 cm cell with a 
Schmidt + Haensch Polartronic H532 polarimeter at room temperature.  
 
TLC analyses were conducted on Merck precoated silica gel (Merck, 60 F254) using UV 
light (254 nm) and the following staining solutions: 
a) p-Anisaldehyde (prepared by addition of 15 mL AcOH and 3.5 mL of p-
Anisaldehyde to a 350 mL ice cold EtOH, then cautiously adding 50 mL of conc. 
H2SO4 dropwise over 60 minutes. The unused portion was stored at 0°C). 
b) Phosphomolybdic acid (prepared by dissolving 10 g of phosphomolybdic acid or 
PMA in 100 mL of absolute EtOH).  
c) Potassium permanganate (prepared by dissolving 1.5 g of KMnO4, 10 g of K2CO3, 
and 1.25 mL of a 10% NaOH solution in 200 mL of water).  
 
Preparative column chromatography was performed using silica gel from Merck, (silica 
60, grain size 0.063-0.200 mm, 70-230 mesh ASTM) or silica gel from Sigma-Aldrich 
(silica 60, 230-400 mesh). Phosphoramidites were purified on deactivated silica. Prior to 
use the silica was treated with the eluent containing 10% of dimethylethylamine. For the 
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purification 1% of dimethylethylamine was added to the eluent. Melting points were 
determined on a Büchi B-540 and are uncorrected.  
 
Automated column chromatography was performed using an Isolera™ Prime, an 
advanced automated flash purification system by Biotage. Silica cartridges (Biotage® 
SNAP KP-Sil 10 g, 25 g, 50 g and 100 g), and silica samplets (Biotage® SNAP Samplet KP-
SIL 1 g, 3 g, and 10 g) were appropriately used depending on the amount of compound to 
purify.  
Expression and purification of recombinant proteins: Wild type PRL-3 was prepared 
as previously described19 yielding pure protein in all cases. BL21 DE3 cells expressing the 
recombinant WT PRL-3 were lysed by sonication in buffer A [50 mM Tris-HCl (pH 7.4) 
containing 500 mM NaCl, 20 mM imidazole, 1 mM dithiothreitol (DTT), and 0.5 mM 
protease inhibitor cocktail]. The protein was purified using a FPLC Histrap HP 1 mL 
column using an elution gradient from 20 to 500 mM imidazole in buffer A. The purified 
PRL-3 was dialyzed against 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 5 mM DTT, and 10% 
glycerol. The integrity of all proteins was confirmed by molecular weight determination 
by electrospray ionization mass spectroscopy (ESI-MS)19. The other 3 proteins (SYNJ1, 
OCRL and INPP5E) were all purchased as purified, recombinant proteins from Origene®. 
The over-expressed recombinant proteins were purified using OriGene’s 4C5-AntiDDK 
antibody (TA50011) affinity column. The proteins were shipped on dry ice, stored at - 80° 
C and divided in several aliquots to avoid repeated freeze/thaw cycles. The purity of each 
protein was examined by SDS-PAGE electrophoresis and coomassie staining. The proteins 
were received each in a vial (20 μg in a buffer solution containing 10% Glycerol, 100 mM 
Glycine, and 25 mM Tris-HCl, pH 7.3), at concentrations of 0.319; 0.174; and 0.409 μg/μL 
for SYNJ1, OCRL and INPP5E, respectively. The material safety data sheet (MSDS) of the 
purchased products is available online: 
http://www.origene.com/support/product/msds.mspx  
 
EnzChek assay: The release of phosphate from lipid substrates was monitored using a 
commercially available phosphatase assay kit, EnzChek, according to the manufacturer's 
instructions. The EnzChek phosphatase assay kit was purchased from Molecular Probes. 
The assay was conducted in 96-well plate format and phosphate release was monitored 
by absorbance at 360 nm over time. PRL-3 (6 μM) in buffer (50 mM Tris-HCl (pH 7.5), 150 
mM NaCl, 1 mM MgCl2, and 4 mM DTT) was incubated with 250 or 500 μM of 
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phosphoinositide substrates in 96-well plates. The assay was conducted at 37 °C with 
shaking in a Tecan Safire TM plate reader. Assays in the absence of enzyme were included 
in the 96-well plate setup in triplicate for all the substrates analyzed. The measurements 
in the absence of enzyme were averaged and subtracted from the data to account for 
nonspecific hydrolysis of the substrates and for background absorption. In all assays, 
measurements were in triplicate and the standard deviation of the measurements is 
represented as error bars. Data were plotted using GraphPad Prism (GraphPad Software, 
Version 5). The protein was expressed and purified as described before19. 
 
Ligand-based virtual screening and computational analysis: To use 3D similarity, a 
reasonable 3D conformer of the template molecule (PI(4,5)P2) is necessary. Here, the 
conformation of the headgroup of a PIP structure was selected from a co-crystallised 
protein-ligand complex which is deposited in the Protein database 
[www.ebi.ac.uk/pdbe/]: Crystal structure of PI3Kalpha in complex with PIP2-pdbcode 
4ovv. This headgroup shows a chair conformation. In order to mimic the attached 
lipophilic tail, an ethyl moeity was added on the 1-O-Phosphorus group (instead of the 
DiC8 glycerol-based lipid chains). The structures to be screened  were downloaded from 
the ZINC database (http://zinc.docking.org/substance/). USRCAT, a pharmacophoric 
extension of USR, was used to screen a single-conformer database with over 23 million 
purchasable molecules. 
 
UFSRAT is available as a web-server (http://opus.bch.ed.ac.uk/ufsrat/)and thus it 
screened a different multi-conformer database of commercially available molecules. 
UFSRAT returns the top 200 molecules in a couple of seconds. The similarity threshold 
(USR score) which was used was 0.7. in the end. 388 compounds were exported as 
structures from the ZINC database, and duplicates (same compound, different vendor) 
were removed, which left 129 compounds. The assignment into families based on 2D 
similarities resulted in 14 clusters and 4 singletons. In order to prioritize the most 
interesting hit compounds they were aligned with another 3D-similarity program which 
is called Surflex-Sim138. In this method, the compounds are aligned on the template and a 
visual analysis is possible. Based on such a visual analysis of the alignments and taking 
into consideration that the final compounds to be synthesized must also contain a big 
lipophilic group, a series of hit structures were selected. 
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Using a manual chemical synthesis-driven method, a selection of the “best” representative 
of a cluster was made, and a series of compounds were selected for synthesis and 
biochemical activity screening. 
 
DiFMUP assay: Phosphatase inhibition was generally carried out using DiFMUP (6,8-
difluoro-4-methylumbelliferyl phosphate) as substrate. PRL -3 enzyme was used at 50 nM 
concentration in assay buffer (20 mM Tris-HCl 7.5; 150 mM NaCl; 10 mM DTT; 0,01% 
Triton-X) and incubated for at least 10 minutes prior to addition of substrate in order to 
ensure full activity due to the presence of high amounts of DTT in the buffer. Reactions 
were performed in 96-well plates from Perkin Elmer (OptiPlate, black). Inhibition kinetics 
were obtained with substrate concentrations at the respective Km value of the respective 
enzyme (for PRL-3 21 μM). For Km determination of phosphatases, reaction kinetics were 
monitored at 358/452 nm for 20 minutes on a multiwell plate reader after addition of 
substrate concentration series. Initial velocities of the obtained data curves were plotted 
against substrate concentration and data were fit for Michaelis-Menten parameters using 
GraphPad Prism software. The kinetics of inhibitor concentration series from 600 µM 
down to 1.17 µM were measured at 358/452 nm for 20 minutes on a multiwell plate 
reader after addition of substrate and corrected for the respective inhibitor baseline. IC50 
data were obtained by plotting initial velocities versus inhibitor concentration 
(logarithmic scale) using GraphPad Prism software. The positive control for this assay 
was the purchased Analog 3 with an IC50 of 31uM53. 
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5.2. Synthetic procedures and analytical data 
5.2.1. Solution synthesis of the lipid tail phosphoramidites 
 
Benzyl (3-phenylpropyl) diisopropylphosphoramidite (38) 
 
 
To a mixture of bis(diisopropylamino)chlorophosphine (1 g, 3.75 mmol) in 25 ml of 
diethyl ether was added diisopropylethylamine (1.96 ml, 11.2 mmol) at 0 °C, followed by 
dropwise addition of benzyl alcohol (311 µl, 3.00 mmol). After stirring for 30 min the 
solvent was evaporated and the residue treated with cyclohexane. The cyclohexane 
fraction was filtered through a filter canula into another schlenk flask and then 
evaporated. The residue was dried overnight in high vacuum. Then DIPA*DCI (411 mg, 
1.88 mmol) in 8 mL of dichloromethane was added and the resulting solution cooled to 0 
°C. Then, a solution of 3-phenyl-propanol (408 µl, 3.00 mmol) in 2 ml dichloromethane 
was added and the reaction mixture stirred for 40 min at 0 °C. After 31P NMR shows full 
conversion, the solvent was evaporated, the residue suspended in cyclohexane/NEtMe2 
(99:1) and subjected to inert column chromatography (cyclohexane/NEtMe2 (99:1)). 
Product fractions were combined and dried in high vacuum to yield the product as a pale 
yellow oil (145 mg, 33%).  
 
 
 
1H NMR (400 MHz, CDCl3) δ (ppm) = 7.30 – 7.09 (m, 10 H), 4.74 – 4.57 (m, 2 H), 3.68 – 
3.53 (m, 4H), 2.64 (pseudo t, 2H), 1.86 (m, 2 H), 1.49 (d, 1H), 1.35 (s, 1H), 1.13 (m, 12 H).   
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13C NMR (400 MHz, CDCl3) δ (ppm) = 142.1, 139.6 (d, J = 7 Hz), 128.5, 128.3, 128.2, 127.2, 
127.0, 125.7, 66.2 (d, J = 18 Hz), 62.9 (d, J = 18 Hz), 43.0 (d, J = 12 Hz), 33.0 (d, J = 8 Hz), 
32.3, 24.7 (d, J = 7 Hz). 
  
31P NMR (162 MHz, CDCl3): δ (ppm) = 146.6 (1P) 
 
1,2-di-O-heptylcarbamoyl-sn-3-benzyloxyglycerol (39) 
 
To (+)-benzyloxyglycerol (1.43 g, 4.42 mmol) in a round bottom flask was added 
heptylisocyanate (5.7 ml, 35.4 mmol) and trimethylamine (800 µL, 4.59 mmol) the 
reaction was stirred for 5 days at room temperature. The reaction was then concentrated 
and subjected to a column chromatography (n-heptane/ethylacetate = 68/32) to afford 
the product as a white solid (1.45 g, 71%). 
 
1H NMR (400 MHz, CDCl3) δ (ppm) = 7.34 – 7.14 (m, 5H, Ar-H), 5.14 – 4.91 (bs, 1H, NH), 
4.61 (s, 1H, H-2’), 4.47 (q, J = 12.1 Hz, 2H, H-1’), 4.25 – 4.11 (m, 2H, H-3’), 3.53 (d, J = 4.9 
Hz, 2H, H-1), 3.18 – 2.99 (m, 4H, H-2), 1.41 (q, J = 5.4 Hz, 2H, H-3), 1.21 (q, J = 4.3 Hz, 14H, 
H-3, H-4, H-5, H-6), 0.81 (t, J = 6.7 Hz, 6H, H-7). 
13C NMR (400 MHz, CDCl3) δ (ppm) = 156.1, 155.7, 137.9, 138.4, 127.7, 127.7, 77.2, 73.3, 
71.1, 68.7, 63.6, 41.1, 31.8, 29.9, 29.9, 29.0, 26.7, 22.6, 14.1  
HRMS (MALDI+): m/z neg.: [M+Na]+  calculated 487.3147, found 487.3142–0.9 ppm 
[α]D 20 = +6.42 (c 1 mg/mL, MeOH) 
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1,2-di-O-heptylcarbamoyl-sn-glycerol (40)  
 
A mixture of 39 (1.45 g, 3.12 mmol) and 20 wt% Pd(OH)2/C (66 mg, 0.09 mmol) in 40 ml 
methanol was stirred under H2 atmosphere for 12 h at room temperature. The reaction 
was filtered through a Celite pad and the filtrate was concentrated in vacuum to obtain 
40 as a white foam (1.12 g, 96%). 
 
1H NMR (400 MHz, CDCl3) δ (ppm) = 4.82 (p, J = 5.3 Hz, 3H, H-1’, H-2’), 4.21 (dt, J = 5.2 Hz, 
2H, H-3’), 3.62 (d, J = 5.0 Hz, 2H, NH), 3.10 (q, J = 6.7 Hz, 4H, H-1), 1.42 (p, J = 7.0 Hz, 4H, 
H-2), 1.31 – 1.07 (m, 16H, H-3,4,5,6), 0.93 – 0.73 (m, 6H, H-7). 
13C NMR (400 MHz, CDCl3) δ (ppm) = 156.6, 156.0, 77.2, 73.2, 62.6, 61.5, 41.2, 31.7, 29.9, 
28.9, 28.9, 26.7, 26.7, 22.6, 14.1 
HRMS(ESI+): m/z neg.: [M+Na]+  calculated 397.2676, found 397.2673 – 0.9 ppm 
[α]D 20 = (+) 4.55 (c = 1 mg/mL, MeOH)  
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(2R)-3-(((benzyloxy)(diisopropylamino)phosphanyl)oxy)propane-1,2-diyl 
bis(heptylcarbamate) (41) 
 
 
To a mixture of bis(diisopropylamino)chlorophosphine (1 g, 3.75 mmol) in 25 ml of 
diethyl ether was added diisopropylethylamine (1.96 ml, 11.2 mmol) at 0 °C, followed by 
dropwise addition of benzyl alcohol (311 µl, 3.00 mmol). After stirring for 30 min the 
solvent was evaporated and the residue treated with cyclohexane. The cyclohexane 
fraction was filtered through a filter canula into another schlenk flask and then 
evaporated. The residue was dried overnight in high vacuum. Then DIPA*DCI (411 mg, 
1.88 mmol) in 8 mL of dichloromethane was added and the resulting solution cooled to 0 
°C. Then, a solution of 1,2-di-O-heptylcarbamoyl-sn-glycerol (1.12 g, 3.0 mmol) in 2 ml 
dichloromethane was added and the reaction mixture stirred for 40 min at 0 °C. After 31P 
NMR shows full conversion, the solvent was evaporated, the residue suspended in 
cyclohexane/NEtMe2 (99:1) and subjected to inert column chromatography 
(cyclohexane/NEtMe2 (99:1)). Product fractions were combined and dried in high 
vacuum to yield the product as pale yellow oil (462 mg, 20%).   
 
1H NMR (400 MHz, CDCl3) δ (ppm) = 0.81 (t, 3H), 1.11 (t, 3H), 1.20 (br s, 8H), 1.35 (t, 6H), 
3.08 (m, 8H), 3.57 (m, 4H), 3.71 (m, 4H), 4.15 (m, 4H), 4.59 (m, 7 H), 4.98 (s, 2H), 7.17 – 
7.29 (m, 5H) 
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13C NMR (400 MHz, CDCl3) δ (ppm) = 156.1, 155.6, 139.5 (d, J = 8 Hz), 139.4 (d, J = 7 Hz), 
128.2, 127.3, 127.0, 71.8, 66.5, 66.3, 63.5, 62.1, 62.0, 43.1, 41.1, 31.8, 30.0, 29.0, 26.9, 26.7, 
24.6, 22.6, 14.1  
31P NMR (400 MHz, CDCl3) δ (ppm) = 148.42 and 148.48 (1P, diastereomers) 
(S)-3-(benzyloxy)propane-1,2-diyl(3S,3'S,5S,5'S,7S,7'S)-bis(adamantane-1-
carboxylate) (42) 
 
 
To a stirred solution of diol 1 (500 mg, 2.13mmol, 1 equiv.) in dry dichloromethane 
(10mL) under nitrogen was added 4-dimethylaminopyridine (33 mg, 0.27 mmol, 
catalytic). The resulting solution was cooled to 08C and dry pyridine (508 mg, 0.524mL, 
6.40 mmol, 3 equiv.) was added dropwise. After stirring for 30 min, adamantancarbonyl 
chloride (1.12 g, 5.88 mmol, 3 equiv.) was added dropwise. The reaction mixture was then 
warmed up to room temperature and heated at 658C overnight. The reaction was 
quenched, once no starting material remained by TLC, by addition of water (30mL) and 
the aqueous phase was extracted with dichloromethane (4 x 30 mL). The combined 
organic layers were washed with 2M aqueous hydrochloric acid (30mL) and the acid 
phase was back-extracted with dichloromethane (30mL). The combined organic layers 
werewashed with brine (35mL), dried overMgSO4, filtered, and the solvent was removed 
under vacuum. Flash chromatography (10–20%ethyl acetate/petroleum spirit v/v) 
afforded the diester 3 (983mg, 1.83mmol, 86%) as a colourless solid. 
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1H NMR (400 MHz, CDCl3) δ (ppm) = 7.42 – 7.16 (m, 5H, Ar-H), 5.24 – 5.19 (m, 1H, H-2’), 
4.54 (s, 2H, H-1’), 4.34 (dd, J = 3.8 Hz, 1H, H-3’), 4.15 (dd, J = 6.3 Hz, 1H, H-3’), 3.58 (dd, J = 
1.3 Hz, 2H, Ad-H), 2.02 (ddq, J = 3.2 Hz, 7H), 1.87 (dd, J = 2.9 Hz, 12H), 1.76 – 1.64 (m, 8H), 
1.31 – 1.21 (m, 4H), 0.95 – 0.84 (m, 2H). 
13C NMR (400 MHz, CDCl3) δ (ppm) = 177.3, 176.9, 159.5, 130.1, 129.5, 114.0, 73.1, 70.0, 
68.1, 62.7, 55.4, 40.9, 39.0, 39.0, 36.7, 36.7, 28.1, 28.1.  
[α]D 20 = (+) 7.38 (c = 0.5, CHCl3) 
HRMS (ESI+) m/z meas. 559.3030; calc. for C33H44O6 [M+Na]+ 559.3030. 
Characterization data of the compound was consistent with previously published work125 
 
(S)-3-hydroxypropane-1,2-diyl(3S,3'S,5S,5'S,7S,7'S)-bis(adamantane-1-
carboxylate) (43) 
 
 
A mixture of 42 (1265 mg, 2.498 mmol) and 20 wt% Pd(OH)2/C (87.7 mg, 0.124 mmol, 
0.05 eq) in 38 ml glacial acetic acid was stirred under H2 atmosphere for 12 h at room 
temperature. The reaction was filtered through a Celite pad and the filtrate was 
concentrated in vacuum to obtain 43 as a white foam (1000 mg, 96%). 
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Rf 0.26 (20% EtOAc:heptane). 
1H NMR (400 MHz, CDCl3) δ (ppm) = 5.07–5.03 (m, 5H, Ar-H), 4.30 (dd, J = 12 Hz, 5, 1H), 
4.20 (dd, J = 6 Hz, 2H, H-3’), 3.71 (d, J = 5 Hz, 2H, H-1’), 2.04–1.98 (m, 6H), 1.89 (dd, J = 3 
Hz, 12H), 1.76– 1.66 (m, 12H).  
13C NMR (400 MHz, CDCl3) δ (ppm) = 71.9, 61.8, 61.7, 40.8, 40.8, 38.8, 38.8, 36.4, 27.8. 
[α]D 20 = (-)1.82 (c 2.0, CHCl3) 
HRMS (ESI+) m/z meas. 439.2455; calc. for C25H36O5 [M+Na]+ 439.2455. 
Characterization data of the compound was consistent with previously published work125 
 
(2R)-3-(((benzyloxy)(diisopropylamino)phosphanyl)oxy)propane-1,2-diyl 
(3R,3'R,5R,5'R,7R,7'R)-bis(adamantane-1-carboxylate) (44) 
 
To a mixture of bis(diisopropylamino)chlorophosphine (800 mg, 3 mmol, 1 eq) in 25 ml 
of diethyl ether was added diisopropylethylamine (1.5 ml, 9 mmol, 3 eq) at 0 °C, followed 
by dropwise addition of benzyl alcohol (249.55 µl, 2.4 mmol, 0.8 eq). After stirring for 30 
min the solvent was evaporated and the residue treated with cyclohexane. The 
cyclohexane fraction was filtered through a filter canula into another schlenk flask and 
then evaporated. The residue was dried overnight in high vacuum. Then DIPA*DCI (328.5 
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mg, 1.5 mmol, 0.5 eq) in 8 mL of dichloromethane was added and the resulting solution 
cooled to 0 °C. Then, a solution of 43 (1000 mg, 2.4 mmol, 0.8 eq) in 2 ml dichloromethane 
was added and the reaction mixture stirred for 40 min at 0 °C. After 31P NMR shows full 
conversion, the solvent was evaporated, the residue suspended in cyclohexane/NEtMe2 
(99:1) and subjected to inert column chromatography (cyclohexane/NEtMe2 (99:1)). 
Product fractions were combined and dried in high vacuum to yield the product as pale 
yellow oil (20%). 
 
Rf 0.9 (30% EtOAc:heptane) 
1H NMR (400 MHz, CDCl3) δ (ppm) = 7.42–7.30 (m, 5H), 5.18–5.12 (m, 1H), 4.76–4.59 (m, 
2H), 4.35–4.30 (m, 1H), 4.16–4.10 (m, 1H), 3.82–3.60 (m, 4H), 2.00 (s, 6H), 1.88–1.86 (m, 
12H), 1.73–1.66 (m, 12H), 1.22–1.15 (m, 12H).  
13C NMR (400 MHz, CDCl3) δ (ppm) = 177.3, 176.9, 128.4, 127.4, 127.1, 70.8, 70.7, 65.6, 
65.5, 65.4, 62.6, 62.5, 62.1, 61.9, 46.4, 43.3, 43.2, 40.9, 39.0, 36.7, 28.1, 24.9, 24.8, 24.7, 
11.8.  
31P NMR (400 MHz, CDCl3) δ (ppm) = 149.6, 149.5.  
HRMS (ESI+) meas. m/z 676.3736; calc. for C38H56N1O6P [M+Na]+ 676.3738. 
Characterization data of the compound was consistent with previously published work125 
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(S)-3-(benzyloxy)propane-1,2-diyl dioctanoate (45) 
 
 To a stirred solution of diol (1000 mg, 5.48 mmol, 1 eq) in dry pyridine (50 mL) under 
nitrogen was added 4-dimethylaminopyridine (33 mg, 0.27 mmol, catalytic). After 
stirring for 30 min, di-octanoyl chloride (1800 mg g, 11.5 mmol, 2.1 equiv.) was added 
dropwise. The reaction mixture was left stirring overnight. The reaction was stopped, 
once no starting material remained by TLC, by removal of pyridine under reduced 
pressure, dissolving in EtOAc and citric acid, and extracting EtOAc (4 x 30 mL). The 
combined organic layers were washed with water, then brine, dried overMgSO4, filtered, 
and the solvent was removed under vacuum. Flash chromatography (10–20% 
EtOAc/heptane) afforded the diester 45 (74%) as a colourless solid. 
 
 
 
Characterization data of the compound was consistent with previously published work120 
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(S)-3-hydroxypropane-1,2-diyl dioctanoate (46) 
 
In a flask under Ar atmosphere 45 (1.278 g, 2.99 mmol, 1 eq) was dissolved in 35 mL 
of dry MeOH and the Pd(OH)2/C catalyst (100 mg, 0.147 mmol, 0.05 mol%) was 
added. Under stirring, the flask was flooded with H2- Gas (1 atm) and left to stir for 20 
h. After the reaction was finished, the reaction mixture was filtered through Celite and 
was washed three times with DCM. The solvent of the filtrate was evaporated under 
reduced pressure, which gave a crude with a quantitative yield of 1.022 g (2.96 mmol, 
99 %). The crude product was used without further purification. 
 
1H-NMR (400.13 MHz, CDCl3) δ (ppm) = 5.12 - 5.05 (m, 1H, H-2), 4.36 - 4.20 (m, 2H, H-1), 
3.77 - 3.67 (m, 2H, H-3), 2.48 - 2.28 (m, 4H, H-4), 1.95 (s, 1H, OH), 1.61 (dt, J = 17.5 Hz, 7.2 
Hz, 4H, H-5), 1.37 - 1.21 (m, 16H, H-6, H-7, H-8, H-9), 0.88 (t, J = 6.9 Hz, 6H, H-10).  
13C-NMR (100.92 MHz, CDCl3) δ (ppm) = 174.1, 173.8 (C=0, 2C), 72.5 (CH, 1C, C-2), 62.4 
(CH2, 1C, C-3), 61.9 (CH2, 1C, C-1), 34.6, 34.5 (CH2. 2C, C-4), 32.0, 29.4, 29.3 (CH2. 4C, C-
6, C-7), 25.3, 25.2 (CH2.2C, C- 5), 23.0, 22.9, 21.4 (CH2, 4C, C-8, C-9), 14.4 (CH3, 2C, C-10). 
HRMS (ESI+) m/z Meas. 345.3; Calc. for C19H37O5 [M+H]+ 345.3. 
Characterization data of the compound was consistent with previously published work120 
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(2R)-3-(((benzyloxy)(diisopropylamino)phosphanyl)oxy)propane-1,2-diyl 
dioctanoate (47) 
 
After suspending the starting material (528 mg, 1.97 mmol, 1 eq) in 15 mL of Et2O in 
a flask under Ar atmosphere and cooling the solution to 0°C, a mixture of BnOH (192 
mg, 1.77 mmol, 0.9 eq) and DIPEA (509 g, 3.94 mmol, 2.0 eq) in 10 mL Et2O was added 
dropwise. The reaction was finished after 30 min stirring as determined by 31P NMR. 
The solvent was evaporated and the precipitate dissolved in 8 mL cyclohexane. The 
solution was filtered under Ar and the solvent of the supernatant was evaporated 
before the product was dried under high vacuum. The yield of the crude product was 
85% (593 mg, 1.75 mmol) with an 85% purity according to 31P NMR. The crude 
product was used without further purification. In a flask under Ar atmosphere, the 
product (1.700 g, 5.027 mmol, 1.8 eq) was dissolved in 20 mL DCM and under stirring 
DCI*DIPA was added. The reaction solution was cooled to 0°C and 46, dissolved in 10 
mL DCM, was added dropwise. The reaction mixture was monitored by 31P NMR. After 
30 min the reaction was complete and the solvent was evaporated under reduced 
pressure. Purification of the crude was achieved with column chromatography (50 g 
SiO2, cyclohexane/Me2Net 95: 5). The product is a colorless liquid and could be 
isolated in a yield of 65%. 
 
31P-NMR (400.13 MHz, DCM locked on deuterated DMSO) δ (ppm) = 148.2 (s, 0.5P), 148.0 
(s, 0.5P). 
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Characterization data of the compound was consistent with previously published work120 
 
5.2.2. Solution synthesis of the alkylated inositol ring 
1-O-t-Butyldiphenylsilyl-2,3-O-cyclohexylidene-myo-inositol (2) 
 
To the solution of tetrol 1 (1 g, 3.84 mmol, 1 eq) and imidazole (587.5 mg, 8.64 mmol, 2.25 
equiv.) in pyridine (25 mL) at -10°C was added TBDPS-Cl (1.58g, 5.77mmol, 1.5 equiv.). 
The reaction mixture was stirred at RT for 24 hrs. After completion the reaction was 
subjected to aqueous work-up. Extraction with ethyl acetate gave the crude product, 
which was purified with column chromatography (4% MeOH in DCM) giving pure product 
(1.27g, 2.5 mmol, 66%) as white foam.  
 
 
1H-NMR (400 MHz, CDCl3) δ 7.79-7.76 (m, 2H), 7.73-7.71 (m, 2H), 7.45-7.26 (m, 6H), 3.91-
3.87 (m, 2H), 3.74-3.64 (m, 2H), 3.64-3.59 (m, 1H), 3.12 (t, J = 9.69 Hz, 1H), 3.03 (brs, 1H), 
2.88 (brs, 1H), 2.57 (brs, 1H), 1.75-1.66 (m, 5H), 1.52-1.40 (m, 5H), 1.32 (m, 1H), 1.10 (s, 
9H, 3xCH3-TBDPS) 
 
13C-NMR (100 MHz, CDCl3) δ 135.94, 133.7, 133.1, 130.11, 130.00, 127.66, 127.5, 78.28, 
77.33, 77.01, 76.70, 75.70, 72.82, 38.2, 34.93, 26.97, 25.00, 24.01, 23.75, 19.5 
 
[α]D 20 = -19.4° (c = 1.0 mg/mL in CH3Cl) 
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Characterization data of the compound was consistent with previously published work120 
 
1-O-t-Butyldiphenylsilyl-2,3-O-cyclohexylidene- 4,5-O-dibenzoyl-myo-inositol (3) 
 
The solution of triol 2 (2.6 g, 5.22 mmol, 1 equiv.) in pyridine (27 mL) was cooled down 
to -40ºC. A solution of BzCl (605 μL, 5.22 mmol, 1 equiv.) in CH3Cl (27 mL) was added 
dropwise to the mixture. The system was stirred at this temperature for 1h. The reaction 
was then quenched with citric acid and extracted with ethyl acetate. The product was 
purified on a Biotage column at a constant concentration of EtOAc (25%) in heptane.  
 
1H-NMR (400 MHz, CDCl3) δ 7.95-7.91 (d, 2H, Ar-H), 7.88-7.86 (d, 2H, Ar-H), 7.84- 7.82 (d, 
2H, Ar-H), 7.73-7.71 (d, 2H, Ar-H), 7.48-7.28 (m, 12H, Ar-H), 5.83 (t, 1H, CH-4-myo), 5.1-
5.05 (t, 1H, CH-5- myo), 4.24-4.20 (t, 1H, CH-6-myo), 4.15-4.10 (m, 2H, CH-2-myo, CH-3-
myo), 4.06-4.00 (dd, J = 8.7 Hz, 1H, CH-1-myo), 2.5 (bs, 1H, 6-OH), 2.03-1.25 (m, 10H, cy), 
1.15 (s, 9H, CH3-TBDPS). 
13C NMR (101 MHz, CDCl3) δ 166.42, 165.56, 136.06, 135.91, 134.81, 133.29, 133.15, 
133.03, 132.94, 130.11, 129.84, 129.62, 129.34, 128.28, 128.20, 127.94, 111.23, 77.35, 
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77.04, 76.72, 75.75, 75.35, 74.43, 73.79, 72.18, 37.46, 34.63, 31.89, 29.03, 27.01, 25.07, 
23.79, 19.46, 14.12. 
Characterization data of the compound was consistent with previously published work120 
1-O-t-Butyldiphenylsilyl-2,3-O-cyclohexylidene- 4,6-O-dibenzoyl-5-O-methyl-myo-
inositol (4) 
 
 
 
To a solution of compound 3 (300 mg, 0.424 mmol) in anhydrous DME (12 ml), NaH (10 
eq, 4.24 mmol, 169.8 mg) was carefully added, then the reaction was treated with methyl 
iodide (131.97 µl, 5 eq, 2.12 mmol). The reaction was allowed to stir at room temperature 
for 2.5 hours, during which monitoring for the product using UPLCMS was undergone. 
The product was purified by flash chromatography in a 10 to 90% EtOAc gradient in 
Heptane.   
To allow better and more simplified structure elucidation NMR studies of the 
abovementioned compound, a cleavage of the cyclohexylidene ketal was undergone first. 
2D NMR studies were attempted on compound 4, but the cyclohexylidene ketal protons 
have crowded the spectra in a way that it was very difficult to analyze the other protons 
(data not shown). The product was purified by flash chromatography in a 23% to 32% 
EtOAc gradient in Heptane (gradient optimized according to Rfs). 
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Compound 4 (74 mg) was dissolved in a solution of 65% formic acid in methanol, and the 
reaction was allowed to stir for 72 hours. It was quenched with NaHCO3 and extracted 
with EtOAc. The product was purified by flash column chromatography using an EtOAc 
gradient of 23% to 32% in heptane. The product was monitored on UPLCMS with the 
corrected mass.  
 
1H-NMR (400 MHz, CDCl3) δ 8.03-8.01(m, 2H, Ar-H), 7.94-7.93 (m, 2H, Ar-H), 7.66-7.64 
(m, 2H, Ar-H), 7.55-7.53 (m, 4H, Ar-H), 7.43-7.31 (m, 8H, Ar-H), 7.25-7.19 (m, 2H, Ar-H), 
5.84 (t, J = 9.52 Hz, 1H, CH-4-myo), 5.61 (t, J = 9.68 Hz, 1H, CH-6-myo), 3.94-3.89 (m, 2H, 
CH-2-myo, CH-3-myo), 3.53-3.43 (m, 2H, CH-1-myo, CH-5-myo), 3.31 (s, 3H, methyl), 2.78 
(m, 1H, OH),2.75 (m, 1H, OH), 0.96 (s, 9H, CH3-TBDPS). 
13C-NMR (100 MHz, CDCl3) δ 166.9, 165.9, 135.8, 135.6, 133.4, 133.1, 133.0, 132.13, 130.3, 
130.1, 129.83, 129.7, 129.2, 128.37, 128.25, 128.18, 127.9, 97.8, 78.2, 74.5, 74.1, 72.3, 
71.8, 71.0, 70.6, 67.6, 58.7, 27.0, 26.9, 19.11 
HRMS (ESI+): m/z meas. 663.2400; calc. for C39H39O8Si [M+Na]+ = 663.2409; 1.3 ppm 
[α]D 20 = only racemate is available 
 
111 
1-O-t-Butyldiphenylsilyl-2,3-O-cyclohexylidene- 4,5-O-dibenzoyl-6-O-methyl-myo-
inositol (6) 
 
A solution of compound 3 (750 mg, 1.06 mmol) in anhydrous DCM (20 ml) was cooled 
down to 0° C. Proton Sponge (1249.4 mg, 5.83 mmol, 5.5 eq) was added, followed by 
trimethyl oxonium tetrafluoroborate (827.6 mg, 5.6 mmol). The reaction was left stirring 
at RT overnight. Monitoring for the product was done using TLC (3:7 EtOAc: Heptane) and 
UPLCMS. The product was purified by flash chromatography in an isocratic solvent 
system (54% EtOAc in Heptane).  
 
1H-NMR (400 MHz, CDCl3) δ 7.98-7.93 (m, 6H, Ar-H), 7.88-7.77 (m, 2H, Ar-H), 7.54- 7.28 
(m, 12H, Ar-H), 5.98 (t, 1H, CH-4-myo), 5.22-5.18 (dd, J = 9.7 Hz, 1H, CH- 5- myo), 4.35-
4.32 (dd, J = 7.8 Hz, 1H, CH-1-myo), 4.15-4.12 (m, 2H, CH-6-myo, CH-3- myo), 4.01 (brs, 
1H, CH-2-myo), 3.27 (s, 3H, H-CH3), 1.99 (m, 1H, cy), 1.84 (m, 1H, cy), 1.74 (m, 2H, cy), 
1.52-1.31 (m, 6H, cy), 1.20 (s, 9H, CH3-TBDPS) 
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13C-NMR (100 MHz, CDCl3) δ 165.8, 165.5, 136.1, 135.8, 133.5, 133.3, 133.0, 132.8, 129.9, 
129.8, 129.7, 129.6, 128.2, 128.1, 127.8, 127.5, 96.7, 75.1, 74.8, 74.2, 71.2, 67.4, 58.8, 37.2, 
34.3, 27.0, 26.9, 25.0, 23.9, 23.8, 19.3 
Rf: 0.63 (in 1:1 heptane:EtOAc) 
[α]D 20 = (-) 7.25 (c = 5mg/mL in CHCl3) 
HRMS (ESI)+ m/z meas. 743.3013; calc. for C43H48O8Si [M+Na]+ 743.3011 -0.4 ppm. 
 (1R,2R,3R,4R,5R,6S)-4-((tert-butyldiphenylsilyl)oxy)-5,6-dihydroxy-3-
methoxycyclohexane-1,2-diyl dibenzoate (7) - Cleavage of the cyclohexylidene 
acetal in compound 6 
 
638 mg of crude compound (6) were dissolved in 10 ml of a TFA solution in water (98:2 
TFA:H2O) and the reaction was stirred (swirled) for 10 minutes. Minute amounts of 
ethylene glycol were added as a scavenger to prevent the starting material from 
reforming upon evaporation of TFA. The reaction was monitored using TLC (1:1 
Heptane:EtOAc) and UPLCMS. When the reaction was deemed finished, TFA was then 
evaporated, then co-evaporated with ethanol (4 times) to get rid of the acid as much as 
possible. The crude was dissolved in NaCO3 to quench any residual acid, and extracted 
with DCM (4 times). The organic layers, after being inspected for the presence of the 
product as opposed to the aqueous layers, were combined, washed with water then brine, 
then dried over sodium sulfate and filtered. The product was purified through flash 
chromatography in a 1:1 EtOAc/heptane solvent system.  
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1H-NMR (400 MHz, CDCl3) δ 7.90- 7.79 (dd, 4H, Ar-H), 7.69- 7.62 (dd, 4H, Ar-H), 7.44-7.22 
(m, 12H, Ar-H), 5.58-5.53 (t, J = 9.9 Hz, 1H, myo-H), 5.32- 5.27 (t, J= 9.7 Hz, 1H, myo-H), 
4.41- 4.39 (m, 1H, myo-H), 3.89-3.83 (m, 1H, myo-H), 3.65 (t, J = 2.8 Hz, 1H, myo-H), 3.44 
(dd, J = 9.9 Hz, 2.9 Hz, 1H, myo-H), 3.35 (s, 3H, methoxy), 1.05 (s, 9H, (CH3)3). 
13C-NMR (100 MHz, CDCl3) δ 167.08, 165.72, 135.98, 135.69, 133.47, 133.18, 133.15, 
132.51, 130.22, 130.03, 129.83, 129.80, 129.69, 129.50, 129.24, 128.39, 128.27, 128.12, 
128.01, 127.78, 81.37, 77.36, 77.24, 77.04, 76.72, 73.87, 73.61, 72.99, 72.45, 70.75, 69.12, 
64.14, 61.28, 60.16, 27.02, 19.41. 
[α]D 20 = - 8.7745455 
HRMS (ESI)+ m/z meas. 663.2391; calc. for C37H40O8Si [M+Na]+ 663.2385 -0.9 ppm. 
1-O-t-Butyldiphenylsilyl-2, 3-O-cyclohexylidene-6-O-methyl-myo-inositol (8) 
 
Compound 7 (156.5 mg, 0.217 mmol) was dissolved in anhydrous THF (10 mL), and the 
reaction mixture was allowed to stir at 0°C. NaOMe (2.5 eq) was added dropwise, and the 
reaction was taken up to room temperature 5 minutes later. 30 minutes later, the reaction 
was stopped, quenched with citric acid, and extracted with EtOAc 4 times. The aqueous 
layers were washed with water, brine, dried over sodium sulfate and filtered. The crude 
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was purified on flash chromatography in a 36% to 99% EtOAc gradient in DCM, with a 
yield of 75%.  
 
 
 
1H-NMR (400 MHz, CDCl3) δ (ppm) 7.78 (t, J = 7.6 Hz, 4H, Ar-H), 7.47 - 7.32 (m, 6H, Ar-H), 
3.94 (md, J = 8.7 Hz, 1H, myo-H-1), 3.72 (t, J = 7.9 Hz, 2H, myo-H-2, myo-H-4), 3.65 (d, J = 
6.3 Hz, 1H, myo-H-3), 3.62 (s, 3H, H-13), 3.44 (t, J = 8.7 Hz, 1H, myo-H-6), 3.17 (t, J = 9.4 
Hz, 1H, myo-H-5), 2.36 (br.s, 2H, OH), 1.80 - 1.63 (m, 4H, H-8, H-12), 1.56 - 1.43 (m, 3H, H-
9, H-11), 1.36 - 1.26 (m, 3H, H-10, H-11), 1.12 (s, 9H, C(CH3)3). 
13C-NMR (100 MHz, CDCl3) δ (ppm) 136.4, 136.3 (CH, 4C, Ar-C), 134.5, 133.7 (Cq, 2C, Ar-
C), 130.2, 128.1, 127.9 (CH, 6C, Ar-C), 111.3 (Cq, 1C, C-7), 83.3 (CH, 1C, myo-C-6), 78.3 (CH, 
1C, myo-C-3), 76.0 (CH, 1C, myo-C-2), 75.8 (CH, 1C, myo-C-4), 73.8 (CH, 1C, myo-C-5), 72.5 
(CH, 1C, myo-C-1), 61.6 (CH3, 1C, C-13), 38. 5 (CH2, 1C, C-12), 35.0 (CH2, 1C, C-8), 27.4 (CH3, 
3C, C(CH3)3), 25.4 (CH2, 1C, C-10), 24.4 (CH2, 1C, C-11), 24.1 (CH2, 1C, C-9), 19.7 (Cq, 1C, 
C(CH3)3). 
[α]D 20 = - 11.7892 
HRMS (ESI)+ m/z meas. 535.2489; calc. for C29H40O6Si [M+Na]+ 535.2486 -0.5 ppm 
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1-O-t-Butyldiphenylsilyl-2,3-O-cycloxexylidene-4,5-di-O-dibenzylphosphoryl-6-O-
methyl-myo-inositol 
 
Compound 8 (230mg, 0.45 mmol) was dissolved in anhydrous DCM (20 ml and allowed 
to stir for a few minutes before adding 1H-tetrazole (0.45 M in ACN, 6mL, 2.7 mmol, 6 eq). 
The phosphoramidite (464.8 mg, 1.34 mmol, 3 eq) was immediately added in anhydrous 
acetonitrile (2.2 ml). The reaction was allowed to stir for 2 hours. The reaction was cooled 
down to -40 ° C, followed by the addition of mcpba (77% w/w, 7.6 mmol, 1255µL) and 
was allowed to stir for one more hour.  
The reaction was quenched with NaCO3- and extracted with DCM (200 ml). The organic 
layer was washed three more times with NaCO3- , then with water and brine, and 
condensed to give oil (pale color). The crude was purified using a 100 g silica biotage 
column, in a gradient from 56% to 60% EtOAc in heptane. Sample loading on the column 
was done twice, as the total mass of the crude (1267 mg) had to be divided in two for 
column loading limit (with respect to the Rfs differences on TLC). 
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1H-NMR (400 MHz, CDCl3) δ 7.81 (d, J = 8.0 Hz, 2H, Ar-H), 7.75 (d, J = 8.0 Hz, 2H, Ar-H), 
7.39 - 7.18 (m, 26H, Ar-H), 5.10 - 4.95 (m, 9H, CH2-Ar, myo-H-4), 4.32 (td, J = 9.2 Hz, 1H, 
myo-H-5), 4.12 - 4.05 (m, 1H, myo-H-1), 4.02 - 3.93 (m, 2H, myo-H-2, myo-H-3), 3.56 - 3.49 
(m, 1H, myo-H-6), 3.20 (s, 3H, H-13), 1.88 - 1.59 (m, 7H, H-8, H-9, H-11, H-12), 1.52 - 1.40 
(m, 3H, H-9, H-10), 1.11 (s, 9H, C(CH3)3). 
13C-NMR (100 MHz, CDCl3) δ 136.5 (CH, 4C, Ar-C) 133.6, 133.6 (Cq, 4C, Ar-C), 130.3, 130.1, 
128.8, 128.8, 128.7, 128.7, 128.7, 128.6, 128.4, 128.4, 128.3, 128.2, 128.2, 128.1, 128.1, 
127.9, 127.8 (CH, 26C, Ar-C), 111.4 (Cq, 1 C, C-7), 82.4 (CH, 1C, myo-C-6), 80.6 (CH, 1C, 
myo-C-4), 79.6 (CH, 1C, myo-C-5), 76.1 (CH, 1C, myo-C-3), 74.8 (CH, 1C, myo-C-2), 69.8 (CH, 
1C, myo-C-1), 69.6, 69.51 (CH2, 4C, CH2-Ar), 60.2 (CH3, 1C, C-13) 37.2, 34.5, 28.0 (CH2, 3C, 
C-12, C-8, C-10) 27.4 (CH3, 3C, C(CH3)3), 25.4, 24.1 (CH2, 2C, C-9, C-11), 19.7 (Cq, 1C, 
C(CH3)3). 
31P-NMR (400.13 MHz, CDCl3) δ (ppm) = - 1.6 (s, 1P), -2.04 (s, 1P). 
[α]D 20 = (-) 2.54 (c = 7 mg/mL in CHCl3) 
HRMS (ESI)+ m/z meas. 1055.3694; calc. for C57H66O12P2Si [M+Na]+ 1055.3691 -0.3 
ppm 
 
2,3-O-cycloxexylidene-4,5-di-O-dibenzylphosphoryl-6-O-methyl-myo-inositol (10) 
 
To a solution of 9 (421 mg, 0.4 mmol) in THF (anhydrous, 15 ml) was added a solution of 
TBAF (707uL, 1.9 eq) in 0.8 ml THF (anhydrous) at 0°C. The reaction was left stirring at 
room temperature. The reaction mixture turned slightly yellow upon addition of the TBAF 
reagent. The reaction was stopped after 2 hours, worked up with NaCO3- and extracted 
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with Ethyl Acetate. The crude was purified using flash column chromatography at 
gradient of 80% to 100% EtOAc in Heptane.  
 
1H NMR (400 MHz, CDCl3) δ 7.33 - 7.29 (m, 8H, Ar-H), 7.27 - 7.22 (m, 12H, Ar-H), 5.13 - 
4.99 (m, 8H, CH2-Ar), 4.94 (dd, J = 8.5 Hz, 1H, myo-H-4), 4.50 - 4.44 (m, 1H, myo-H-5), 4.42 
(dd, J = 6.5 Hz, 1H, myo-H-2), 4.26 (t, J = 7.0 Hz, 1H, myo-H-3), 3.98 (dd, J = 6.9 Hz, 1H, myo-
H-1), 3.75 - 3.70 (m, 1H, myo-H-6), 3.44 (s, 3H, H-7), 2.54 (br. s, 1H, OH), 1.77 - 1.71 (m, 
2H, H-12), 1.66 - 1.53 (m, 6H, H-11, H-9, H-8), 1.37 - 1.31 (m, 2H, H-10). 
13C NMR (101 MHz, CDCl3) δ (ppm) = 136.3, 136.2 (Cq, 4C, Ar-C), 128.8, 128.8, 128.7, 
128.6, 128.6, 128.6, 128.3, 128.3, 128.2, 128.1 (CH, 20C, Ar-C), 111.7 (Cq, 1C, C-7), 82.0 
(CH, 1C, myo-C-6), 80.1 (CH, 1C, myo-C-4), 79.3 (CH, 1C, myo-C-5), 76.2 (CH, 1C, myo-C-3), 
74.4 (CH, 1C, myo-C-2), 69.9, 69.7, 69.7, 69.7, 69.6, 69.6 (CH2, 4C, CH2-Ar), 68.5 (CH, 1C, 
myo-C-1), 59.9 (CH3, 1C, C-13), 37.0 (CH2, 1C, C-12), 34.7, 25.3, 24.2 (CH2, 3C, C-11, C-9, 
C-8), 23.9 (CH2, 1C, C-10). 
31P-NMR (400.13 MHz, CDCl3): δ - 1.84 (s, 1P), - 2.08 (s, 1P). 
[α]D 20 = (-) 3.2 (c = 8 mg/mL in CHCl3) 
HRMS (ESI)+ m/z meas. 817.2512; calc. for C41H48O12P2 [M+Na]+ 817.2513. 
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(3aR,4S,5R,6R,7R,7aS)-4-((tert-butyldiphenylsilyl)oxy)-5-
ethoxyhexahydrospiro[benzo[d][1,3]dioxole-2,1'-cyclohexane]-6,7-diyl 
dibenzoate (13) 
 
A solution of compound 3 (325 mg, 0.46 mmol) in anhydrous DCM (15 ml) was cooled 
down to 0° C. Proton Sponge (985.826 mg, 4.6 mmol, 10 eq) was added, followed by 
triethyl oxonium tetrafluoroborate (873.9 mg, 4.6 mmol, 10 eq). The reaction was left 
stirring at RT overnight. Monitoring for the product was done using TLC (3:7 EtOAc: 
Heptane) and UPLCMS. The product was purified by flash chromatography in an isocratic 
solvent system (54% EtOAc in Heptane). 
 
1H-NMR (400.13 MHz, CDCl3) δ (ppm) = 7.92 (t, J = 6.7 Hz, 4H, Ar-H), 7.85 (d, J = 6.7 Hz, 
2H, Ar-H), 7.75 (d, J = 6.8 Hz, 2H, Ar-H), 7.54 - 7.27 (m, 12H, Ar-H), 5.95 (t, J = 9.1 Hz, 1H, 
myo-H-4), 5.15 (md, J = 10.1 Hz, 1H, myo-H-5), 4.24 (md, J = 7.3 Hz, 1H, myo-H-1), 4.18 - 
4.13 (m, 1H, myo-H-3), 4.07 (t, J = 4.2 Hz, 1H, myo-H-2), 3.64 (t, J = 5.9 Hz, 1H, myo-H-6), 
3.56 (q, J = 6.9 Hz, 2H, H-13), 2.04 - 1.96 (m, 1H, H-12), 1.88 - 1.78 (m, 1H, H-12), 1.72 (t, J 
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= 8.1 Hz, 2H, H-8), 1.51 (m, 4H, H-9/11), 1.43 - 1.30 (m, 2H, H-10), 1.16 (s, 9H, C(CH3)3), 
0.97 (t, J = 7.0 Hz, 3H, H-14). 
13C-NMR (100.92 MHz, CDCl3) δ (ppm) = 166.1, 166.0 (C=O, 2C), 136.6, 136.4 (CH, 4C, Ar-
C), 134.0, 133.9 (Cq, 2C, Ar-C), 133.3, 133.2, 130.2, 130.1 (CH, 4C, Ar-C), 130.1, 130.1 (CH, 
4C, Ar-C), 128.6, 128.5, 128.04, 127.9 (CH, 8C, Ar-C), 111.3 (Cq, 1C, C-7), 80.1 (CH, 1C, myo-
C-6), 75.5 (CH, 1C, myo-C-3), 75.2 (CH, 1C, myo-C-2), 74.6 (CH, 2C, myo-C-5, myo-C-4), 71.2 
(CH, 1C, myo-C-1), 68.2 (CH2, 1C, C-13), 37.6 (CH2, 1C, C-12), 34.8 (CH2, 1C, C-8), 27.4 (CH3, 
3C, C(CH3)3)), 25.5 (CH2, 1C, C-10), 24.4 (CH2, 1C, C-11), 24.2 (CH2, 1C, C-9), 19.7 (Cq, 1C, 
C(CH3)3), 15.7 (CH3, 1C, C-14). 
[α]D 20 = (-) 7.36 (c= 3 mg/mL in CHCl3) 
HRMS (ESI)+ m/z meas. 757.3171; calc. for C44H50O8Si [M+Na]+ 757.3167 -0.5 ppm. 
 
(3aR,4S,5R,6S,7S,7aR)-4-((tert-butyldiphenylsilyl)oxy)-5-
ethoxyhexahydrospiro[benzo[d][1,3]dioxole-2,1'-cyclohexane]-6,7-diol (14) 
 
The solution of compound 13 (225 mg, 0.306 mmol, 1 eq) in dry THF (10 mL) was cooled 
down to 0°C and under stirring was treated, dropwise, with a 30% solution of NaOMe in 
MeOH (175 μL, 0.766 mmol, 2.5 eq). The reaction mixture was slowly warmed to RT while 
stirring for 1 h. The reaction solution was quenched with 5 mL of a conc. solution of citric 
acid in MeOH and 3 mL water. The aqueous phase was washed three times with EtOAc 
and the combined organic phases first dried with NaSO4, before the solvent was 
evaporated. The product was purified Biotage column in a gradient of 25% to 100% 
EtOAc in heptane. The product is a white solid and was isolated in 99% yield. 
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Rf (1:1 DCM:EtOAc) = 0.43 
1H-NMR (400.13 MHz, CDCl3) δ (ppm) = 7.81 - 7.75 (m, 4H, Ar-H), 7.45 - 7.32 (m, 6H, Ar-
H), 4.01 - 3.93 (m, 2H, myo-H-1, H-13), 3.76 - 3.67 (m, 3H, myo-H-2, myo-H-4, H-13), 3.64 
(dd, J = 5.2 Hz, 1H, myo-H-3), 3.53 (t, J = 8.8 Hz, 1H, myo-H-6), 3.17 (dd, J = 9.0 Hz, 1H, myo-
H-5), 1.79 - 1.63 (m, 4H, H-8, H-12), 1.55 - 1.40 (m, 3H, H-9, H-11), 1.34 - 1.26 (m, 3H, H-
10, H-11), 1.21 (t, J = 7.0 Hz, 3H, H-14), 1.10 (s, 9H, C(CH3)3). 
13C-NMR (100.92 MHz, CDCl3) δ (ppm) = 136.4, 136.3 (CH, 4C, Ar-C), 134.5, 133.7 (Cq, 2C, 
Ar-C), 130.2, 130.2, 128.0, 127.9 (CH, 6C, Ar-C), 110.7 (Cq, 1C, C-7), 81.4 (CH, 1C, myo-C-
6), 78.3 (CH, 1C, myo-C-3), 75.9 (CH, 1C, myo-C-2), 75.8 (CH, 1C, myo-C-4), 73.6 (CH, 1C, 
myo-C-5), 72.7 (CH, 1C, myo-C-1), 69.2 (CH3, 1C, C-13), 38.4 (CH2, 1C, C-12), 34.9 (CH2, 1C, 
C-8), 27.4 (CH3, 3C, C(CH3)3), 25.4 (CH2, 1C, C-10), 24.4 (CH2, 1C, C-11), 24.1 (CH2, 1C, C-
9), 19.7 (Cq, 1C, C(CH3)3), 15.9 (CH3, 1C, C-14). 
[α]D 20 = (-) -5.1133333 (c = 3 mg/mL in CHCl3) 
HRMS (ESI)+ m/z meas. 549.2645; calc. for C30H42O6Si [M+Na]+ 549.2643 -0.4 ppm 
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Tetrabenzyl((3aR,4S,5S,6R,7R,7aS)-4-((tert-butyldiphenylsilyl)oxy)-5-
ethoxyhexahydrospiro[benzo[d][1,3]dioxole-2,1'-cyclohexane]-6,7-diyl) 
bis(phosphate) (15) 
 
 
Compound 14 (150 mg, 0.285 mmol) was dissolved in anhydrous DCM (6 mL) and 
allowed to stir for a few minutes before adding 1H-tetrazole (0.45 M in ACN, 3.8 mL, 1.71 
mmol, 6 eq). The reaction was brought down to 0 °C before the phosphoramidite (265.82 
mg, 0.769 mmol, 2.7 eq) was immediately added in anhydrous DCM (2 ml). The reaction 
was allowed to stir for 3 hours at RT. After product formation, monitored by TLC 
measurements, the reaction was cooled down to -40 ° C, followed by the addition of 
mcpba (77% w/w, 1.14 mmol, 255.4µL, 4eq) and was allowed to stir for one more hour. 
After being deemed finished, the reaction was quenched with NaCO3- and extracted with 
DCM (200 ml). The organic layer was washed three more times with NaCO3- , then with 
water and brine, and condensed to give oil (pale color). The crude was purified using a 50 
g silica Biotage column, in an isocratic gradient of 23% EtOAc in heptane. The product 
was obtained as a colorless oil with a yield of 67%. 
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1H-NMR (400.13 MHz, CDCl3) δ (ppm) = 7.82 (d, J = 7.3 Hz, 2H, Ar-H), 7.76 (d, J = 7.3 Hz, 
2H, Ar-H), 7.37 - 7.21 (m, 26H, Ar-H), 5.10 - 4.95 (m, 9H, CH2-Ar, myo-H-4), 4.35 (td, J = 
9.1, Hz, 1H, myo-H-5), 4.13 (s, 1H, myo-H-1), 4.07 (s, 2H, myo-H-2, myo-H-3), 3.58 (t, J = 
4.7 Hz, 1H, myo-H-6), 3.35 (s, 1H, H-13), 3.26 (s, 1H, H-13), 1.90 - 1.79 (m, 2H, H-12), 1.75 
- 1.57 (m, 3H, H-8, H-10), 1.53 - 1.35 (m, 5H, H-9, H-10, H-11), 1.11 (s, 9H, C(CH3)3), 0.90 
(t, J = 6.8 Hz, 3H, H-14). 
13C-NMR (100.92 MHz, CDCl3) δ (ppm) = 136.6, 136.6 (CH, 4C, Ar-C), 133.8, 133.8 (Cq, 4C, 
Ar-C), 130.2, 130.1, 128.9, 128.8, 128.7, 128.7, 128.7, 128.6, 128.4, 128.4, 128.3, 128.2, 
128.1, 128.0, 127.8, 127.8 (CH, 26C, Ar-C), 111.2 (Cq, 1C, C-7), 80.8 (CH, 1C, myo-C-6), 
80.7(CH, 1C, myo-C-4), 80.1 (CH, 1C, myo-C-5), 75.9 (CH, 1C, myo-C-3), 74.5 (CH, 1C, myo-
C-2), 69.8 (CH, 1C, myo-C-1), 69.5, 69.4 (CH2, 4C, CH2-Ar), 67.3 (CH2, 1C, C-13) 36.9, 34.4 
(CH2, 2C, C-12, C-8) 27.3 (CH3, 3C, C(CH3)3), 25.5, 24.3, 24.1 (CH2, 3C, C-9, C-10, C-11), 19.6 
(Cq, 1C, C(CH3)3), 15.4 (CH3, 1C, C-14). 
31P-NMR (400.13 MHz, CDCl3) δ (ppm) = - 1.68 (s, 1P), -2.04 (s, 1P). 
[α]D 20 = (-) 15.584444 (c = 9 mg/mL in CHCl3) 
HRMS (ESI)+ m/z meas. 1069.3856; calc. for C58H68O12P2Si [M+Na]+ 1069.3847 -0.8 
ppm. 
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Tetrabenzyl((3aS,4S,5S,6R,7R,7aS)-5-ethoxy-4-hydroxyhexahydrospiro 
[benzo[d][1,3]dioxole-2,1'-cyclohexane]-6,7-diyl)bis (phosphate) (16) 
 
 
To a solution of 15 (170 mg, 0.162 mmol) in THF (anhydrous, 8.5 ml) was added a solution 
of TBAF (308uL, 1.9 eq) in 0.8 ml THF (anhydrous) at 0°C. The reaction was left stirring 
at room temperature. The reaction mixture turned slightly yellow upon addition of the 
TBAF reagent. The reaction was stopped after 2 hours, worked up with NaCO3- and 
extracted with Ethyl Acetate. The crude was purified using flash column chromatography 
at gradient of 30% to 100% EtOAc in Heptane. The product was purified as a colorless oil 
and was isolated in a yield of 73%.  
 
1H-NMR (400.13 MHz, CDCl3) δ (ppm) = 7.30 (d, J = 6.0 Hz, 9H, Ar-H), 7.25 (d, J = 4.3 Hz, 
11H, Ar-H), 5.17 - 5.00 (m, 8H, CH2-Ar), 4.98 (dd, J = 14.3 Hz, 1H, myo-H-4), 4.51 - 4.41 (m, 
2H, myo-H-5, myo-H-2), 4.28 (t, J = 7.2 Hz, 1H, myo-H-3), 4.02 - 3.96 (m, 1H, myo-H-1), 3.89 
- 3.82 (m, 1H, myo-H6), 3.79 - 3.69 (m, 1H, H-13), 3.59 - 3.50 (m, 1H, H-13), 2.12 (s, 1H, 
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OH), 1.80 - 1.69 (m, 2H, H-12), 1.67 - 1.45 (m, 6H, H-11, H-9, H-8), 1.40 - 1.30 (m, 2H, H-
10), 1.08 (t, J = 6.9 Hz, 3H, H-14). 
13C-NMR (100.92 MHz, CDCl3) δ (ppm) = 136.6, 136.5, 136.2, 136.3 (Cq, 4C, Ar-C), 128.8, 
128.8, 128.7, 128.6, 128.6, 128.5, 128.4, 128.3, 128.2, 128.1 (CH, 20C, Ar-C), 111.6 (Cq, 1C, 
C-7), 80.3 (CH, 1C, myo-C-6), 80.2 (CH, 1C, myo-C-4), 79.8 (CH, 1C, myo-C-5), 76.0 (CH, 1C, 
myo-C-3), 74.3 (CH, 1C, myo-C-2), 69.9, 69.7, 69.7, 69.6, 69.6 (CH2, 4C, CH2-Ar), 68.3 (CH, 
1C, myo-C-1), 67.5 (CH2, 1C, C-13), 36.9 (CH2, 1C, C-12), 34.7, 25.3, 24.2 (CH2, 3C, C-11, C-
9, C-8), 23.9 (CH2, 1C, C-10), 15.7 (CH3, 1C, C-14). 
31P-NMR (400.13 MHz, CDCl3) δ (ppm) = - 1.9 (s, 1P), -2.1 (s, 1P). 
[α]D 20 = (-) 3.1086667 (c = 30 mg/mL in CH3Cl) 
HRMS (ESI)+ m/z meas. 831.2673; calc. for C42H50O12P2 [M+Na]+ 831.2670 -0.4 ppm. 
 
(1R,2R,3R,4R,5R,6S)-4-((tert-butyldiphenylsilyl)oxy)-3,5,6-
trimethoxycyclohexane-1,2-diyldibenzoate(19),  
and  
(1R,2R,3R,4R,5R,6S)-4-((tert-butyldiphenylsilyl)oxy)-5-hydroxy-3,6-
dimethoxycyclohexane-1,2-diyl dibenzoate (20) 
 
 
A solution of compound 7 (216.4 mg, 0.35 mmol) in anhydrous DCM (15 ml) was cooled 
down to 0° C. Proton Sponge (757.43 mg, 3.53 mmol, 10 eq) was added, followed by 
trimethyl oxonium tetrafluoroborate (522.12 mg, 3.53 mmol, 10 eq). The reaction was 
left stirring at RT for 3 days. Monitoring for the product was done using TLC (3:7 EtOAc: 
Heptane) and UPLCMS. The reaction mixture was filtered and the solvent of the 
supernatant removed under reduced pressure. Products 19 and 20 were purified by 
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flash chromatography in an isocratic solvent system (25% EtOAc in Heptane), in a 19% 
and 44% yield, respectively.  
 
 
1H-NMR (400.13 MHz, CD3OD) δ (ppm) = 7.99 - 7.94 (m, 2H, Ar-H), 7.89 - 7.85 (m, 2H, Ar-
H), 7.80 (td, J = 8.0 Hz, 4H, Ar-H), 7.50 - 7.28 (m, 12H, Ar-H), 5.72 (t, J = 10.0 Hz, 1H, myo-
H-4), 5.36 - 5.30 (m, 1H, myo-H-5), 3.92 (t, J = 9.5 Hz, 1H, myo-H-6), 3.81 (dd, J = 9.6 Hz, 
1H, myo-H-1), 3.51 (s, 3H, H-7), 3.44 (s, 3H, H-9), 3.15 (s, 1H, myo-H-2), 2.97 (s, 3H, H-8), 
2.94 (d, J = 1.9 Hz, 1H, myo-H-3), 1.15 (s, 9H, C(CH3)3). 
13C-NMR (100.92 MHz, CDCl3) δ (ppm) = 165.3, 165.1 (C=O, 2C), 136.5, 136.3, 133.3, 
133.1 (CH, 6C, Ar-C), 132.0, 131.9 (Cq, 2C, Ar-C), 130.4, 130.2, 130.1, 130.0 (CH, 6C, Ar-
C), 129.9 (Cq, 2C, Ar-C), 128.6, 128.5, 128.4, 128.2, 128.1 (CH, 8C, Ar-C), 82.0 (CH, 1C, 
myo-C-6), 81.0 (CH, 1C, myo-C-3), 77.6 (CH, 1C, myo-C-2), 74.4 (CH, 1C, myo-C-1), 74.3 
(CH, 1C, myo-C-5), 72.5 (CH, 1C, myo-C-4), 61.9 (CH3, 1C, C-7), 61.4 (CH3, 1C, C-9), 58.2 
(CH3, 1C, C-8), 27.4 (CH3, 3C, C(CH3)3), 19.7 (Cq, 1C, C(CH3)3). 
[α]D 20 = (-) 24.191111 (c = 17 mg/mL in CH3Cl) 
HRMS (ESI)+ m/z meas. 691.2699; calc. for C39H44O8Si [M+Na]+ 691.2698. 
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1H-NMR (400.13 MHz, CD3OD) δ (ppm) = 7.97 - 7.93 (m, 2H, Ar-H), 7.88 - 7.84 (m, 2H, Ar-
H), 7.83 - 7.76 (m, 4H, Ar-H), 7.49 - 7.39 (m, 8H, Ar-H), 7.38 - 7.29 (m, 4H, Ar-H), 5.77 (t, J 
= 10.0 Hz, 1H, myo-H-4), 5.32 (t, J = 9.9 Hz, 1H, myo-H-5), 3.97 (t, J = 9.5 Hz, 1H, myo-H-6), 
3.81 (d, J = 9.4 Hz, 1H, myo- H-1), 3.68 (s, J = 2.52 Hz, 1H, myo-H-2), 3.48 (s, 3H, H-7), 3.06 
(s, 3H, H-8), 3.03 (d, J = 2.6 z, 1H, myo-H-3), 2.34 (s, 1H, OH), 1.13 (s, 9H, C(CH3)3). 
13C-NMR (100.92 MHz, CDCl3) δ (ppm) = 166.2, 166.1 (C=O, 2C), 136.4, 136.2, 133.4, 
133.2, (CH, 6C, Ar-C), 132.6, 130.6 (Cq, 2C, Ar-C), 130.4, 130.3, 130.1, 130.1, 130.0 (CH, 6C, 
Ar-C), 129.9 (Cq, 2C, Ar-C), 128.7, 128.6, 128.2, 128.1 (CH, 8C, Ar-C), 81.7 (CH, 1C, myo-C-
6), 79.5 (CH, 1C, myo-C-3), 74.1 (CH, 1C, myo-C-1), 73.9 (CH, 1C, myo-C-5), 72.1 (CH, 1C, 
myo-C-4), 68.9 (CH, 1C, myo- C-2), 61.8 (CH3, 1C, C-7), 58.3 (CH3, 1C, C-8), 27.3 (CH3, 3C, 
C(CH3)3), 19.8 (Cq, 1C, C(CH3)3). 
[α]D 20 = (-) 21.92514 (c = 17 mg/mL in CH3Cl) 
HRMS (ESI)+ m/z meas. 677.2548; calc. for C38H42O8Si [M+Na]+ 677.2541. 
 
Figure 2 Constructed diagram of 19 after structure elucidation using COSY, HSQC and HMBC. Protons 
are marked in red, carbons in black 
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(1R,2R,3R,4R,5R,6S)-4-((tert-butyldiphenylsilyl)oxy)-3,5,6-
trihydroxycyclohexane-1,2-diyl dibenzoate (21) 
 
3 (358.80 mg, 0.51 mmol, 1 eq) was dissolved in 10 mL DCM and 1 mL water and 
stirred while adding 15 mL of TFA dropwise. 1 mL of ethylene glycol was added at the 
reaction start. The reaction mixture was stirred for 30 min before diluting it with 10 
mL cyclohexane, then removing the solvent mixture and TFA in vacuo. Purification of 
the compound was reached through column chromatography (cyclohexane/EtOAc 
4:1). The product is a white solid and could be obtained in 85% yield. 
 
Rf (Cyclohexane/EtOAc 2:1) = 0.44. 
1H-NMR (400.13 MHz, CDCl3) δ (ppm) = 7.96 - 7.86 (m, 4H, Ar-H), 7.78 - 7.69 (m, 4H, Ar-
H), 7.50 - 7.37 (m, 8H, Ar-H), 7.37 - 7.28 (m, 4H, Ar-H), 5.70 (t, J = 9.9 Hz, 1H, myo-H-4), 
5.28 (t, J = 9.9 Hz, 1H, myo-H-5), 4.31 (t, J = 9.5 Hz, 1H, myo-H-6), 3.97 (s, 1H, myo-H-2), 
3.73 (dd, J = 9.3 Hz, 1H, myo-H-1), 3.61 (dd, J = 9.9 Hz, 1H, myo-H-3), 2.96 (s, 1H, OH), 2.89 
(s, 1H, OH), 2.71 (br.s, 1H, OH), 1.12 (s, 9H, C(CH3)3).  
13C-NMR (100.92 MHz, CDCl3) δ (ppm) = 167.4, 166.6 (C=O, 2C), 136.2, 136.0, 133.5, 
133.5, 133.2 (CH, 6C, Ar-C), 132.9, 130.7 (Cq, 2C, Ar-C), 130.6, 130.5, 130.2, 130.1 (CH, 6C, 
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Ar-C), 129.7, 129.6 (Cq, 2C, Ar-C), 128.6, 128.6, 128.4, 128.4 (CH, 8C, Ar-C), 75.0 (CH, 1C, 
myo-C-1), 74.0 (CH, 1C, myo-C-4), 73.2 (CH, 1C, myo-C-5), 72.9 (CH, 1C, myo-C-2), 72.4 (CH, 
1C, myo-C-6), 71.3 (CH, 1C, myo- C-3), 27.4 (CH3, 3C, C(CH3)3), 19.7 (Cq, 1C, C(CH3)3).  
[α]D 20 = (-) 3.74 (c = 4 mg/ml in CHCl3) 
HRMS (ESI+) m/z meas. 649.2231; calc. for C36H38O8Si [M+Na]+ 649.2228 -0.4 ppm 
 
(1R,2R,3R,4R,5R,6S)-4-((tert-butyldiphenylsilyl)oxy)-3,5,6-triethoxycyclohexane-
1,2-diyl dibenzoate (22) and (1R,2R,3R,4R,5R,6S)-4-((tert-butyldiphenylsilyl)oxy)-
3,6-diethoxy-5-hydroxycyclohexane-1,2-diyl dibenzoate (23) 
 
22 and 23 were obtained from 21 (116 mg, 0.185 mmol, 1 eq) analogously as the 
procedure described for 19 and 20 with proton sponge (792.9 g, 3.7 mmol, 20 eq), 
Et3OBF4 (626.96 g, 3.3 mmol, 18 eq) and stirring for 48 h. The products were colorless 
solids. 22 was isolated with 15% yield and 23 in a yield of 45%. 
 
1H-NMR (400.13 MHz, CD3OD) δ (ppm) = 8.01 - 7.96 (m, 2H, Ar-H), 7.89 - 7.76 (m, 6H, 
Ar-H), 7.49 - 7.29 (m, 12H, Ar-H), 5.70 (t, J = 10.0 Hz, 1H, myo-H-4), 5.33 (t, J = 9.7 Hz, 
1H, myo-H-5), 4.02 (t, J = 9.5 Hz, 1H, myo-H-6), 3.93 - 3.86 (m, 1H, H-7), 3.83 (dd, J = 
9.6 Hz, myo-H-1) 3.72 - 3.60 (m, 2H, H-7, H-9), 3.32 (dq, J = 14.1 Hz, 1H, H-9), 3.16 - 
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3.06 (m, 2H, myo-H-2, H-9), 3.04 - 2.93 (m, 2H, myo-H-3, H-9), 1.20 (t, J = 7.0 Hz, 3H, 
H-9‘), 1.14 (s, 9H, C(CH3)3), 1.01 (t, J = 7.0 Hz, 3H, H-7‘), 0.80 (t, J = 7.0 Hz, 3H, H-8‘). 
13C-NMR (100.92 MHz, CDCl3) δ (ppm) = 166.2, 166.1 (C=O, 2C), 136.5, 136.3 (CH, 4C, 
Ar-C), 135.1, 133.6 (Cq, 2C, Ar-C), 133.2, 133.0 (CH, 2C, Ar-C), 130.5, 130.3 (Cq, 2C, Ar-
C), 130.3, 130.1, 130.0, 129.9, 128.6, 128.5, 128.1, 128.0 (CH, 14C, Ar-C), 79.9 (CH, 1C, 
myo-C-6), 79.0 (CH, 1C, myo-C-3), 77.3 (CH, 1C, myo-C-2), 74.3 (CH, 1C, myo-C-1), 74.3 
(CH, 1C, myo-C-5), 72.6 (CH, 1C, myo-C-4), 69.5 (CH2, 1C, C-7), 68.7 (CH2, 1C, C-9), 65.9 
(CH2, 1C, C-8), 27.4 (CH3, 3C, C(CH3)3), 19.6 (Cq, 1C, C(CH3)3), 16.2 (CH3, 1C, C-9’), 16.0 
(CH3, 1C, C-7’), 15.4 (CH3, 1C, C-8’). 
[α]D 20 = (-) 3.204 (c = 5 mg/ml in CHCl3) 
HRMS (ESI)+ m/z meas. 733.3176; calc. for C42H50O8Si [M+Na]+ 733.3167 -1.2 ppm 
 
1H-NMR (400.13 MHz, CD3OD) δ (ppm) = 7.97 - 7.92 (m, 2H, Ar-H), 7.88 - 7.78 (m, 6H, 
Ar-H), 7.50 - 7.28 (m, 12H, Ar-H), 5.74 (t, J = 10.0 Hz, 1H, myo-H-4), 5.32 (t, J = 9.9 Hz, 
1H, myo-H-5), 4.06 (t, J = 9.5 Hz, 1H, myo-H-6), 3.89 - 3.82 (m, 2H, myo-H-1, H-7), 3.69 
- 3.61 (m, 1H, H-7), 3.53 (t, J = 2.5 Hz, 1H, myo-H-2), 3.27 - 3.20 (m, 1H, H-8), 3.11 (qd, 
J = 7.0 Hz, 2H, myo-H-4), 1.13 (s, 9H, C(CH3)3), 0.98 (t, J = 7.0 Hz, 3H, H-7‘), 0.86 (t, J = 
7.0 Hz, 3H, H-8‘). 
13C-NMR (100.92 MHz, CDCl3) δ (ppm) =  166.2, 166.0 (C=O, 2C), 136.4, 136.2 (CH, 4C, 
Ar-C), 134.6 (Cq, 1C, Ar-C), 133.3, 133.2 (CH, 2C, Ar-C), 133.1 (Cq, 1C, Ar-C), 130.4, 
130.2 (CH, 2C, Ar-C), 130.1 (Cq, 2C, Ar-C), 130.0, 129.9, 128.7, 128.6, 128.2, 128.1 (CH, 
12C, Ar-C), 79.6 (CH, 1C, myo-C-6), 77.9 (CH, 1C, myo-C-3), 74.3 (CH, 1C, myo-C-1), 73.8 
(CH, 1C, myo-C-5), 72.1 (CH, 1C, myo-C- 4), 70.0 (CH, 1C, myo-C-2), 69.5 (CH2, 1C, C-7), 
66.3 (CH2, 1C, C-8), 27.3 (CH3, 3C, C(CH3)3), 19.7 (Cq, 1C, C(CH3)3), 15.9 (CH3, 1C, C-7’), 
15.5 (CH3, 1C, C-8’). 
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[α]D 20 = (-)13.906 (c = 10 mg/mL in CHCl3) 
HRMS (ESI)+ m/z meas. 705.2858; calc. for C40H46O8Si [M+Na]+ 705.2854 -0.6 ppm 
 
(1S,2S,3R,4S,5R,6R)-4-((tert-butyldiphenylsilyl)oxy)-3,5,6-
trimethoxycyclohexane-1,2-diol (24) 
 
Compound 24 was obtained by dissolving 19 (253 mg, 0.378 mmol, 1 eq) in anhydrous 
THF (8mL), and adding NaOMe (216 uL, 0.946 mmol, 2.5 eq) dropwise at 0°C. The reaction 
solution turned turbid and pale yellow upon addition of the NaOMe solution. The reaction 
solution was left stirring at rtf o 1.5 hours. Monitoring for the product was done using TLC 
(3:7 EtOAc: Heptane) and UPLCMS. The reaction mixture was quenched with citric acid, 
extracted 4 times with EtOAc, washed with water, then with brine, dried over NaSO4 and 
condensed, yielding a crude weighing 260 mg. The product was purified over flash column 
chromatography at a gradient of 40% to 100% EtOAc in Heptane, yielding a colorless solid 
with a yield of 78%. 
 
1H-NMR (400.13 MHz, CD3OD) δ (ppm) = 7.69-7.71 (m, 3H, Ar-H), 7.39-7.32 (m, 6H, Ar-
H), 7.19-7.18 (m, 1H, Ar-H), 3.65 (s, 3H, H-7), 3.57 (t, J = 10.0 Hz, 1H, myo-H-4), 3.46 (m, 
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1H, myo-H-5), 3.28 (s, 3H, H-9), 3.19-3.17 (t, J = 9.5 Hz, 1H, myo-H-6), 2.94 (s, 3H, H-8), 
2.49-2.45 (m, 3H, myo-H-1,2,3), 1.07 (s, 9H, C(CH3)3). 
13C-NMR (100.92 MHz, CDCl3) δ (ppm) = 136.13, 136.00, 134.70, 133.10 (CH, 4C, Ar-C), 
130.14, 130.03 (Cq, 2C, Ar-C), 129.82, 128.46, 127.88, 127.70 (CH, 4C, Ar-C), 82.87 (CH, 
1C, myo-C-6), 81.88 (CH, 1C, myo-C-3), 77.36 (CH, 1C, myo-C-2), 77.04 (CH, 1C, myo-C-
5), 74.53 (CH, 1C, myo-C-1), 71.87 (CH, 1C, myo-C-4), 61.82 (CH3, 1C, C-7), 60.82 (CH3, 
1C, C-8), 57.06 (CH3, 1C, C-9), 27.11 (CH3, 3C, C(CH3)3), 19.21 (Cq, 1C, C(CH3)3). 
[α]D 20 = (-) 2.0621359 (c = 10.3 mg/mL in CH3Cl) 
HRMS (ESI)+ m/z meas. 483.2179; calc. for C25H36O6Si [M+Na]+ 483.2173 -1.1 ppm. 
Tetrabenzyl((1R,2R,3S,4R,5R,6S)-4-((tert-butyldiphenylsilyl)oxy)-3,5,6-
trimethoxycyclohexane-1,2-diyl) bis(phosphate) (25) 
 
 
Compound 24 (126 mg, 0.273 mmol) was dissolved in anhydrous DCM (7 mL) and 
allowed to stir for a few minutes before adding 1H-tetrazole (0.45 M in ACN, 3.6 mL, 1.642 
mmol, 6 eq). The reaction was brought down to 0 °C before the phosphoramidite (275.86 
mg, 0.821 mmol, 3 eq) was immediately added in anhydrous DCM (2 ml). The reaction 
was allowed to stir for 3 hours at RT. After product formation, monitored by TLC 
measurements, the reaction was cooled down to -40 ° C, followed by the addition of 
mcpba (77% w/w, 1.642 mmol, 367.99mg, 6eq) and was allowed to stir for one more 
hour. After being deemed finished, the reaction was quenched with NaCO3- and extracted 
with DCM (200 ml). The organic layer was washed three more times with NaCO3- , then 
with water and brine, and condensed to give oil (pale color). The crude (605 mg) was 
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purified using a 10 g silica Biotage column, in a gradient of 23% to 33% EtOAc in heptane. 
The product was obtained as a colorless oil with a yield of 99%. 
 
1H-NMR (400.13 MHz, CD3OD) δ (ppm) = 7.69 (d, J = 7.1 Hz, 2H, Ar-H), 7.41 – 7.30 (m, 4H, 
Ar-H), 7.30 – 7.21 (m, 6H, Ar-H), 7.18 – 7.12 (m, 16H, Ar-H), 4.99 (ddd, J = 9.7 Hz, 2H, CH2-
Ar), 4.94 (d, J = 5.9 Hz, 3H, CH2-Ar, myo-H-6), 4.90 (d, J = 7.1 Hz, 4H, CH2-Ar), 4.63 (d, J = 
9.2 Hz, 1H, myo-H-5), 4.27 (m, 1H, myo-H-4), 3.66-3.56 (m, 2H, myo-H-6, myo-H-3), 3.52 
(s, 3H, H-9), 3.24 (s, 3H, H-8), 2.74 (s, 3H, H-7), 1.16 (m, 2H, myo-H-1, myo-H-2), 1.06 (s, 
9H, C(CH3)3). 
13C-NMR (100.92 MHz, CDCl3) δ (ppm) = 136.22 (CH, 4C, Ar-C), 136.06, 135.91, 134.56, 
132.86 (Cq, 4C, Ar-C), 130.07, 129.95, 129.08, 128.75, 128.60, 128.57, 128.52, 128.42, 
128.33, 128.27, 128.19, 128.08, 128.02, 128.00, 127.96, 127.93, 127.83, 127.80, 127.60, 
127.45 (CH, 22C, Ar-C), 81.36 (CH, 1C, myo-C-6), 77.35 (CH, 1C, myo-C-5), 77.24 (CH, 1C, 
myo-C-3), 77.03 (CH, 1C, myo-C-4), 76.72 (CH, 1C, myo-C-2), 76.11 (CH, 1C, myo-C-1), 
74.01, 73.55, 71.03, 70.96, 69.33l, 69.20, 61.80, 60.86 (CH2, 8C, CH2-Ar), 57.00 (CH3, 3C, 
C(CH3)3), 27.08 (CH3, 3C, C(CH3)3), 22.57 (CH3, 3C, C(CH3)3), 19.25 (Cq, 1C, C(CH3)3). 
31P-NMR (400.13 MHz, CDCl3) δ (ppm) = - 1.69 (s, 1P), -2.54 (s, 1P). 
[α]D20= (-) 6.5072727 (c = 11 mg/mL in CH3Cl) 
 
HRMS (ESI)+ m/z meas. 1003.3381; calc. for C53H62O12P2Si [M+Na]+ 1003.3378 -0.3 
ppm. 
 
 
133 
Tetrabenzyl((1R,2R,3S,4R,5S,6S)-4-hydroxy-3,5,6-trimethoxycyclohexane-1,2-
diyl) bis(phosphate) (26) 
 
 
To a solution of 25 (275 mg, 0.28 mmol) in THF (anhydrous, 15 ml) was added a solution 
of TBAF (500uL, 1.8 eq) in 0.8 ml THF (anhydrous) at 0°C. The reaction was left stirring 
at room temperature. The reaction mixture turned slightly yellow upon addition of the 
TBAF reagent. The reaction was stopped after 2 hours, worked up with NaCO3- and 
extracted with Ethyl Acetate. The crude (298mg) was purified using flash column 
chromatography at gradient of 80% to 100% EtOAc in Heptane, and was obtained as a 
pale yellow oil (solid) with a 69% yield. 
 
1H NMR (400 MHz, CDCl3) δ = 7.21 (s, 10H, Ar-H), 7.17 (t, J = 3.5 Hz, 10H, Ar-H), 4.97 (m, 
8H, CH2-Ar), 4.75 (d, J = 9.1 Hz, 1H, myo-H-4), 4.33 (d, J = 8.9 Hz, 1H, myo-H-5), 3.77 (m, 
1H, myo-H-6), 3.56 (s, 3H, H-7), 3.49 – 3.44 (m, 1H, myo-H-3), 3.42 (s, 3H, H-8), 3.40 (d, J 
= 9.2 Hz, 1H, myo-H-2), 3.27 (s, 1H, H-9), 3.15 (dd, J = 9.5, 1.8 Hz, 1H, myo-H-1).  
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13C NMR (101 MHz, CDCl3) δ (ppm) = 136.20, 136.12, 136.04 (Cq, 8C, Ar-C), 128.45, 
128.41, 128.36, 128.34, 128.27, 128.18, 128.15, 128.12, 127.92, 127.87, 127.83, 127.69 
(Cq, 12C, Ar-C), 81.76 (Cq, 1C, C-7), 81.12 (Cq, 1C, C-8), 78.80 (Cq, 1C, C-9), 77.96 (CH, 1C, 
myo-C-6), 77.35 (CH, 1C, myo-C-4), 77.24 (CH, 1C, myo-C-5), 77.04 (CH, 1C, myo-C-3), 
76.72 (CH, 1C, myo-C-2), 71.86 (CH, 1C, myo-C-1), 69.43, 69.37, 69.29, 69.21 (CH2, 4C, 
CH2-Ar). 
31P-NMR (400.13 MHz, CDCl3): δ - 1.6 (s, 1P), - 2.05 (s, 1P). 
[α]D 20 = (-) 14.218462 (c = 13 mg/mL in CH3Cl) 
HRMS (ESI)+ m/z meas. 765.2202; calc. for C37H44O12P2 [M+Na]+ 765.2200 -0.2 ppm. 
 
(3aR,4S,5R,6R,7R,7aS)-4-((tert-butyldiphenylsilyl)oxy)-5-((2-
methoxyethoxy)methoxy)hexahydrospiro[benzo[d][1,3]dioxole-2,1'-
cyclohexane]-6,7-diyl dibenzoate (29) 
 
 
Compound 3 (2501 mg, 3.56mmol, 1 eq) was dissolved in anhydrous CHCl3 (35 mL) under 
Argon atmosphere. DIPEA (dry, 8.7 mL, 49.9 mmol, 14 eq) was then added at room 
temperature, followed by MEMCl (3.98 mL, 34.93 mmol, 9.8 eq). The reaction was heated 
to 60°C under reflux, and was left stirring overnight. When deemed finished, the reaction 
was quenched with NaCO3-, extracted three times with EtOAc, washed with water, then 
brine, dried over NaSO4 and condensed to yield a crude weighing 3001 mg. Purification 
of the product was achieved by column chromatography (isocratic gradient 18% EtOAc 
in heptane). The product is a colourless oil and was isolated with a 60% yield. 
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Rf: 0.34 (in 7:3 heptane:EtOAc) 
1H NMR (400 MHz, CDCl3) δ (ppm) = 7.87 – 7.82 (m, 2H, Ar-H), 7.77 (ddd, J = 18.5 Hz, 4H, 
Ar-H), 7.68 – 7.61 (m, 2H, Ar-H), 7.44 – 7.18 (m, 12H, Ar-H), 5.13 (dd, J = 9.8 Hz, 1H, CH-
4-myo), 4.91 (d, J = 6.5 Hz, 1H, CH- 5- myo), 4.65 (d, J = 6.9 Hz, 1H, CH-1-myo), 4.24 (dd, J 
= 7.9 Hz, 1H, CH-3- myo), 4.03 (d, J = 9.1 Hz, 1H, CH-6-myo), 3.90 (s, 1H, CH-2-myo), 3.52 – 
3.23 (m, 2H, H-14), 3.11 (s, 1H, H-16), 3.07 – 2.86 (m, 2H, H-15), 1.92 (d, J = 14.2 Hz, 1H, 
cy), 1.72 (dd, J = 12.8 Hz, 2H, cy), 1.39 (d, J = 24.4 Hz, 4H, cy), 1.20 (d, J = 12.0 Hz, 3H, cy), 
1.06 (s, 9H, CH3-TBDPS). 
13C-NMR (100.92 MHz, CDCl3) δ (ppm) = 165.87, 165.53 (C=O, 2C), 136.16, 135.86, 133.57, 
133.27 (CH, 4C,Ar-C), 133.07, 132.88 (Cq, 2C, Ar-C), 129.97, 129.87, 129.81, 129.70 (CH, 
4C, Ar-C), 129.65, 129.57, 128.27, 128.16 (CH, 4C, Ar-C), 127.85, 127.59 (CH, 2C, Ar-C), 
111.11 (Cq, 1C, C-7), 96.79 (CH, C-13), 77.35 (CH, 1C, myo-C-6), 77.23 (CH, 1C, myo-C-3), 
77.03 (CH, 1C, myo-C-2), 76.72 (CH, 2C, myo-C-5, myo-C-4), 75.11 (CH, C-14), 74.81 (CH, 
C-15), 71.75 (CH, 1C, myo-C-1), 67.44 (CH, C-16), 58.83, 37.31 (CH2, 1C, C-12), 34.34 (CH2, 
1C, C-8), 27.08 (CH3, 3C, C(CH3)3), 25.08 (CH2, 1C, C-10), 23.99 (CH2, 1C, C-11), 23.82 (CH2, 
1C, C-9), 19.35 (Cq, 1C, C(CH3)3). 
[α]D 20 = (-)7.3428571 (c = 7 mg/ml in CHCl3) 
HRMS (ESI)+ m/z meas. 817.3387; calc. for C46H54O10Si [M+Na]+ 817.3378 -1.1 ppm. 
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(3aR,4S,5R,6S,7S,7aR)-1-((tert-butyldiphenylsilyl)oxy)-6-((2-
methoxyethoxy)methoxy)hexahydrospiro[benzo[d][2,3]dioxole-2,1'-
cyclohexane]-4,5-diol (30) 
 
Compound 29 (1700 mg, 2.14 mmol, 1 eq) was dissolved in THF (dry, 40 mL) and the 
reaction mixture was cooled down to 0°C. NaOMe solution was added dropwise, and the 
reaction was brought up to RT by removing the ice bath 10 minutes after the reaction 
start. The reaction mixture turned yellow upon addition of NaOMe. 1 hour later, the 
reaction was deemed finished, stopped and worked up by quenching with citric acid, 
extracting 4 times with EtOAc. The organic layers were then combined, washed with 
water, brine, then dried over NaSO4-, filtered and condensed, yielding a yellow crude with 
a sharp aromatic smell, weighing 1880 mg. Purification of the product was achieved by 
column chromatography (gradient of 20%-100% EtOAc in heptane). The product was 
isolated with >99% quantitative yield. 
 
 
1H NMR (400 MHz, CDCl3) δ (ppm) = 7.68 (ddd, J = 17.5 Hz, 4H, Ar-H), 7.44 – 7.17 (m, 6H, 
Ar-H), 4.69 (q, J = 7.3 Hz, 2H, C-13), 3.81 (ddd, J = 27.0 Hz, 3H, CH-4-myo, CH-5-myo, CH-
6-myo), 3.63 (ddd, J = 12.7 Hz, 4H, H-14, H-15), 3.48 (p, J = 2.3 Hz, 2H, CH-3-myo, CH-1-
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myo), 3.31 (s, 3H, H-16), 3.04 (t, J = 9.0 Hz, 1H, CH-2-myo), 1.63 (d, J = 10.5 Hz, 4H, H-12, 
H-8), 1.31 (d, J = 4.9 Hz, 6H, H-9, H-10, H-11), 1.02 (s, 9H, CH3 -TBDPS). 
13C-NMR (100.92 MHz, CDCl3) δ (ppm) = 136.01, 135.95, 135.80, 135.78 (CH, 4C,Ar-C), 
133.91, 133.45 (Cq, 2C, Ar-C), 133.28, 133.20, 130.11, 129.83 (CH, 4C, Ar-C), 127.84, 
127.64 (CH, 2C, Ar-C), 110.47 (Cq, 1C, C-7), 97.76 (CH, C-13), 97.68 (CH, C-14), 85.45 (CH, 
C-15), 83.83 (CH, C-16), 77.57 (CH, 1C, myo-C-6), 77.36 (CH, 1C, myo-C-3), 77.04 (CH, 1C, 
myo-C-2), 76.72 (CH, 1C, myo-C-5), 75.60 (CH, 1C, myo-C-4), 75.56 (CH, 1C, myo-C-1), 
38.18 (CH2, 1C, C-12), 34.78 (CH2, 1C, C-8), 27.00 (CH3, 3C, C(CH3)3), 25.02 (CH2, 1C, C-
10), 24.01 (CH2, 1C, C-11), 23.79 (CH2, 1C, C-9), 19.35 (Cq, 1C, C(CH3)3). 
[α]D 20 = (+) 30.28875 (c = 16 mg/mL in CH3Cl) 
HRMS (ESI)+ m/z meas. 609.2877; calc. for C32H46O8Si [M+Na]+ 609.2854 -3.8 ppm  
 
Tetrabenzyl((3aR,4S,5S,6R,7R,7aS)-1-((tert-butyldiphenylsilyl)oxy)-6-((2-
methoxyethoxy)methoxy)hexahydrospiro[benzo[d][2,3]dioxole-2,1'-
cyclohexane]-4,5-diyl) bis(phosphate) (31) 
 
 
Compound 30 (1100 mg, 1.8 mmol) was dissolved in anhydrous DCM (20 ml and allowed 
to stir for a few minutes before adding 1H-tetrazole (0.45 M in ACN, 24 mL, 11 mmol, 6 
eq). The phosphoramidite (1.8 mL, 5.6 mmol, 3 eq) was immediately added in anhydrous 
acetonitrile (2.2 ml). The reaction was allowed to stir for 3 hours. The reaction was cooled 
down to -40 ° C, followed by the addition of mcpba (77% w/w, 11 mmol, 2465.28 mg, 6 
eq) and was allowed to stir for one more hour.  
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The reaction was quenched with NaCO3- and extracted with DCM (200 ml). The organic 
layer was washed three more times with NaCO3- , then with water and brine, and 
condensed to give oil (pale color). The crude (2 g) was purified using a 100 g silica biotage 
column, in a gradient from 15% to 100% EtOAc in heptane. Sample loading on the column 
was done twice, as the total mass of the crude had to be divided in two for column loading 
limit (with respect to the Rfs differences on TLC). The product could be isolated with a 
yiled of 99%.  
 
Rf: 0.39 (in 3:2 EtOAc:Heptane) 
1H NMR (400 MHz, CDCl3) δ (ppm) = 7.77 – 7.61 (m, 4H, Ar-H), 7.41 – 7.06 (m, 26H, Ar-
H), 5.26 – 5.08 (m, 2H, H-13), 5.07 – 4.80 (m, 8H, CH2-Ar), 4.47 – 4.27 (m, 2H, myo-H-4, 
myo-H-5), 4.16 – 3.96 (m, 3H, myo-H-1, H-14), 3.48 (s, 1H, myo-H-2), 3.39 – 3.22 (m, 4H, 
myo-H-3, myo-H-6, H-15), 3.22 – 3.14 (s, 3H, H-16), 1.38 (d, J = 21.9 Hz, 10H, H8-9-10-11-
12), 1.03 (s, 9H, C(CH3)3).  
13C-NMR (100.92 MHz, CDCl3) δ (ppm) = 136.29, 136.14, 136.01 (CH, 4C, Ar-C), 133.33 
(Cq, 4C, Ar-C), 129.93, 129.71, 129.08, 128.75, 128.65, 128.59, 128.56, 128.45, 128.40, 
128.36, 128.33, 128.26, 128.09, 128.04, 128.01, 127.81, 127.70, 127.46 (CH, 26C, Ar-C), 
110.98 (Cq, 1 C, C-7), 99.99 (CH, 1C, myo-C-6), 77.36 (CH, 1C, myo-C-4), 77.24 (CH, 1C, 
myo-C-5), 77.04 (CH, 1C, myo-C-3), 76.72 (CH, 1C, myo-C-2), 73.92 (CH, 1C, myo-C-1), 
71.56 (CH2, 4C, CH2-Ar), 71.03 (CH3, 1C, C-13), 70.96 (CH3, 1C, C-14), 69.48 (CH3, 1C, C-
15), 69.16 (CH3, 1C, C-16), 67.58, 58.90, 33.86 (CH2, 3C, C-12, C-8, C-10), 27.08, 25.18 (CH3, 
3C, C(CH3)3), 23.98, 23.73 (CH2, 2C, C-9, C-11), 19.24 (Cq, 1C, C(CH3)3). 
31P-NMR (400.13 MHz, CDCl3) δ (ppm) = - 1.51 (s, 1P), -2.01 (s, 1P). 
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[α]D 20 = (+)6.252546 (c = 20 mg/mL in CH3Cl) 
HRMS (ESI+) m/z meas. 1129.4065; Calc. for C60H72O14P2Si [M+Na]+ 1129.4059 -
0.6ppm 
Tetrabenzyl((3aS,4S,5S,6R,7R,7aS)-4-hydroxy-5-((2-methoxyethoxy)methoxy) 
hexahydrospiro[benzo[d][1,3]dioxole-2,1'-cyclohexane]-6,7-diyl)bis(phosphate) 
(32) 
 
 
To a solution of 31 (1981 mg, 1.79 mmol) in THF (anhydrous, 35 ml) was added a solution 
of TBAF (3.2 mL, 1.8 eq) in 0.8 ml THF (anhydrous) at 0°C. The reaction was left stirring 
at room temperature. The reaction mixture turned slightly yellow upon addition of the 
TBAF reagent. The reaction was stopped after 2 hours, worked up with NaCO3- and 
extracted with Ethyl Acetate. The product was purified using flash column 
chromatography at gradient of 20% to 100% EtOAc in Heptane. The product was purified 
as a colorless oil and was isolated in a yield of 85%.  
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Rf: 0.28 (in 4:1 EtOAc:Hep) 
1H NMR (400 MHz, CDCl3) δ (ppm) = 7.31 – 7.03 (m, 20H, Ar-H), 5.29 – 4.78 (m, 6H, CH2-
Ar), 4.65 (dd, J = 15.0, 7.1 Hz, 2H, CH2-Ar), 4.45 – 4.27 (m, 2H, H-13), 4.13 (dd, J = 7.0, 5.3 
Hz, 1H, myo-H-4), 4.05 (q, J = 7.1 Hz, 1H, myo-H-5), 3.87 (t, J = 8.7 Hz, 1H, myo-H-2), 3.79 
– 3.64 (m, 2H, H-14), 3.52 – 3.45 (m, 1H, myo-H-3), 3.42 (dd, J = 5.2, 3.6 Hz, 2H, H-15), 3.29 
(s, 3H, H-16), 1.96 (d, J = 15.8 Hz, 2H, myo-H-1, myo-H-6), 1.75 – 1.15 (m, 10H, H-8-9-10-
11-12). 
13C NMR (101 MHz, CDCl3) δ (ppm) = 136.13, 135.92, 135.85 (Cq, 4C, Ar-C), 128.54, 
128.51, 128.47, 128.44, 128.43, 128.37, 128.34, 128.29, 128.22, 128.10, 128.02, 127.98, 
127.93, 127.89, 127.81 (CH, 20C, Ar-C), 111.42 (Cq, 1C, C-7), 97.20 (CH, 1C, C-13), 80.63 
(CH, 1C, myo-C-6), 80.13 (CH, 1C, myo-C-4), 77.35 (CH, 1C, myo-C-5), 77.24 (CH, 1C, myo-
C-3), 77.04 (CH, 1C, myo-C-2), 76.72 (CH, 1C, C-14), 76.37 (CH, 1C, C-15), 71.53 (CH, 1C, C-
16), 69.56, 69.50, 69.32, 68.53 (CH2, 4C, CH2-Ar), 67.79 (CH, 1C, myo-C-1), 37.27 (CH2, 1C, 
C-12), 35.01, 24.90, 23.82 (CH2, 3C, C-11, C-9, C-8), 23.54 (CH2, 1C, C-10). 
31P-NMR (400.13 MHz, CDCl3) δ (ppm) = - 1.5 (s, 1P), -2.05 (s, 1P). 
[α]D 20 = (-)21.628571 (c = 14 mg/mL in CH3Cl) 
HRMS (ESI)+ m/z meas. 891.2881; calc. for C76H95O21P3 [M+Na]+ 891.2881 -1.1 ppm 
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5.2.3. Solution synthesis of PI(4,5)P2 analogues 
 
(2R)-3-(((benzyloxy)(((3aS,4R,5R,6S,7S,7aR)-4,5-bis((bis(benzyloxy)phosphoryl) 
oxy)-6-methoxyhexahydrospiro[benzo[d][1,3]dioxole-2,1'-cyclohexan]-7-yl)oxy) 
phosphoryl)oxy)propane-1,2-diyldioctanoate (11) 
 
 
                                                                      
Compound 10 (100 mg, 0.12 mmol, 1 eq) and 0.45 M 1H-Tetrazole in ACN (0.8 mL, 0.375 
mmol, 3 eq) were dissolved in 8 mL DCM in a flask under Ar atmosphere. The solution 
was cooled to 0°C before the DiC8-phosphoramidite 47 (109.8 mg, 0.18 mmol, 1.5 eq) 
dissolved in DCM (1mL) was added dropwise. After removing the ice bath and stirring for 
1 h, the reaction mixture was cooled to -40°C and mCPBA (56 mg, 0.25 mmol, 2 eq) 
dissolved in 1.5 mL DCM was added. After warming the solution slowly to RT, the reaction 
mixture was quenched with 2 mL of a 10%- solution of KHSO4 in water. The organic phase 
was washed with sat. NaHCO3- solution, water and brine, before it was dried with NaSO4 
and the solvent evaporated under reduced pressure. Purification of the product was 
achieved by column chromatography (heptane/ EtOAc linear gradient 12% to 86%). The 
product is a colourless oil and was isolated with a 70% yield. 
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1H NMR (400 MHz, CDCl3) δ 7.41 - 7.27 (m, 14H, Ar-H), 7.26 - 7.19 (m, 11H, Ar-H), 5.26 - 
5.17 (m, 1H, H-2‘), 5.16 - 4.96 (m, 10H, CH2-Ar), 4.78 (td, J = 14.9 Hz, 1H, myo-H-4), 4.62 
(ddt, J = 14.0 Hz, 1H, myo-H-1), 4.58 - 4.51 (m, 1H, myo-H-2), 4.51 - 4.42 (m, 1H, myo-H-
5), 4.37 - 4.25 (m, 1H, H-1‘), 4.25 - 4.16 (m, 3H, myo-H-3, H-3‘), 4.16 - 4.06 (m, 1H, H-1‘), 
3.84 - 3.74 (m, 1H, myo-H-6), 3.44, 3.40 (s, 3H, H-13), 2.27 (dt, J = 14.5 Hz, 4H, H-4‘), 1.79 
- 1.72 (m, 2H, H-12), 1.66 - 1.41 (m, 10H, H-5‘, H-8, H-9, H-11), 1.33 (s, 2H, H-10), 1.26 (s, 
16H, H-6‘, H-7‘, H-8‘, H-9‘), 0.87 (t, J = 5.7 Hz, 6H, H-10‘). 
13C-NMR (100.92 MHz, CDCl3): δ (ppm) = 173.5, 173.1 (C=O, 2C), 136.2, 136.2, 136.1, 
136.1, 136.0 (Cq, 5C, Ar-C), 129.0, 129.0, 128.9, 128.8, 128.8, 128.7, 128.7, 128.6, 128.6, 
128.3, 128.3, 128.3, 128.2, 128.2, 128.14 (CH, 20C, Ar-C), 112.1 (Cq, 1C, C-7), 80.2 (CH, 1C, 
myo-C-6), 79.4 (CH, 1C, myo-C-4), 78.5 (CH, 1C, myo-C-5), 76.3 (CH, 1C, myo-C-3), 75.5 (CH, 
1C, myo-C-1), 73.8 (CH, 1C, myo-C-2), 70.0, 69.9, 69.8, 69.8, 69.7 (CH2, 5C, CH2-Ar), 69.6 
(CH, 1C, C-2’), 66.0 (CH2, 1C, C-3’), 62.0 (CH2, 1C, C-1’), 60.7 (CH3, 1C, C-13), 37.1, 37.0 (CH2, 
2C, C-12), 34.8 (CH2, 1C, C-8), 34.5, 34.3 (CH2, 2C, C-4’), 32.0, 29.4, 29.3 (CH2, 6C, C-6’, C-7’, 
C-8’), 25.2, 25.2 (CH2, 3C, C-5’, C-10), 24.2, 23.9 (CH2, 1C, C-9, C-11), 22.9 (CH2, 2C, C-9’), 
14.4 (CH3, 2C, C-10’). 
31P-NMR (400.13 MHz, CDCl3): δ (ppm) = -1.68 (d, 1P), -1.79 (s, 0.5P), -1.92 (s, 0.5P), -2.09 
(d, 1P). 
[α]D 20 = (-)6.6171429 (c = 7 mg/ml in CHCl3) 
 
HRMS (ESI)+ m/z meas. 1313.5125; calc. for C67H89O19P3 [M+Na]+ 1313.5103 -1.6ppm. 
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(2R)-3-(((((1R,2R,3S,4R,5R,6S)-2,3-dihydroxy-6-methoxy-4,5-
bis(phosphonooxy)cyclohexyl) oxy)(hydroxy)phosphoryl) oxy)propane-1,2-diyl 
dioctanoate (12) 
 
Compound 11 (100 mg, 0.077 mmol, 1 eq) was dissolved in 2 mL THF in a flask under Ar 
atmosphere and cooled to 0°C. TMSBr (2 mL, excess) was diluted in 1 mL THF, added and 
stirred for 5 min before ice bath was removed and the reaction warmed to RT. After 
stirring for 1 h, TMSBr and THF were evaporated and the precipitate dissolved in 5.6 mL 
dry MeOH. The reaction solution was stirred for 1 h before the solvent was removed 
under reduced pressure. The product could be isolated as a white solid in a quantitative 
yield. (70 mg, 0.092 mmol). 
 
1H-NMR (400.13 MHz, CD3OD) δ (ppm) = 5.33 - 5.22 (m, 1H, H-2’), 4.50 (q, J = 9.2 Hz, 1H, 
myo-H-4), 4.45 - 4.37 (m, 1H, H-1’), 4.28 - 4.06 (m, 6H, myo-H-1, myo-H-2, myo-H-5, H-1’, 
H-3’), 3.69 - 3.61 (m, 2H, myo-H-3, myo-H-6), 3.59 (s, 3H, H-7), 2.41 - 2.29 (m, 4H, H-4’), 
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1.67 - 1.55 (m, 4H, H-5’), 1.38 - 1.25 (m, 16H, H-6’, H-7’, H-8’, H-9’), 0.91 (t, J = 6.8 Hz, 6H, 
H-10’).  
13C-NMR (100.92 MHz, CDCl3) δ (ppm) = 174.9, 174.5 (C=O, 2C), 81.6 (CH, 1C, myo-C-6), 
80.5 (CH, 1C, myo-C-5), 80.0 (CH, 1C, myo-C-4), 78.7 (CH, 1C, myo-C-1), 72.3 (CH, 1C, myo-
C-2), 71.3 (CH, 1C, myo-C-3), 71.3 (CH2, 1C, C-2’), 66.2 (CH2, 1C, C-3’), 63.2 (CH, 1C, C-1’), 
61.8 (CH3, 1C, C-7), 35.1, 34.9 (CH2, 2C, C-4’) 33.7, 32.9, 30.2, 30.1, 30.1 (CH2, 6C, C-6’, C-
7’, C-8’), 26.0 (CH2, 2C, C-5’), 23.9, 23.7 (CH2, 2C, C-9’), 14.4 (CH2, 2C, C-10’).  
31P-NMR (400.13 MHz, CDCl3) δ (ppm) = 0.68 (s, 1P), -0.8 (s, 1P), -2.75 (s, 1P) 
[α]D 20 = (-) 0.9547826 
HRMS (ESI)+ m/z meas. 759.2168; calc. for C26H50O19P3 [M+H]+ 759.2165 -0.4 ppm. 
 (2R)-3-(((benzyloxy)(((3aS,4R,5R,6S,7S,7aR)-4,5-bis((bis(benzyloxy) 
phosphoryl)oxy)-6-ethoxyhexahydrospiro[benzo[d][1,3]dioxole-2,1'-cyclohexan]-
7-yl)oxy)phosphoryl)oxy)propane-1,2-diyl dioctanoate (17) 
 
Compound 16 (63 mg, 0.078 mmol, 1 eq) and 0.45 M 1H-Tetrazole in ACN (0.52 mL, 
0.234 mmol, 3 eq) were dissolved in 5 mL DCM in a flask under Ar atmosphere. The 
solution was cooled to 0°C before the DiC8-phosphoramidite 47 (67.9 mg, 0.11 mmol, 1.5 
eq) dissolved in DCM (1.5 mL) was added dropwise. After removing the ice bath and 
stirring for 2 h, the reaction mixture was cooled to -40°C and mCPBA (26.92 mg, 0.156 
mmol, 2 eq) dissolved in 0.8 mL DCM was added dropwise. After warming the solution 
slowly to RT, the reaction mixture was quenched with 2 mL of a 10%- solution of KHSO4 
in water. The organic phase was washed with sat. NaHCO3- solution, water and brine, 
before it was dried with NaSO4 and the solvent evaporated under reduced pressure. 
Purification of the product was achieved by biotage column chromatography (25g Silica 
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cartridge; linear gradient of 12% to 100% EtOAc in Heptane). The product is a colourless 
oil and was isolated with a 54% yield. 
 
 
1H-NMR (400.13 MHz, CDCl3) δ (ppm) = 7.41 - 7.17 (m, 25H, Ar-H), 5.26 - 5.13 (m, 1H, H-
2‘), 5.15 - 4.93 (m, 10H, CH2-Ar), 4.88 - 4.74 (m, 1H, myo-H-4), 4.69 - 4.52 (m, 2H, myo-H-
1, myo-H-2), 4.48 (dt, J = 15.9 Hz, 1H, myo-H-5), 4.35 - 4.04 (m, 5H, myo-H-3, H-1‘, H-3‘), 
3.92 (dt, J = 14.3, 6.8 Hz, 1H, myo-H-6), 3.68 (dt, J = 20.3 Hz, 1H, H-13), 3.62 - 3.51 (m, 1H, 
H-13), 2.32 - 2.16 (m, 4H, H-4‘), 1.74 (s, 4H, H-12, H-8), 1.64 - 1.34 (m, 10H, H-10, H-9, H-
8, H-5‘), 1.26 (s, 16H, H-6‘, H-7‘, H-8‘,H-9‘), 1.04 (dt, J = 14.2 Hz, 3H, H-14), 0.87 (t, J = 6.0 
Hz, 6H, H-10‘).  
13C-NMR (100.92 MHz, CDCl3) δ (ppm) = 173.5, 173.3 (C=O, 2C),136.3, 136.2, 136.1, (Cq, 
5C, Ar-C), 129.0, 128.9, 128.8, 128.8, 128.8, 128.7, 128.7, 128.6, 128.6, 128.4, 128.3, 128.3, 
128.2, 128.1 (CH, 25C, Ar-C), 112.0 (Cq, 1C, C-7), 79.2 (CH, 1C, myo-C-4), 79.0 (CH, 1C, 
myo-C-5), 78.4 (CH, 1C, myo-C-6), 76.1 (CH, 1C, myo-C-3), 74.9 (CH, 1C, myo-C-1), 73.5 (CH, 
1C, myo-C-2), 70.0, 69.9, 69.8, 69.7 (CH2, 5C, CH2-Ar), 69.6 (CH, 1C, C-2’), 68.0 (CH2, 1C, C-
13), 66.0 (CH2, 1C, C-3’), 62.0 (CH2, 1C, C-1’), 36.9, 36.8 (CH2, 2C, C-12), 34.7 (CH2, 1C, C-
8), 34.5, 34.3 (CH2, 2C, C-4’), 32.0, 29.4, 29.4, 29.3 (CH2, 6C, C-6’, C-7’, C-8’), 25.3, 25.2, 25.1 
(CH2, 3C, C-5’, C-10), 24.2, 23.9 (CH2, 1C, C-9, C-11), 22.9 (CH2, 2C, C-9’), 15.5 (CH3, 1C, C-
14), 14.4 (CH3, 2C, C-10’).  
31P-NMR (400.13 MHz, CDCl3) δ (ppm) = -1.77 (dd, J= 4.43 Hz, 1P), -1.93 (s, 0.5P), -2.06 (s, 
0.5P), 2.11 (dd, J = 4.84 Hz, 1P). 
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[α]D 20 = (-) 1.3037 (c = 9 mg/mL in CH3Cl) 
HRMS (ESI)+ m/z meas. 1327.5310; calc. for C68H91O19P3 [M+Na]+ 1327.5260 -3.8 ppm. 
 
(2R)-3-(((((1R,2S,3R,4R,5S,6R)-2-ethoxy-5,6-dihydroxy-3,4-
bis(phosphonooxy)cyclohexyl)oxy)(hydroxy)phosphoryl)oxy)propane-1,2-diyl 
dioctanoate (18) 
 
Compound 17 (55 mg, 0.04 mmol, 1 eq) was dissolved in 1.3 mL THF in a flask under Ar 
atmosphere and cooled to 0°C. TMSBr (0.9 mL, excess) was diluted in 0.5 mL THF, added 
and stirred for 5 min before ice bath was removed and the reaction warmed to RT. After 
stirring for 1 h, TMSBr and THF were evaporated and the precipitate dissolved in 3 mL 
dry MeOH. The reaction solution was stirred for 1 h before the solvent was removed 
under reduced pressure. The product could be isolated as a white solid in a quantitative 
yield. (20 mg, 0.023 mmol). 
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1H-NMR (400.13 MHz, CD3OD) δ (ppm) = 5.27 (d, J = 4.3 Hz, 1H, H-2‘), 4.49 (d, J = 8.1 Hz, 
1H, myo-H-4), 4.41 (dd, J = 12.0, 2.8 Hz, 1H, H-1‘), 4.29 - 4.07 (m, 6H, myo-H-2, myo-H-5, 
H-1’, H-3’), 3.88 - 3.68 (m, 3H, H-6, H-7), 3.60 (d, J = 8.9 Hz, 1H, myo-H-3), 2.42 - 2.27 (m, 
4H, H-4’), 1.61 (d, J = 6.6 Hz, 4H, H-5‘), 1.32 (s, 16H, H-6‘, H-7‘, H-8‘, H-9‘), 1.21 (t, J = 6.8 
Hz, 3H, H-8), 0.90 (t, J = 6.3 Hz, 6H, H-10‘).  
13C-NMR (100.92 MHz, CDCl3) δ (ppm) = 174.9, 174.5 (C=O, 2C), 80.6 (CH, 1C, myo-C-5), 
80.0 (CH, 1C, myo-C-4), 79.5 (CH, 1C, myo-C-6), 78.8 (CH, 1C, myo-H-1), 72.3 (CH, 1C, myo-
C-2), 71.4 (CH, 1C, myo-C-3), 71.3, 71.2 (CH2, 1C, C-2’), 70.1 (CH2, 1C, C-7), 66.2, 66.2 (CH2, 
1C, C-3’), 63.1, 63.1 (CH, 1C, C-1’), 35.0, 34.9 (CH2, 2C, C-4’), 32.9, 30.2, 30.1, 30.1 (CH2, 6C, 
C-6’, C-7’, C-8’), 26.0 (CH2, 2C, C-5’),23.7 (CH2, 2C, C-9’), 15.8 (CH3, 1C, C-8), 14.4 (CH2, 2C, 
C-10’).  
31P-NMR (400.13 MHz, CDCl3) δ (ppm) = -0.79 (br. S, 2P), -2.77 (br. s, 1P). 
[α]D 20 = (-) 1.464 (c = 9 mg/mL in CH3Cl) 
HRMS (ESI)+ m/z meas. 775.4163; calc. for C27H53O9P3 [M+H]+ 775.4156 -1.0 ppm. 
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(2R)-3-(((benzyloxy)(((1R,2S,3R,4R,5S,6R)-4,5-bis((bis(benzyloxy)phosphoryl) 
oxy)-2,3,6-trimethoxycyclohexyl)oxy)phosphoryl)oxy)propane-1,2-diyl 
dioctanoate (27) 
 
Compound 26 (150 mg, 0.2 mmol, 1 eq) and 0.45 M 1H-Tetrazole in ACN (1.3 mL, 0.6 
mmol, 3 eq) were dissolved in 10 mL DCM in a flask under Ar atmosphere. The solution 
was cooled to 0°C before the DiC8-phosphoramidite 47 (174.53 mg, 0.3 mmol, 1.5 eq) 
dissolved in DCM (1.5 mL) was added dropwise. After removing the ice bath and stirring 
for 1 h, the reaction mixture was cooled to -40°C and mCPBA (89.64 mg, 0.4 mmol, 2 eq) 
dissolved in 1 mL DCM was added. After warming the solution slowly to RT, the reaction 
mixture was quenched with 2 mL of a 10%- solution of KHSO4 in water. The organic phase 
was washed with sat. NaHCO3- solution, water and brine, before it was dried with NaSO4 
and the solvent evaporated under reduced pressure. Purification of the product was 
achieved by column chromatography (heptane/ EtOAc linear gradient 20% - 100%). The 
product is a colourless oil and was isolated with a 76% yield. 
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Rf = 0.4 m (4:1 EtOAC:Heptane) 
1H NMR (400 MHz, CDCl3) δ (ppm) = 7.30 (qd, J = 7.5 Hz, 5H, Ar-H), 7.26 – 7.09 (m, 20H, 
Ar-H), 5.14 (d, J = 5.1 Hz, 1H, H-2’) 5.10 – 4.86 (m, 10H, CH2-Ar), 4.74 (d, J = 9.1 Hz, 1H, 
myo-H-4), 4.33 (m, 1H, myo-H-1), 4.26 – 4.18 (m, 1H, myo-H-2), 4.14 – 4.00 (m, 4H, H-1’ 
H-3‘), 3.96 (d, J = 8.2 Hz, 1H, myo-H-3), 3.63 (t, J = 8.4 Hz, 1H, myo-H-5), 3.52 (s, 3H, H-7), 
3.33 (s, 3H, H-9), 3.24 (s, 3H, H-8), 3.10 (t, J = 10.8 Hz, 1H, myo-H-6), 2.26 – 2.14 (m, 4H, 
H-4’), 1.51 (q, J = 9.5 Hz, 4H, H-5’), 1.20 (dd, J = 9.5 Hz, 16H, H-6’, H-7’, H-8’, H-9’), 0.85 – 
0.72 (m, 6H, H-10’).  
13C-NMR (100.92 MHz, CDCl3) δ (ppm) = 173.21, 172.82 (C=O, 2C), 136.29, 136.16, 136.04, 
135.97, 135.42 (Cq, 5C, Ar-C), 130.09, 129.71, 128.87, 128.79, 128.74, 128.72, 128.44, 
128.41, 128.36, 128.33, 128.30, 128.18, 128.11, 128.06, 127.94, 127.88, 127.68 (CH, 20C, 
Ar-C), 80.08 (CH, 1C, myo-C-6), 79.71 (CH, 1C, myo-C-4), 78.78 (CH, 1C, myo-C-5), 78.16 
(CH, 1C, myo-C-3), 77.83 (CH, 1C, myo-C-1), 77.35 (CH, 1C, myo-C-2), 77.24, 77.04, 76.72, 
76.07, 69.83 (CH2, 5C, CH2-Ar), 69.78 (CH, 1C, C-2’), 69.53 (CH2, 1C, C-3’), 69.47 (CH2, 1C, 
C-1’), 69.39 (CH3, 1C, C-7), 69.13 (CH3, 1C, C-9), 69.07 (CH3, 1C, C-8), 58.12, 34.12 (CH2, 
2C, C-4’), 34.00, 33.98, 31.66, 29.72, 29.07, 29.03 (CH2, 6C, C-6’, C-7’, C-8’), 28.94, 24.83 
(CH2, 2C, C-5’), 22.61 (CH2, 2C, C-9’), 14.09 (CH3, 2C, C-10’). 
31P-NMR (400.13 MHz, CDCl3): δ (ppm) = -1.66 (d, 1P), -1.76 (s, 0.5P), -1.86 (s, 0.5P), -2.11 
(d, 1P). 
[α]D 20 = (-) 10.596667 (c = 12 mg/mL in CH3Cl). 
HRMS (ESI)+ m/z meas. 1261.4813; calc. for C63H85O19P3 [M+Na]+ 1261.4790 ppm 
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(2R)-3-((hydroxy(((1R,2R,3S,4R,5R,6S)-2,3,6-trimethoxy-4,5-
bis(phosphonooxy)cyclohexyl)oxy) phosphoryl)oxy)propane-1,2-diyl dioctanoate 
(28) 
 
Palladium catalyst (10 wt. %,  35.8 mg, 0.028 mmol, 0.36 eq) was dissolved in glacial acetic 
acid (4 mL) containing the starting material 27 (118 mg, 0.095 mmol, 1 eq) at room 
temperature. The air in reaction flask was removed under reduced pressure, and filled 
with H2 three times, before the double H2 balloon was kept while the reaction stirred. 
When deemed finished, the reaction was stopped, filtered over celite, frozen in liquid N2, 
then freeze dried using a cooled-down condenser trap. The product was obtained as a 
white powder, with a yield of 84%.  
 
1H NMR (400 MHz, CDCl3) δ (ppm) = 5.18 (d, J = 5.7 Hz, 1H, H-2’), 4.44 – 4.34 (m, 1H, myo-
H-4), 4.34 – 4.30 (m, 1H, H-1’), 4.09 (t, J = 6.4 Hz, 3H, myo-H-2, myo-H-5, H-3’), 3.97 (s, 1H, 
myo-H-3), 3.50 (d, J = 15.3 Hz, 6H, H-7, H-8), 3.40 (s, 3H, H-9), 2.25 (dt, J = 11.7 Hz, 4H, 
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myo-H-1, myo-H-6, H-1’, H-3’), 1.52 (q, J = 7.1 Hz, 4H, H-4’), 1.21 (dt, J = 8.1 Hz, 20H, H-5’, 
H-6‘, H-7‘, H-8‘, H-9‘), 0.81 (t, J = 6.5 Hz, 6H, H-10’). 
13C-NMR (100.92 MHz, CDCl3) δ (ppm) = 175.27, 174.91 (C=O, 2C), 82.33 (CH, 1C, myo-C-
6), 81.63 (CH, 1C, myo-C-5), 79.12 (CH, 1C, myo-C-4), 78.75 (CH, 1C, myo-C-1), 71.82 (CH, 
1C, myo-C-2), 71.74 (CH, 1C, myo-C-3), 66.42 (CH2, 1C, C-2’), 63.64 (CH2, 1C, C-3’), 59.54 
(CH, 1C, C-1’), 49.92 (CH3, 1C, C-7), 49.85 (CH3, 1C, C-8), 49.71 (CH3, 1C, C-9), 49.00, 48.79 
(CH2, 2C, C-4’), 35.47, 35.28, 33.31, 31.19, 30.59 (CH2, 6C, C-6’, C-7’, C-8’), 30.57, 30.55 
(CH2, 2C, C-5’), 26.43, 24.13 (CH2, 2C, C-9’), 14.87 (CH2, 2C, C-10’). 
31P-NMR (400.13 MHz, CDCl3) δ (ppm) = -0.32 (d, J = 25.6 Hz, 2P), -1.71 (s, 1P). 
[α]D 20 = (-) 1.3266055 (c = 10.9 mg/mL in CH3Cl). 
HRMS (ESI)+ m/z meas. 789.2635; calc. for C76H95O21P3 [M+H]+ 789.2623 -1.5 ppm 
 
 (2R)-3-(((benzyloxy)(((3aS,4R,5R,6S,7S,7aR)-4,5-bis((bis(benzyloxy) 
phosphoryl)oxy)-6-((2-methoxyethoxy)methoxy)hexahydrospiro[benzo[d] 
[1,3]dioxole-2,1'-cyclohexan]-7-yl)oxy)phosphoryl)oxy)propane-1,2-
diyl(3R,3'R,5R,5'R,7R,7'R)-bis(adamantane-1-carboxylate) (33) 
 
 
Compound 32 (90.36 mg, 0.104 mmol, 1 eq) and 0.45 M 1H-Tetrazole in ACN (1.04 mL, 
0.468 mmol, 3 eq) were dissolved in 8 mL DCM in a flask under Ar atmosphere. The 
solution was cooled to 0°C before compound 44 (102 mg, 0.156 mmol, 1.5 eq) dissolved 
in DCM (1 mL) was added dropwise. After removing the ice bath and stirring for 2 h, the 
reaction mixture was cooled to -40°C and mCPBA (104.88 mg, 0.468 mmol, 3 eq) 
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dissolved in 1 mL DCM was added dropwise. After warming the solution slowly to RT, the 
reaction mixture was quenched with 2 mL of a 10%- solution of KHSO4 in water. The 
organic phase was washed with sat. NaHCO3- solution, water and brine, before it was 
dried with NaSO4 and the solvent evaporated under reduced pressure. Purification of the 
product was achieved by biotage column chromatography (50g Silica cartridge; linear 
gradient of 50% to 90% EtOAc in Heptane). The product is a colourless oil and was 
isolated with a 50% yield. 
 
1H NMR (400 MHz, CDCl3) δ (ppm) = 7.44 – 7.30 (m, 8H, Ar-H), 7.30 – 7.19 (m, 17H, Ar-
H), 5.30 (s, 2H, H-13), 5.14 – 4.94 (m, 10H, CH2-Ar), 4.87 – 4.78 (m, 2H, myo-H-4, myo-H-
1), 4.75 (dd, J = 9.8 Hz, 1H, H-2’), 4.67 – 4.59 (m, 2H, H-1’, H-3’), 4.33 – 4.22 (m, 3H, myo-
H-5, H-1’, H-3’), 4.21 – 4.10 (m, 2H, myo-H-6, H-14), 4.05 (d, J = 5.9 Hz, 2H, H-15), 3.73 – 
3.57 (m, 2H, myo-H-2, myo-H-3), 3.27 (s, 3H, H-16), 2.07 – 1.90 (m, 8H, H-9’, H-4’), 1.84 (q, 
J = 3.2 Hz, 12H, H-10’, H-5’, H-7’, H-6’, H-11’, H-8’), 1.69 (q, J = 12.0 Hz, 8H-cy), 1.47 (d, J = 
14.5 Hz, 2H).  
13C NMR (101 MHz, CDCl3) δ (ppm) = 174.2, 173.8, 135.8, 135.5, 133.1, 126.0, 125.9, 125.8, 
125.7, 125.3, 125.25, 125.2, 125.1, 124.9, 124.7, 124.6, 77.3, 75.3, 74.6, 74.3, 74.0, 73.5, 
73.1, 72.8, 66.9, 58.9, 38.1, 36.2, 36.1, 33.9, 25.3, 25.2, 20.4 
31P-NMR (400.13 MHz, CDCl3) δ (ppm) = -1.64 (d, J = 2.4 Hz, 1P), -1.92 (d, J = 45.6 Hz, 1P), 
-2.18 (d, J = 3.0 Hz, 1P) 
[α]D 20 = (-)5.8571429 (c = 7.7 mg/mL in CH3Cl) 
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HRMS (ESI)+ m/z meas. 1459.5492; calc. for C76H95O21P3 [M+Na]+ 1459.5471 -1.5 ppm 
 
(2R)-3-((hydroxy(((1R,2R,3S,4R,5R,6S)-2,3,6-trihydroxy-4,5-bis(phosphonooxy) 
cyclohexyl)oxy)phosphoryl)oxy)propane-1,2-diyl(3R,3'R,5R,5'R,7R,7'R)-
bis(adamantane-1-carboxylate) (34) 
 
Compound 33 (70 mg, 0.0487 mmol, 1 eq) was thoroughly dried before dissolving it in 
anhydrous THF (3 mL) at rt, under argon atmosphere. The solvents used for this reaction 
was dried over molecular sieves. The reaction mixture was allowed to stir at 0°C. TMSBr 
(0.9 mL, excess), was added dropwise to the stirring reaction, and the reaction was slowly 
brought up to rt and stirred for an hour. TMSBr and THF were evaporated and the 
precipitate dissolved in 3 mL dry MeOH. The reaction solution was stirred for 1 h before 
the solvent was removed under reduced pressure. The crude was then dissolved in a 2 
mL solution of TFA:DCM:H2O mixture (8:1:1) and allowed to stir for 6 minutes before 
diluting with cyclohexane and co-evaporating under reduced pressure.  Upon 
condensation, the product was formed as a white solid and could be isolated with a 50% 
yield.  
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1H NMR (400 MHz, CDCl3) δ (ppm) = 5.35–5.27 (m, 1H, CH2CHCH2), 4.49 (dd, J = 12 Hz, 3, 
1H), 4.30–4.22 (m, 3H), 4.15– 3.90 (m, 5H), 3.71 (dd, J = 10 Hz, 3, 1H), 2.05–2.00 (m, 6H), 
1.93– 1.86 (m, 12H), 1.89–1.68 (m, 12H). 
13C NMR (101 MHz, CDCl3) δ (ppm) = 180.2, 179.9, 77.8, 77.7, 75.9, 75.8, 71.3, 71.2, 70.9, 
70.7, 70.6, 63.7, 62.6, 40.9, 40.8, 38.3, 35.8, 35.7, 27.5, 27.4. 
31P-NMR (400.13 MHz, CDCl3) δ (ppm) = 0.49 (d, J = 67.1 Hz, 2P), -1.50 (s, 1P) 
Characterization data of the compound was consistent with previously published work125 
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(2R)-3-(((benzyloxy)(((3aS,4R,5R,6S,7S,7aR)-4,5-bis((bis(benzyloxy) 
phosphoryl)oxy)-6-((2-methoxyethoxy)methoxy)hexahydrospiro[benzo[d] 
[1,3]dioxole-2,1'-cyclohexan]-7-yl)oxy)phosphoryl)oxy)propane-1,2-diyl 
bis(heptylcarbamate) (35) 
 
Compound 32 (207.3 mg, 0.238 mmol, 1 eq) and 0.45 M 1H-Tetrazole in ACN (1.58 mL, 
0.714 mmol, 3 eq) were dissolved in 15 mL DCM in a flask under Ar atmosphere. The 
solution was cooled to 0°C before compound 41 (219 mg, 0.358 mmol, 1.5 eq) dissolved 
in DCM (2 mL) was added dropwise. After removing the ice bath and stirring for 2 h, the 
reaction mixture was cooled to -40°C and mCPBA (160 mg, 0.714 mmol, 3 eq) dissolved 
in 2 mL DCM was added dropwise. After warming the solution slowly to RT, the reaction 
mixture was quenched with 2 mL of a 10% solution of KHSO4- in water. The organic phase 
was washed with sat. NaHCO3- solution, water and brine, before it was dried with NaSO4 
and the solvent evaporated under reduced pressure. Purification of the product was 
achieved by biotage column chromatography (25g Silica cartridge; linear gradient of 30% 
to 100% EtOAc in Heptane). The product is a colourless oil and was isolated with a 38% 
yield. 
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1H NMR (400 MHz, CDCl3) δ (ppm) = 7.32 (dd, J = 6.0 Hz, 2H, NH), 7.29 – 7.11 (m, 25H, Ar-
H), 5.03 (ddd, J = 9.6 Hz, 5H, CH2-Ar, H-13, H-2’), 4.99 – 4.88 (m, 8H, CH2-Ar), 4.76 (dd, J = 
6.9 Hz, 2H, H-1’), 4.67 (dd, J = 6.9 Hz, 2H, H-3’), 4.58 – 4.42 (m, 2H, myo-H-4, myo-H-1), 
4.29 – 4.17 (m, 2H, H-14), 4.14 (dq, J = 9.9 Hz, 2H, H-15), 4.04 (t, J = 7.2 Hz, 1H, myo-H-5), 
3.65 – 3.52 (m, 1H, myo-H-3), 3.34 (dt, J = 4.5 Hz, 2H, myo-H-2, myo-H-6), 3.21 (s, 3H, H-
16), 3.09 – 2.92 (m, 4H, H-4’), 1.73 – 1.59 (m, 2H, H-5’), 1.27 – 1.04 (m, 28H, H-
8,9,10,11,12, H-6’,7’,8’,9’), 0.81 – 0.75 (m, 6H, H-10’).  
13C NMR (101 MHz, CDCl3) δ (ppm) = 155.83, 155.36, 136.00, 135.92, 135.74, 135.67, 
135.63, 129.15, 128.76, 128.66, 128.61, 128.56, 128.53, 128.48, 128.45, 128.42, 128.39, 
128.35, 128.30, 128.28, 128.04, 128.01, 127.99, 127.96, 127.91, 127.87, 127.79, 127.73, 
111.72, 111.66, 96.24, 79.11, 77.36, 77.25, 77.05, 76.73, 75.51, 74.14, 72.94, 71.66, 71.62, 
70.12, 69.67, 69.61, 69.54, 69.49, 69.42, 67.82, 67.77, 66.47, 62.47, 60.41, 58.89, 58.87, 
41.16, 36.35, 34.25, 31.76, 29.91, 29.88, 29.82, 28.97, 28.93, 26.75, 26.69, 24.94, 23.88, 
23.58, 22.61, 21.08, 14.22, 14.08, 1.04. 
31P-NMR (400.13 MHz, CDCl3) δ (ppm) = -1.69 (d, J = 11.8 Hz, 1P), -1.99 – -2.63 (m, 2P).  
[α]D 20 = (-)8.1460123 (c = 16.3 mg/mL in CH3Cl) 
HRMS (ESI)+ m/z meas. 1417.5715; calc. for C70H97N2O21P3 [M+Na]+ 1417.5689 -1.9 
ppm 
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(2R)-3-((hydroxy(((1R,2R,3S,4R,5R,6S)-2,3,6-trihydroxy-4,5-
bis(phosphonooxy)cyclohexyl)oxy)phosphoryl)oxy)propane-1,2-diyl 
bis(heptylcarbamate) (36) 
Compound 35 (120 mg, 0.086 mmol, 1 eq) was thoroughly dried before dissolving it in 
anhydrous DCM (2.5 mL) at rt, under argon atmosphere. The solvents used for this 
reaction was dried over molecular sieves. The reaction mixture was allowed to stir at 0°C. 
TMSBr (1 mL, excess), was added dropwise to the stirring reaction, and the reaction was 
slowly brought up to rt and stirred for an hour. TMSBr and DCM were evaporated and the 
precipitate dissolved in 2.5 mL dry MeOH. The reaction solution was stirred for 1 h before 
the solvent was removed under reduced pressure. The crude was then dissolved in a 2 
mL solution of TFA:DCM:H2O mixture (8:1:1) and allowed to stir for 6 minutes before 
diluting with cyclohexane and co-evaporating under reduced pressure.  Upon 
condensation, the product was formed as a white solid and could be isolated with a 50% 
yield. 
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1H NMR (400 MHz, DMSO) δ (ppm) = 7.19 (dt, J = 39.7 Hz, 2H, NH), 4.85 (t, J = 5.1 Hz, 1H, 
H-2’), 4.06 – 3.83 (m, 4H, H-1’,3’), 3.64 – 3.40 (m, 2H, myo-H-1, myo-H-4), 2.87 (dq, J = 12.8 
Hz, 4H, H-4’), 2.42 (p, J = 1.8 Hz, 4H, myo-H-5, myo-H-2, myo-H-3, myo-H-6), 1.41 – 0.97 
(m, 24H, H-5’-9’), 0.77 (t, J = 6.8 Hz, 6H, H-10’). 
13C NMR (101 MHz, DMSO) δ (ppm) = 155.63, 155.05, 70.72, 69.68, 68.41, 63.69, 60.21, 
53.94, 53.87, 53.67, 53.60, 53.40, 53.33, 53.13, 52.86, 41.70, 41.10, 41.10, 40.44, 31.74, 
31.14, 28.92, 26.65, 22.58, 13.80. 
31P-NMR (400.13 MHz, DMSO) δ (ppm) = 0.56 (s, 1 P), -0.14 (d, J = 40.2 Hz, 1P), -0.73 (s, 
0.5P), -1.91 (s, 0.5P) 
[α]D 20 = 6.5133333 (c = 3 mg/ml in CHCl3) 
HRMS (ESI)+ m/z meas. 835.4610; calc. for C37H75N4O9P3 [M+Na]+ 835.4639, 3.5 ppm  
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(2R)-3-(((benzyloxy)(((3aS,4R,5R,6S,7S,7aR)-4,5-bis((bis(benzyloxy) 
phosphoryl)oxy)-6-((2-methoxyethoxy)methoxy)hexahydrospiro[benzo[d] 
[1,3]dioxole-2,1'-cyclohexan]-7-yl)oxy)phosphoryl)oxy)propane-1,2-diyl 
dioctanoate (51) 
 
Compound 32 (97 mg, 0.11 mmol, 1 eq) and 0.45 M 1H-Tetrazole in ACN (1.46 mL, 0.66 
mmol, 6 eq) were dissolved in 15 mL DCM in a flask under Ar atmosphere. The solution 
was cooled to 0°C before compound 47 (129.98 mg, 0.22 mmol, 2 eq) dissolved in DCM 
(2 mL) was added dropwise. After removing the ice bath and stirring for 2 h, the reaction 
mixture was cooled to -40°C and mCPBA (147.9 mg, 0.66 mmol, 6 eq) dissolved in 2 mL 
DCM was added dropwise. After warming the solution slowly to RT, the reaction mixture 
was quenched with 2 mL of a 10% solution of KHSO4- in water. The organic phase was 
washed with sat. NaHCO3- solution, water and brine, before it was dried with NaSO4 and 
the solvent evaporated under reduced pressure. Purification of the product was achieved 
by biotage column chromatography (10g Silica cartridge; linear gradient of 25% to 100% 
EtOAc in Heptane). The product is a colorless oil and was isolated with an 85% yield. 
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1H NMR (400 MHz, CDCl3) δ (ppm) = 7.32 – 7.25 (m, 4H, Ar-H), 7.25 – 7.20 (m, 8H, Ar-H), 
7.19 – 7.14 (m, 13H, Ar-H), 5.06 – 4.98 (m, 5H, CH2-Ar), 4.98 – 4.88 (m, 5H, CH2-Ar), 4.76 
(dd, J = 16.3 Hz, 2H, H-13, H-2’), 4.68 (dd, J = 9.1 Hz, 1H, H-13), 4.57 (ddt, J = 10.1 Hz, 2H, 
H1’), 4.26 – 4.16 (m, 3H, myo-H-4, H-14), 4.15 – 4.10 (m, 1H, myo-H-1), 4.09 – 3.97 (m, 2H, 
H-3’), 3.59 (ddd, J = 11.9 Hz, 2H, H-14), 3.35 – 3.26 (m, 2H, myo-H-5, myo-H-3), 3.20 (d, J = 
2.0 Hz, 3H, myo-H-2, H-15), 2.19 (dtd, J = 12.9, 7.1, 6.7, 4.5 Hz, 4H, H-4’), 1.66 (d, J = 6.2 Hz, 
7H, H-16, H-5’), 1.27 – 1.11 (m, 22H, H-8,9,10,11,12, H-6’,7’,8’,9’), 0.80 (dq, J = 6.7 Hz, 6H, 
H-10’). 
13C NMR (101 MHz, CDCl3) δ (ppm) = 173.18, 173.17, 172.80, 172.76, 136.00, 135.88, 
135.80, 135.44, 128.64, 128.63, 128.52, 128.50, 128.48, 128.46, 128.44, 128.42, 128.37, 
128.34, 128.28, 128.03, 128.01, 127.97, 127.94, 127.93, 127.86, 127.83, 111.62, 111.60, 
96.28, 96.20, 78.66, 77.35, 77.23, 77.03, 76.71, 75.69, 73.18, 71.64, 69.65, 69.55, 69.49, 
67.76, 61.64, 58.88, 36.48, 34.24, 34.08, 33.97, 31.67, 29.73, 29.08, 29.04, 28.95, 24.83, 
24.82, 24.80, 23.88, 23.59, 22.62, 14.09. 
31P-NMR (400.13 MHz, CDCl3) δ (ppm) = -1.62 (d, J = 4.4 Hz, 1P), -1.86 (d, J = 22.6 Hz, 1P), 
-2.14 (d, J = 4.5 Hz, 1P) 
[α]D 20 = (-)5.9584615  
HRMS (ESI+) m/z meas. 1387.5483; calc. for C70H95O21P3 [M+Na]+ 1387.5471 -0.9 ppm 
 
161 
(2R)-3-((hydroxy(((1R,2R,3S,4R,5R,6S)-2,3,6-trihydroxy-4,5-
bis(phosphonooxy)cyclohexyl)oxy)phosphoryl)oxy)propane-1,2-diyl dioctanoate 
(52) 
Compound 51 (120 mg, 0.0879 mmol, 1 eq) was thoroughly dried before dissolving it in 
anhydrous DCM (0.5 mL) at rt, under argon atmosphere. The solvents used for this 
reaction was dried over molecular sieves. The reaction mixture was allowed to stir at 0°C. 
TMSBr (1 mL, excess), was added dropwise to the stirring reaction, and the reaction was 
slowly brought up to rt and stirred for an hour. TMSBr and DCM were evaporated and the 
precipitate dissolved in 2.5 mL dry MeOH. The reaction solution was stirred for 1 h before 
the solvent was removed under reduced pressure. The crude was then dissolved in a 2 
mL solution of TFA:DCM:H2O mixture (8:1:1) and allowed to stir for 10 minutes before 
diluting with cyclohexane and co-evaporating under reduced pressure. Resuspension in 
water and freeze drying yielded a white solid as the product (85%). 
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Characterization data of the compound was consistent with previously published work120 
 
5.2.4. Solid phase synthesis of lipid tail-modified PI(4,5)P2 analogues 
 
1-O-[(3-phenylpropanoyl)benzyl]phosphoryl-2,3-O-(p-Wang-resin-oxy) 
benzylidene-4,5-di-O-(di-O-benzyl-phosphate)-6-O-methoxyethoxymethyl-myo-
inositol (48) 
 
 
To the preswelled resin prepared according to previously established and published 
procedures120 (148 mg, 0.077 mmol, loading 0.522 mmol/g) in anhydrous CH2Cl2 (2 mL) 
was added dicyanoimidazole (91 mg, 0.772 mmol) in acetonitrile (1 mL), followed by 
immediate addition of phosphoramidite 38 (284 mg, 0.772 mmol) in acetonitrile (1 mL). 
The resin was then allowed to shake for 40 h at room temperature, which was then cooled 
to –30°C, followed by addition of peracetic acid (167 µL, 0.92 mmol, 40% in acetic acid). 
After careful stirring of the resin for 1 h at the same temperature, it was filtered and 
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washed with DCM (3 X), DMF (3x), MeOH (3x), and finally DCM (3x). The resin was dried 
overnight in vacuo. The formation of the product was confirmed by test cleavage using 
10% TFA in DCM.  
MS (ESI): m/z (%): 1071.3 (100) [M+H]+ (TFA test cleavage) 
1-O-[(3-phenylpropanoyl)benzyl]phosphoryl-4,5-di-O-(di-O-benzyl-phosphate)-6-
O-methoxyethoxymethyl-myo-inositol (49) 
 
 
 
To the pre-swelled resin 48 (168 mg, 0.068 mmol, loading 0.469 mmol/g) in CH2Cl2 was 
added a mixture of 10% TFA in CH2Cl2 containing 1% methanol. The resin was shaken for 
1 h, filtered and washed with CH2Cl2 for several times. All the washings were combined 
and evaporated to give the crude product, which was purified by HPLC yielding a mixture 
of free hydroxyl and MEM protected hydroxyl group at the 6-position. This mixture was 
used directly for the next step. 
HPLC conditions: 
tR = 18.4 min; m/z (%): 989 [M-MEM+H]+. The area under the peak represents 1. 
tR = 18.9 min; m/z (%): 1100 [M+Na]+. The area under the peak represents 1. 
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1H NMR (400 MHz, CDCl3) δ (ppm) = 7.66-7.88 (m, 25 H, Ar-H), 4.56–4.48 (q, J = 9.7 Hz, 
1H, CH-4-myo), 4.22 (m, 1H, CH2), 4.19–4.05 (m, 5H, CH-2-myo, CH-5-myo, CH2), 4.01–
3.96 (m, 1H, CH-1-myo), 3.64 (m, 1H, CH-6 myo), 3.62 (m, 1H, CH-3-myo), 2. 
31P-NMR (400.13 MHz, CDCl3) δ (ppm) = 0.61 (d, 1P), –0.16 (d, 1P), –1.26 (d, 2P) 
M-MEM: [α]D 20 = (–)3.122 (c = 0.9 mg/mL, CHCl3)  
HRMS (ESI+): m/z pos.: [M-MEM+H]+ calculated, 989.2827 found 989.2836 –0.9 ppm 
[M-MEM+Na]+ calculated, 1011.2646, found 1011.2653–0.7 ppm 
[M-MEM+K]+ calculated, 1027.2385, found 1027.2396–1.0 ppm 
 
1-O-[(3-phenylpropanoyl)]phosphoryl-4,5-di-O-(phosphate)-myo-inositol (50): 
 
 
To compound 49 (19.6 mg, 0.019 mmol) in 0.5 mL of THF in a Schlenk flask was added 
bromotrimethylsilane (1.0 mL, excess) and the reaction was stirred for 2 h at room 
temperature. The reaction was then concentrated under vacuum to remove excess TMSBr 
and other byproducts. The residue was then stirred with methanol (2.5 mL) for 1 h 
followed by removal of the solvent under vacuum to give the product as white solid, which 
was dissolved in a methanol/ water mixture (1:1) and stirred with 20 mg of prewashed 
Chelex Na+ ion exchanger resin for 24 h. The resin was filtered off and washed three times 
with water. The combined filtrates were concentrated in vacuo and then lyophilized to 
obtain 50 as an off-white solid (8.6 mg, 84%). 
1H NMR (400 MHz, CDCl3) δ (ppm) = 7.66-7.88 (m, 25 H, Ar-H), 4.56–4.48 (q, J = 9.7 Hz, 
1H, CH-4-myo), 4.22 (m, 1H, CH2), 4.19–4.05 (m, 5H, CH-2-myo, CH-5-myo, CH2, H-CH2), 
4.01–3.96 (m, 1H, CH-1-myo), 3.64 (m, 1H, CH-6 myo), 3.62 (m, 1H, CH-3-myo), 2. 
31P-NMR (400.13 MHz, CDCl3) δ (ppm) = 0.61 (d, 1P), –0.16 (d, 1P), –1.26 (d, 2P) 
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M–MEM: [α]D 20 = –2.90 (c = 0.004, CHCl3)  
HRMS (ESI+): m/z pos.: [M-MEM+H]+ calculated, 989.2827 found 989.2836 –0.9 ppm 
[M-H]- calculated, 537.0334, found 537.0342–1.6 ppm 
 
5.2.5. Synthesis of the PI(4,5)P2 computational screen hit analogues (by the 
CBCF) 
 
The synthesis of the final molecule which showed inhibition of PRL-3 is depicted in the 
scheme below: 
 
The designed final compound is termed 62 and its negative control benzyl ester 69. The 
synthesis of product 61, which was not completed and only yielded compound 70, is 
depicted in the scheme below:  
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The analytics of the abovementioned three compounds (62, 69 and 70) are shown below.  
 
 
1H NMR (400 MHz, CDCl3) δ (ppm) = 7.70 (s, 1H, NH), 7.35 (s, 5H, Ar-H), 5.27 (s, 1H, H-2), 
5.19 (s, 1H, H-13), 5.16 (s, 1H, H-13), 4.37 (s, 1H, H-1), 4.23 (d, J = 25.4 Hz, 4H, H-11, H-3), 
4.14 (dd, J = 5.8 Hz, 2H, H-7), 4.08 (s, 1H, H-9), 3.95 (m, 1H, H-9), 3.37 (d, J = 3.0 Hz, 2H, H-
5), 2.30 (m, 4H, CH2), 1.60 (m, 2H, CH2), 1.27 (s, 16H, CH-lipid chain), 0.87 (s, 6H, CH3 x2). 
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13C NMR (101 MHz, CDCl3) δ (ppm) = 173.38 (C-14), 173.07 (C-15), 169.53, 169.33 (C-6), 
168.33, 168.22 (C-8), 168.10, 167.91 (C8), 164.91 (C-4), 135.03, 134.54 (C-7), 129.03 C-
Ph), 128.91, 128.79, 128.76, 128.73, 128.49, 128.38, 128.04 (C-10), 122.80, 122.46, 
120.02, 119.67, 68.61, 68.22 (C-13), 67.56, 63.53 (C-13), 61.94 (C-13), 49.60, 49.26, 49.20, 
48.92, 48.64, 47.92 (C-9), 47.58, 47.24 (C-11), 46.90, 41.47 (C-11), 41.24, 41.04 (C-9), 
40.96 (C-5), 34.23, 34.12, 31.75, 29.15, 29.10, 29.00, 24.94, 22.70 (C-CH2), 14.16 (C-CH3). 
19F NMR (CDCl3) δ (ppm) = -70.11, -70.47 
HRMS (ESI+): m/z = [M+H]+ 713.3 (UPLCM/MS data) 
 
 
 
1H NMR (400 MHz, MeOD) δ (ppm) = 5.35 – 5.21 (m, 1H, H-2), 4.37 (dd, J = 4.0 Hz, 2H, H-
3), 4.30 – 4.09 (m, 8H, H-1, H-5, H-9, H-7), 3.42 (d, J = 6.3 Hz, 1H), 2.33 (td, J = 2.5 Hz, 4H, 
H-CH2), 1.67 – 1.54 (m, 4H, H-CH2), 1.39 – 1.22 (m, 16H, CH2), 0.91 (t, J = 6.7 Hz, 6H, CH3). 
13C NMR (101 MHz, CDCl3) δ (ppm) = 173.63, 173.60, 173.31, 173.27, 171.07, 170.75, 
170.04, 169.74, 168.53, 168.23, 166.10, 166.06, 125.75, 125.46, 122.97, 122.68, 120.18, 
77.48, 77.16, 76.84, 65.16, 63.59, 62.12, 62.08, 49.36, 49.07, 47.66, 47.31, 41.89, 41.23, 
41.05, 40.91, 34.28, 34.15, 31.78, 29.19, 29.13, 29.04, 24.96, 22.73. 
19F NMR (CDCl3) δ (ppm) = -70.20, -70.65 
HRMS (ESI+): m/z = [M+H]+ 627.2 (UPLCM/MS data) 
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1H NMR (400 MHz, CDCl3) δ (ppm) = 5.63 (d, J = 7.8 Hz, 1H, NH), 5.28 (td, J = 5.1Hz, 
1H, H-2), 4.39 (dd, J = 11.9 Hz, 4H, H-1, H-3), 4.29 (d, J = 4.5 Hz, 2H, H-4), 4.24 – 
4.10 (m, 6H, H-5, H-6), 4.10 – 3.99 (m, 3H, H-7), 2.32 (td, J = 7.6 Hz, 4H, 2xH-9), 
1.61 (dt, J = 7.6 Hz, 4H, 2xH-10), 1.33 – 1.22 (m, 16H, 2xH11-14), 1.15 (d, J = 6.6 
Hz, 6H, 2xH-15). 
13C NMR (101 MHz, CDCl3) δ (ppm) = 173.38, 173.11, 169.42, 168.23, 164.69, 156.90, 
77.48, 77.16, 76.84, 63.80, 61.84, 50.55, 44.04, 41.94, 34.27, 34.14, 31.78, 29.83, 29.18, 
29.14, 29.03, 24.98, 24.97. 
HRMS (ESI+): m/z = [M+H]+ 585.3 (UPLCM/MS data). 
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Chapter 6. Summary  
 
In this doctoral work, the objective was to develop and establish a strategy for the total 
organic synthesis of PI(4, 5)P2 analogues, alkylated on the inositol ring, in order to study 
the mechanisms of interaction between PI(4, 5)P2 and the metastasis-promoting 
phosphatase PRL-3.  
 
After the development of the synthetic route, the effort for the synthesis of 6-O-
methylated PI(4,5)P2 was made. To establish the route, each reaction step was 
optimized by testing different reaction conditions. After developing the needed 
protecting group strategy for selective inositol ring alkylation, the reaction with the 
alkylating Meerwein salt as reagent was carried out, gave good yields, and was further 
used for different alkylated analogues.  
 
Moreover, and using both solid phase and solution phase organic synthesis strategies, 
lipid chain-modified PI(4,5)P2 analogues were also synthesized to gain more insight on 
the importance of the functional groups in the natural substrate binding to PRL-3. By 
using the established synthetic route, a bigger and more versatile library of differently 
substituted alkylated PI(4,5)P2 and other PIPn analogues could be synthesized in the 
future. These analogues synthesized here were utilized for SAR studies to gain 
information for binding requirements of the following PI(4,5)P2-metabolizing proteins: 
PRL-3, SYNJ1, OCRL and INPP5E. Curiously, the inositol-alkylated analogues were 
specific to PRL-3 with respect to the other phosphatases, and the lipid tail-modified 
analogues showed more significant activity with the other phosphatases than with PRL-
3. This sets the initial basis for specificity of these analogues with a phosphatase that 
bears an unusually shallow and hydrophobic active site (PRL-3).  
 
Complementary to the main work of this project, in silico shape similarity screening 
methods were used with PI(4,5)P2 as a template, to search for specific PRL-3-active lead 
compound which could support designing an optimal inhibitor. This computational 
experiment led to an active compound (further optimized through synthesis before 
testing), underlying the potential of prediction tools in finding inhibitors for challenging 
targets.  
 
The synthesized PI(4,5)P2 analogues will be valuable in many applications, ranging from 
investigating the binding requirements of specific PIPn- metabolizing phosphatases, to 
 
170 
designing ligands through in silico and synthetic methods to modulate their interaction 
with interesting targets like phosphatases. Generally, such adaptable analogues could 
forge novel agents in chemical biology, both in probing biological activity and in the 
treatment of diseases.  
 
 
 
 
Figure 42 Overview of the structures of the PI(4,5)P2 original substrate (52) and its six analogues (12, 18, 
28, 34, 36 and 50), all of which were synthesized as part of this work.  
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Chapter 7. Appendices 
7.1. Structural Directory 
 
 
172 
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7.2. Abbreviation directory 
 
PIPn  
 
 
phosphatidylinositol-phosphates  
AcCN/ACN  acetonitrile  
AM  acetyloxymethyl  
Ar  Argon  
BnOH  benzylalcohol  
BzCl  benzoylchloride  
CHD22 Cadherin 22 
COSY homonuclear correlation 
spectroscopy 
DAG  diacylglycerol  
DCM  dichloromethane  
DIC  N,N'-diisopropylcarbodiimide  
DIPA*DCI  diisopropylcarbodiimide  
DIPEA  (N,N'-di-iso-propyl)-ethylamine  
DMAP  4-Dimethylaminopyridine  
DMF dimethylformamide 
DMSO  dimethylsufoxide  
DUSPs/DSPs Dual specificity phosphatases 
EMT Epithelial-mesenchymal transition 
ESI  electrospray ionization  
Et  ethyl  
Et2O  diethylether  
EtOAc  ethylacetate  
HMBC Heteronuclear Multiple Bond 
Correlation. 
HR-MS  high resolution mass spectrometry  
HSQC Heteronuclear Multiple Quantum 
Correlation 
InsP  inositol-phosphates  
mCPBA  meta-chloroperoxybenzoic acid  
Me  methyl  
MEM 2-Methoxyethoxymethyl ether  
MEMCl 2-Methoxyethoxymethyl chloride 
MeOH  methanol  
MHz  megaherz  
MMT Monomethoxy trityl 
MTM  myotubularin  
NaOMe  sodium methoxide  
NHERF1 Na+/H+ Exchanger Regulatory 
Factor 
NMR  nuclear magnetic resonance  
NOE  nuclear overhauser effect  
PIC  phospholipase C  
PIKfyve  phosphoinositide kinase with fyve 
Znn-motive  
PIS  phosphatidylinositol synthase  
PM  propionyloxymethyl  
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PRD Proline-rich domain 
PSTPs 
 
Protein serine/threonine 
phosphatases 
PTPs Protein Tyrosine phosphatases 
PTEN  Phosphatase and tensin homolog 
deleted on chromosome 10  
RT  room temperature  
SAR Structure-activity relationships 
TBAF Tetra-n-butylammonium fluoride 
TBDPS Tert-butyl diphenylsilane 
TBDPSCl Tert-butyl diphenylsilylchloride 
THF tetrahydrofuran 
TMSBr bromotrimethylsilane 
TLC Thin layer chromatography 
TFA Trifluoroacetic acid 
USR Ultrafast shape recognition 
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7.3. NMR Spectra 
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7.4. Supplementary Figures  
 
 
 
 
 
Figure S1 The dephosphorylation activity of PRL-3 toward the PI(4,5)P2 analogues, at 5 different 
concentrations (25, 50, 100, 200 and 250 μM). The slopes are shown until 1500-3000 seconds of 
measurements because of the signal variation observed after that time point in all assays, which could either 
be due to the precipitation of the protein or the interaction of the analogues with the photoactive component 
in the assay. A) Absorbance measurements of compound 28. B) Absorbance measurements of compound 18. 
C) Absorbance measurements of compound 34. D) Absorbance measurements of compound 12. E) and F), 
Absorbance measurements of compounds 36 and 50, respectively: those compounds were not active against 
PRL-3. Graphs are shown with error bars, depicted as dotted lines above and below each respective curve. 
The lower the signal intensity, the higher the relative error in the assay18,19,120, leading to error bars that 
would mask other curves.   
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Figure S2 Activity of the six synthesized analogues with three different PI(4,5)P2-metabolizing 
phosphatases, with respect to the parent substrate (control) PI(4,5)P2. The results shown in the graphs take 
into consideration the error margins (dotted lines above and below each curve) of each experiment 
replicates.   
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(8) Fahs, S., Lujan, P., and Köhn, M. (2016) Approaches to Study Phosphatases. ACS 
Chem. Biol. 11, 2944–2961. 
(9) Li, X., Wilmanns, M., Thornton, J., and Köhn, M. (2013) Elucidating human 
phosphatase-substrate networks. Sci. Signal. 6, rs10. 
(10) Tonks, N. K. (2013) Protein tyrosine phosphatases - From housekeeping enzymes 
to master regulators of signal transduction. FEBS J. 280, 346–378. 
(11) Brautigan, D. L. (2013) Protein Ser/Thr phosphatases--the ugly ducklings of cell 
signalling. FEBS J. 280, 324–345. 
(12) Duan, G., Li, X., and Köhn, M. (2015) The human DEPhOsphorylation database 
DEPOD: a 2015 update. Nucleic Acids Res. 43, D531–D5315. 
(13) Shi, Y. (2009) Review Serine / Threonine Phosphatases : Mechanism through 
Structure. Cell 139, 468–484. 
(14) Chen, M. J., Dixon, J. E., and Manning, G. (2017) Genomics and evolution of protein 
phosphatases. Sci. Signallig 54, 1–18. 
(15) Hsu, F., and Mao, Y. (2015) The structure of phosphoinositide phosphatases: 
Insights into substrate specificity and catalysis. Biochim. Biophys. Acta 1851, 698–710. 
(16) Liu, Y., and Bankaitis, V. A. (2010) Phosphoinositide Phosphatases in Cell Biology 
and Disease. Prog. Lipid Res. 49, 201–217. 
 
238 
(17) Oganesian, A., Poot, M., Daum, G., Coats, S. A., Wright, M. B., Seifert, R. A., and 
Bowen-Pope, D. F. (2003) Protein tyrosine phosphatase RQ is a phosphatidylinositol 
phosphatase that can regulate cell survival and proliferation. PNAS 100, 7563–7568. 
(18) Hoeger, B., Rios, P., Berteotti, A., Hoermann, B., Duan, G., and Köhn, M. (2017) 
Mutational Analysis of a Conserved Glutamate Reveals Unique Mechanistic and 
Structural Features of the Phosphatase PRL-3. ACS Omega 2, 9171–9180. 
(19) McParland, V., Varsano, G., Li, X., Thornton, J., Baby, J., Aravind, A., Meyer, C., Pavic, 
K., Rios, P., and Köhn, M. (2011) The metastasis-promoting phosphatase PRL-3 shows 
activity toward phosphoinositides. Biochemistry 50, 7579–7590. 
(20) Rios, P., Li, X., and Köhn, M. (2013) Molecular mechanisms of the PRL phosphatases. 
FEBS J. 280, 505–524. 
(21) Xie, L., Zhang, Y. L., and Zhang, Z. Y. (2002) Design and characterization of an 
improved protein tyrosine phosphatase substrate-trapping mutant. Biochemistry 41, 
4032–4039. 
(22) Foy, M., Anézo, O., Saule, S., and Planque, N. (2017) PRL-3/PTP4A3 phosphatase 
regulates integrin β1 in adhesion structures during migration of human ocular 
melanoma cells. 
(23) Sharlow, E. R., Wipf, P., Mcqueeney, K. E., Bakan, A., and Lazo, J. S. (2014) 
Investigational inhibitors of PTP4A3 phosphatase as antineoplastic agents. Expert Opin. 
Investig. Drugs 23, 1–13. 
(24) Zhang, Z.-Y. (1998) Protein-Tyrosine Phosphatases: Biological Function, Structural 
Characteristics, and Mechanism of Catalysis. Crit. Rev. Biochem. Mol. Biol. 33, 1–52. 
(25) Kozlov, G., Cheng, J., Ziomek, E., Banville, D., Gehring, K., and Ekiel, I. (2004) 
Structural Insights into Molecular Function of the Metastasis-associated Phosphatase 
PRL-3. J. Biol. Chem. 279, 11882–11889. 
(26) Xiao, J., Engel, J. L., Zhang, J., Chen, M. J., Manning, G., and Dixon, J. E. Structural and 
functional analysis of PTPMT1, a phosphatase required for cardiolipin synthesis. 
(27) Ríos, P., Nunes-Xavier, C. E., Tabernero, L., Köhn, M., and Pulido, R. (2014) Dual-
Specificity Phosphatases as Molecular Targets for Inhibition in Human Disease. Antioxid. 
Redox Signal. 20, 2251–2273. 
(28) Tautz, L., Critton, D. A., and Grotegut, S. (2013) Protein Tyrosine Phosphatases: 
Structure, Function, and Implication in Human Disease, pp 179–221. Humana Press, 
Totowa, NJ. 
(29) Bessette, D. C., Qiu, D., and Pallen, C. J. (2008) PRL PTPs: mediators and markers of 
cancer progression. Cancer Metastasis Rev 27, 231–252. 
(30) Thura, M., Qader Omer Al-Aidaroos, A., Peng Yong, W., Kono, K., Gupta, A., Bin Lin, 
 
239 
Y., Mimura, K., Paul Thiery, J., Cher Goh, B., Tan, P., Soo, R., William Hong, C., Wang, L., 
Joyce Lin, S., Chen, E., Young Rha, S., Cheol Chung, H., Li, J., Nandi, S., Fung Yuen, H., 
Zhang, S.-D., Khay Guan, Y., and Zeng, Q. (2016) PRL3-zumab, a first-in-class humanized 
antibody for cancer therapy. JCI Insight 1, 1–15. 
(31) Xing, X., Peng, L., Qu, L., Ren, T., Dong, B., Su, X., and Shou, C. (2009) Prognostic value 
of PRL-3 overexpression in early stages of colonic cancer. Histopathology 54, 309–318. 
(32) Wang, Z., Cai, S.-R., He, Y.-L., Zhan, W.-H., Zhang, C.-H., Wu, H., Peng, J.-J., Xu, J.-B., 
Zhang, X.-H., Wang, L., and Song, W. (2009) Elevated PRL-3 expression was more 
frequently detected in the large primary gastric cancer and exhibits a poor prognostic 
impact on the patients. J. Cancer Res. Clin. Oncol. 135, 1041–1046. 
(33) Wang, L., Peng, L., Dong, B., Kong, L., Meng, L., Yan, L., Xie, Y., and Shou, C. (2006) 
Overexpression of phosphatase of regenerating liver-3 in breast cancer: association with 
a poor clinical outcome. Ann. Oncol. 17, 1517–1522. 
(34) Polato, F., Codegoni, A., Fruscio, R., Perego, P., Mangioni, C., Saha, S., Bardelli, A., and 
Broggini, M. (2005) PRL-3 phosphatase is implicated in ovarian cancer growth. Clin. 
Cancer Res. 11, 6835–9. 
(35) Al-Aidaroos, A. Q. O., and Zeng, Q. (2010) PRL-3 phosphatase and cancer metastasis. 
J. Cell. Biochem. 111, 1087–1098. 
(36) Ming, J., Liu, N., Gu, Y., Qiu, X., and Wang, E.-H. (2009) PRL-3 facilitates angiogenesis 
and metastasis by increasing ERK phosphorylation and up-regulating the levels and 
activities of Rho-A/C in lung cancer. Pathology 41, 118–126. 
(37) Liu, Y., Zhou, J., Chen, J., Gao, W., Le, Y., Ding, Y., and Li, J. (2009) PRL-3 promotes 
epithelial mesenchymal transition by regulating cadherin directly. Cancer Biol. Ther. 8, 
1352–9. 
(38) Sun, Y., Carroll, S., Kaksonen, M., Toshima, J. Y., and Drubin, D. G. (2007) 
PtdIns(4,5)P2 turnover is required for multiple stages during clathrin- and actin-
dependent endocytic internalization. J. Cell Biol. 177, 355–367. 
(39) Rubio, T., and Köhn, M. Regulatory mechanisms of phosphatase of regenerating 
liver (PRL)-3. 
(40) Krndija, D., Münzberg, C., Maass, U., Hafner, M., Adler, G., Kestler, H. a, Seufferlein, T., 
Oswald, F., and von Wichert, G. (2012) The phosphatase of regenerating liver 3 (PRL-3) 
promotes cell migration through Arf-activity-dependent stimulation of integrin α5 
recycling. J. Cell Sci. 125, 3883–9382. 
(41) Forte, E., Orsatti, L., Talamo, F., Barbato, G., De Francesco, R., and Tomei, L. (2007) 
Ezrin is a specific and direct target of protein tyrosine phosphatase PRL-3. 
(42) Zheng, P., Liu, Y.-X., Chen, L., Liu, X.-H., Xiao, Z.-Q., Zhao, L., Li, G.-Q., Zhou, J., Ding, Y.-
 
240 
Q., and Li, J.-M. Stathmin, a New Target of PRL-3 Identified by Proteomic Methods, Plays 
a Key Role in Progression and Metastasis of Colorectal Cancer. 
(43) Mizuuchi, E., Semba, S., Kodama, Y., and Yokozaki, H. (2009) Down-modulation of 
keratin 8 phosphorylation levels by PRL-3 contributes to colorectal carcinoma 
progression. Int. J. Cancer 124, 1802–1810. 
(44) Fang, X.-Y., Song, R., Chen, W., Yang, Y.-Y., Gu, Y.-H., Shu, Y.-Q., Wu, X.-D., Wu, X.-F., 
Sun, Y., Shen, Y., and Xu, Q. (2015) PRL-3 Promotes the Malignant Progression of 
Melanoma via Triggering Dephosphorylation and Cytoplasmic Localization of NHERF1. J. 
Invest. Dermatol. 135154, 2273–2282. 
(45) Prl, V., Jeong, K., Kang, D., Lee, E., Shin, A., Jin, B., Park, Y., Lee, C., Kim, E., Jeon, Y. H., 
Kim, E. E., and Kim, Y. (2014) Structure and Backbone Dynamics of Vanadate-Bound 
PRL-3: Comparison of 15 N Nuclear Magnetic Resonance Relaxation Pro fi les of Free 
and Vanadate-Bound PRL ‑ 3. Biochemistry 53, 4814–4825. 
(46) Kim, K.-A., Song, J.-S., Jee, J., Sheen, M. R., Lee, C., Lee, T. G., Ro, S., Cho, J. M., Lee, W., 
Yamazaki, T., Jeon, Y. H., and Cheong, C. (2004) Structure of human PRL-3, the 
phosphatase associated with cancer metastasis. FEBS Lett. 565, 181–187. 
(47) Bunney, T. D., and Katan, M. (2010) Phosphoinositide signalling in cancer: beyond 
PI3K and PTEN. 
(48) He, R., Zeng, L.-F., He, Y., Zhang, S., and Zhang, Z.-Y. (2013) Small molecule tools for 
functional interrogation of protein tyrosine phosphatases. FEBS J. 280, 731–750. 
(49) Cole, P. A., Courtney, A. D., Shen, K., Zhang, Z., Qiao, Y., Lu, W., and Williams, D. M. 
(2003) Chemical Approaches to Reversible Protein Phosphorylation. Acc. Chem. Res. 36, 
444–452. 
(50) Vintonyak, V. V, Waldmann, H., and Rauh, D. (2011) Using small molecules to target 
protein phosphatases. Bioorg. Med. Chem. 19, 2145–2155. 
(51) Pathak, M. K., Dhawan, D., Lindner, D. J., Borden, E. C., Farver, C., Yi, T., and Center, T. 
C. (2002) Pentamidine Is an Inhibitor of PRL Phosphatases with Anticancer Activity. Mol. 
Cancer Ther. 1, 1255–1264. 
(52) Daouti, S., Li, W., Qian, H., Huang, K.-S., Holmgren, J., Levin, W., Reik, L., McGady, D. 
L., Gillespie, P., Perrotta, A., Bian, H., Reidhaar-Olson, J. F., Bliss, S. a, Olivier, A. R., Sergi, J. 
a, Fry, D., Danho, W., Ritland, S., Fotouhi, N., Heimbrook, D., and Niu, H. (2008) A 
selective phosphatase of regenerating liver phosphatase inhibitor suppresses tumor cell 
anchorage-independent growth by a novel mechanism involving p130Cas cleavage. 
Cancer Res. 68, 1162–1169. 
(53) Hoeger, B., Diether, M., Ballester, P. J., and Köhn, M. (2014) Biochemical evaluation 
of virtual screening methods reveals a cell-active inhibitor of the cancer-promoting 
 
241 
phosphatases of regenerating liver. Eur. J. Med. Chem. 88, 1–12. 
(54) Ballester, P. J. (2011) Ultrafast shape recognition : method and applications. Futur. 
Med. Chem. 3, 65–78. 
(55) Ballester, P. J., and Richards, W. G. (2006) Ultrafast Shape Recognition to Search 
Compound Databases for Similar Molecular Shapes. Wiley Intersci. 28, 1711–1723. 
(56) Zhang, H., Kozlov, G., Li, X., Wu, H., Gulerez, I., and Gehring, K. PRL3 phosphatase 
active site is required for binding the putative magnesium transporter CNNM3. 
(57) Ballester, P. J., Finn, P. W., and Richards, W. G. (2009) Ultrafast shape recognition: 
Evaluating a new ligand-based virtual screening technology. J. Mol. Graph. Model. 27, 
836–845. 
(58) Best, M. D., Zhang, H., and Prestwich, G. D. (2010) Inositol polyphosphates, 
diphosphoinositol polyphosphates and phosphatidylinositol polyphosphate lipids: 
structure, synthesis, and development of probes for studying biological activity. Nat. 
Prod. Rep. 27, 1403–1430. 
(59) Michell, R. H. (2008) Inositol derivatives: evolution and functions. Nat. Rev. Mol. Cell 
Biol. 9, 151–161. 
(60) Cho, W., and Stahelin, R. V. (2005) MEMBRANE-PROTEIN INTERACTIONS IN CELL 
SIGNALING AND MEMBRANE TRAFFICKING. Annu. Rev. Biophys. Biomol. Struct 34, 119–
51. 
(61) Sprong, H., van der Sluijs, P., and van Meer, G. (2001) How proteins move lipids and 
lipids move proteins. Nat. Rev. Mol. Cell Biol. 2, 504–513. 
(62) Toker, A. Phosphoinositides and signal transduction. 
(63) Corvera, S. (2001) Phosphatidylinositol 3‐Kinase and the Control of Endosome 
Dynamics: New Players Defined by Structural Motifs. Traffic 2, 859–866. 
(64) Czech, M. P. (2000) PIP2 and PIP3: Complex Roles Minireview at the Cell Surface 
movements of the PI3K rather than PIP3 itself. Now, effective reagents for localization of 
PIP2 and PIP3 within cells have become available with the discovery. Cell 100, 603–606. 
(65) Di Paolo, G., and De Camilli, P. Phosphoinositides in cell regulation and membrane 
dynamics. 
(66) Pendaries, C., Tronchère, H., Plantavid, M., and Payrastre, B. (2003) 
Phosphoinositide signaling disorders in human diseases. FEBS Lett. 546, 25–31. 
(67) Vicinanza, M., Dangelo, G., Campli, A. Di, and De Matteis, M. A. Phosphoinositides as 
regulators of membrane trafficking in health and disease. 
(68) Wymann, M. P., and Schneiter, R. (2008) Lipid signalling in disease. Nat. Rev. Mol. 
Cell Biol. 9, 162–176. 
(69) Lemmon, M. A. (2008) Membrane recognition by phospholipid-binding domains. 
 
242 
Nat. Rev. Mol. Cell Biol. 9, 99–111. 
(70) Wymann, M. P., Zvelebil, M., and Laffargue, M. Phosphoinositide 3-kinase signalling 
– which way to target? 
(71) Wymann, M. P., and Schneiter, R. (2008) Lipid signalling in disease. Nat Rev Mol Cell 
Biol.  9, 162–176. 
(72) Krauss, M., and Haucke, V. (2007) Phosphoinositide-metabolizing enzymes at the 
interface between membrane traffic and cell signalling. EMBO Rep. 8, 241–6. 
(73) Poccia, D., and Larijani, B. (2009) Phosphatidylinositol metabolism and membrane 
fusion. Biochem. J. 418, 233–46. 
(74) Sasaki, T., Takasuga, S., Sasaki, J., Kofuji, S., Eguchi, S., Yamazaki, M., and Suzuki, A. 
(2009) Mammalian phosphoinositide kinases and phosphatases. Prog. Lipid Res. 48, 
307–343. 
(75) Harris, S. J., Parry, R. V, Westwick, J., and Ward, S. G. (2008) Phosphoinositide lipid 
phosphatases: natural regulators of phosphoinositide 3-kinase signaling in T 
lymphocytes. J. Biol. Chem. 283, 2465–9. 
(76) HURLEY, J. (2006) Membrane binding domains. Biochim. Biophys. Acta - Mol. Cell 
Biol. Lipids 1761, 805–811. 
(77) Hurley, J. H., and Misra, S. (2000) Signaling and Subcellular Targeting by 
Membrane-Binding Domains. Annu. Rev. Biophys. Biomol. Struct. 29, 49–79. 
(78) Lemmon, M. A. (2003) Phosphoinositide recognition domains. Traffic 4, 201–13. 
(79) Lemmon, M. A. (2007) Pleckstrin homology (PH) domains and phosphoinositides. 
Biochem. Soc. Symp. 74, 81–93. 
(80) Lemmon, M. A., and Ferguson, K. M. (2000) Signal-dependent membrane targeting 
by pleckstrin homology (PH) domains. Biochem. J 350, 1–18. 
(81) Mclaughlin, S., Wang, J., Gambhir, A., and Murray, D. (2002) PIP 2 AND PROTEINS: 
Interactions, Organization, and Information Flow. Annu. Rev. Biophys. Biomol. Struct 31, 
151–75. 
(82) Hirose, K., Kadowaki, S., Tanabe, M., Takeshima, H., and Iino, M. (1999) 
Spatiotemporal dynamics of inositol 1,4,5-trisphosphate that underlies complex Ca2+ 
mobilization patterns. Science 284, 1527–30. 
(83) Kutateladze, T. G. (2006) Phosphatidylinositol 3-phosphate recognition and 
membrane docking by the FYVE domain. Biochim. Biophys. Acta 1761, 868–77. 
(84) Bravo, J., Karathanassis, D., Pacold, C. M., Pacold, M. E., Ellson, C. D., Anderson, K. E., 
Butler, P. J., Lavenir, I., Perisic, O., Hawkins, P. T., Stephens, L., and Williams, R. L. (2001) 
The crystal structure of the PX domain from p40(phox) bound to phosphatidylinositol 3-
phosphate. Mol. Cell 8, 829–39. 
 
243 
(85) Canals, D., Roddy, P., and Hannun, Y. A. (2012) Protein phosphatase 1 alpha 
mediates ceramide-induced ERM protein dephosphorylation. J. Biochem. 287, 10145–
10155. 
(86) Holmes, A. B., Margaret Brimble, P. A., Conway, S. J., Gardiner, J., A Grove, S. J., Johns, 
M. K., Lim, Z.-Y., Painter, G. F., J E Robinson, D. E., Schieber, C., Thuring, J. W., S-M Wong, 
L., Yin, M.-X., Burgess, A. W., Catimel, B., Hawkins, P. T., Ktistakis, N. T., and Stephens, L. 
R. (2010) Synthesis and biological evaluation of phosphatidylinositol phosphate affinity 
probes. Org. Biomol. Chem. 8, 1477–520. 
(87) Ozaki, S., Watanabe, Y., Ogasawara, T., Kondo, Y., Shiotani, N., Nishii, H., and 
Matsuki, T. (1986) Total synthesis of optically active myo-inositol 1,4,5-tris(phosphate). 
Tetrahedron Lett. 27, 3157–3160. 
(88) Potter, B. V. L. (1990) Recent Advances in the Chemistry and Biochemistry of 
lnositol Phosphates of Biological Interest. Nat. Prod. Rep. 7, 1. 
(89) Billington, D. C. (1989) Recent Developments in the Synthesis of myo-Inositol 
Phosphates. Chem. Soc. Rev. 18, 83–122. 
(90) Kiely, D. E., Abruscato, G. J., and Baburao, V. (1974) A synthesis of (±)myo-inositol 
1-phosphate. Carbohydr. Res. 34, 307–313. 
(91) Kubiak, R. J., and Bruzik, K. S. (2003) Comprehensive and Uniform Synthesis of All 
Naturally Occurring Phosphorylated Phosphatidylinositols involving inositol 
phospholipids ( PIPn ) and phosphates 6061, 960–968. 
(92) Watanabe, Y., Komoda, Y., Ebisuya, K., and Oxaki, S. (1990) An efficient 
phosphorylation method using a new phosphitylating agent, 2-diethylamino-1,3,2-
benzodioxaphosphepane. Tetrahedron Lett. 31, 255–256. 
(93) Yu, K.-L., and Fraser-Reid, B. (1988) A novel reagent for the synthesis of myo-
inositol phosphates: N,N-Diisopropyl dibenzyl phosphoramidite. Tetrahedron Lett. 29, 
979–982. 
(94) Watanabe, Y., Nakahira, H., Bunya, M., and Ozaki, S. (1987) An efficient method for 
phosphorylation of inositol derivatives. Tetrahedron Lett. 28, 4179–4180. 
(95) Cooke, A. M., Noble, N. J., Payne, S., Gigg, R., and Potters, B. V. L. (1989) Synthesis of 
myo-lnositol 1,4-Bisphosphate-5-phosphorothioate. J. Chem. Soc., Chem, Commun. 
120519, 269–271. 
(96) Dreef, C. E., Elie, C. J. J., Hoogerhout, P., van der Marel, G. A., and van Boom, J. H. 
(1988) Synthesis of 1-O-(1,2,-Di-O-Palmitoyl-SN-Glycero-3-phospho-D-myo-inosital 4,5-
bisphosphate: an analogue of naturally occuring (Ptd)Ins(4,5)P2. Tetrahedron Lett. 29, 
6513–6516. 
(97) Baudin, G., Glänzer, B. I., Swaminathan, K. S., and Vasella, A. (1988) A Synthesis of 1 
 
244 
D - and 1 L -myo-Inositol 1,3,4,5,-Tetraphosphate. Helv. Chim. Acta 71, 1367–1378. 
(98) Vacca, J. P., deSolms, S. J., R. Huff, J., Billington, D. C., Baker, R., Kulagowski, J. J., and 
Mawer, I. M. (1989) The total synthesis of myo-inositol polyphosphates. Tetrahedron 45, 
5679–5702. 
(99) Anderson, R. J., Osborne, S. L., Meunier, F. A., and Painter, G. F. (2010) 
Regioselective Approach to Phosphatidylinositol 3,5-Bisphosphates: Syntheses of the 
Native Phospholipid and Biotinylated Short-Chain Derivative. J. Org. Chem 75, 3541–
3551. 
(100) Xu, Y., Sculimbrene, B. R., and Miller, S. J. (2006) Streamlined Synthesis of 
Phosphatidylinositol (PI), PI3P, PI3,5P 2 , and Deoxygenated Analogues as Potential 
Biological Probes. J. Org. Chem. 71, 4919–1928. 
(101) Conway, S. J., and Miller, G. J. (2007) Biology-enabling inositol phosphates, 
phosphatidylinositol phosphates and derivatives. Nat. Prod. Rep. 24, 687. 
(102) Potter, B. V. L., and Lampe, D. (1995) Chemistry of Inositol Lipid Mediated Cellular 
Signaling. Angew. Chemie Int. Ed. English 34, 1933–1972. 
(103) Irvine, R. F., and Schell, M. J. (2001) Back in the water: the return of the inositol 
phosphates. Nat. Rev. Mol. Cell Biol. 2, 327–338. 
(104) Hatch, A. J., and York, J. D. (2010) SnapShot: Inositol Phosphates. Cell 143, 1030–
1030.e1. 
(105) Chakraborty, A., Kim, S., and Snyder, S. H. (2011) Inositol Pyrophosphates as 
Mammalian Cell Signals. Sci. Sig. 4, re1. 
(106) Gillaspy, G. E. (2011) The cellular language of myo-inositol signaling. New Phytol. 
192, 823–839. 
(107) Michell, R. H. (2011) Inositol and its derivatives: Their evolution and functions. 
Adv. Enzyme Regul. 51, 84–90. 
(108) Lee, J.-Y., Kim, Y., Park, J., and Kim, S. (2012) Inositol polyphosphate multikinase 
signaling in the regulation of metabolism. Ann. N. Y. Acad. Sci. 1271, 68–74. 
(109) Croze, M. L., and Soulage, C. O. (2013) Potential role and therapeutic interests of 
myo-inositol in metabolic diseases. Biochimie 95, 1811–1827. 
(110) Billington, D. C., Baker, R., Kulagowski, J. J., Mawer, I. M., Vacca, J. P., Jane, S., Huff, J. 
R., Sharp, M., and Point, W. (1989) The Total Synthesis of myo-lnositol Phosphates via 
myo-lnositol Orthoformate. J. Chem.Soc. Perkin. Trans. I 1423–1429. 
(111) Thomas, M. P., Mills, S. J., and Potter, B. V. L. (2016) The “Other” Inositols and 
Their Phosphates: Synthesis, Biology, and Medicine (with Recent Advances in myo-
Inositol Chemistry). Angew. Chem. Int. Ed. Engl. 55, 1614–50. 
(112) Billington, D. C., Baker, R., Kulagowski, J. J., Mawer, I. M., Vacca, J. P., DeSolms, S. J., 
 
245 
and Huff, J. R. (1989) The total synthesis of myo-inositol phosphates via myo-inositol 
orthoformate. J. Chem. Soc. Perkin Trans. 1 1, 1423–1429. 
(113) Pettitt, T. R., Dove, S. K., Lubben, A., Calaminus, S. D. J., and Wakelam, M. J. O. 
(2006) Analysis of intact phosphoinositides in biological samples. J. Lipid Res. 47, 1588–
1596. 
(114) Bruzik, K. S., and Tsai, M.-D. (1992) Efficient and Systematic Syntheses of 
Enantiomerically Pure and Regiospecifically Protected myo-Inositols. J. Am. Chem. Soc 
114, 6361–6374. 
(115) Zhang, H., Xu, Y., Markadieu, N., Beauwens, R., Erneux, C., and Prestwich, G. D. 
(2008) Synthesis and biological activity of phosphatidylinositol-3,4,5-
trisphosphorothioate. Bioorg. Med. Chem. Lett. 18, 762–766. 
(116) Miller, D. J., Bashir-Uddin Surfraz, M., Akhtar, M., Gani, D., and Allemann, R. K. 
(2004) Removal of the phosphate group in mechanism-based inhibitors of inositol 
monophosphatase leads to unusual inhibitory activity. Org. Biomol. Chem. 2, 671–688. 
(117) Dinkel, C., Moody, M., Traynor-Kaplan, A., and Schultz, C. (2001) Membrane-
Permeant 3-OH-Phosphorylated Phosphoinositide Derivatives. Angew. Chemie Int. Ed. 
40, 3004–3008. 
(118) Vajanaphanich, M., Schultz, C., Rudolf, M. T., Wasserman, M., Enyedi, P., Craxton, A., 
Shears, S. B., Tsien, R. Y., Barrett, K. E., and Traynor-Kaplan, A. (1994) Long-term 
uncoupling of chloride secretion from intracellular calcium levels by lns(3,4,5,6)P4. 
Nature 371, 711–714. 
(119) Schultz, C. (2010) Challenges in studying phospholipid signaling. Nat. Chem. Biol. 
www.nature.com/naturechemicalbiology 6. 
(120) Bru, M., Kotkar, S. P., Kar, N., and Kohn, M. (2012) Development of a solid phase 
synthesis strategy for soluble phosphoinositide analogues. Chem. Sci. 3, 1893–1902. 
(121) Poon, K. W. C., and Dudley, G. B. (2006) Mix-and-Heat Benzylation of Alcohols 
Using a Bench-Stable Pyridinium Salt. 
(122) Paterson, I., and Coster, M. J. (2002) Total synthesis of altohyrtin A (spongistatin 
1): An alternative synthesis of the CD-spiroacetal subunit. Tetrahedron Lett. 
(123) Dvorakova, M., Nencka, R., Dejmek, M., Zbornikova, E., Brezinova, A., Pribylova, M., 
Pohl, R., Migaud, M. E., and Vanek, T. (2013) Organic &amp; Biomolecular Chemistry 
Synthesis of alkylcarbonate analogs of O-acetyl-ADP-ribose. Org. Biomol. Chem 11. 
(124) Yu, K.-L., and Fraser-Reid, B. (1988) A novel reagent for the synthesis of myo-
inositol phosphates: N,N-Diisopropyl dibenzyl phosphoramidite. Tetrahedron Lett. 29, 
979–982. 
(125) Gregory, M., Meng-Xin, A., Yin, A., Mcconville, M. J., Williams, E., Bullock, A. N., 
 
246 
Conway, S. J., Burgess, A. W., Catimel, B., and Holmes, A. B. (2015) Synthesis of Highly 
Water-Soluble Adamantyl Phosphoinositide Derivatives. Aust. J. Chem. 68, 543–548. 
(126) Bru, M., Kotkar, S. P., Kar, N., and Köhn, M. (2012) Development of a solid phase 
synthesis strategy for soluble phosphoinositide analogues. Chem. Sci. 3, 1893–1902. 
(127) Roberts, S. J., Stewart, A. J., Sadler, P. J., and Farquharson, C. (2004) Human 
PHOSPHO1 exhibits high specific phosphoethanolamine and phosphocholine 
phosphatase activities. Biochem. J. 382, 59–65. 
(128) Sun, J.-P., Luo, Y., Yu, X., Wang, W.-Q., Zhou, B., Liang, F., and Zhang, Z.-Y. (2007) 
Phosphatase activity, trimerization, and the C-terminal polybasic region are all required 
for PRL1-mediated cell growth and migration. J. Biol. Chem. 282, 29043–51. 
(129) Atkins, W. M. (2005) Non-Michaelis-Menten kinetics in cytochrome P450-
catalyzed reactions. Annu. Rev. Pharmacol. Toxicol. 45, 291–310. 
(130) Kisseleva, M. V., Wilson, M. P., and Majerus, P. W. (2000) The isolation and 
characterization of a cDNA encoding phospholipid- specific inositol polyphosphate 5-
phosphatase. J. Biol. Chem. 275, 20110–20116. 
(131) Billcliff, P. G., Noakes, C. J., Mehta, Z. B., Yan, G., Mak, L., Woscholski, R., and Lowe, 
M. (2015) OCRL1 engages with the F-BAR protein pacsin 2 to promote biogenesis of 
membrane-trafficking intermediates. Mol. Biol. Cell 27, 90–107. 
(132) Chang-Ileto, B., Frere, S. G., Chan, R. B., Voronov, S. V, Lien Roux, A., and Di Paolo, G. 
(2011) Synaptojanin 1-Mediated PI(4,5)P 2 Hydrolysis Is Modulated by Membrane 
Curvature and Facilitates Membrane Fission. Dev. Cell 20, 206–218. 
(133) Guo, S., Stolz, L. E., Lemrow, S. M., and York, J. D. (1999) SAC1-like domains of 
yeast SAC1, INP52, and INP53 and of human synaptojanin encode polyphosphoinositide 
phosphatases. J. Biol. Chem. 274, 12990–5. 
(134) McPherson, P. S., Garcia, E. P., Slepnev, V. I., David, C., Zhang, X., Grabs, D., Sossini, 
W. S., Bauerfeind, R., Nemoto, Y., and De Camilli, P. (1996) A presynaptic inositol-5-
phosphatase. Nature 379, 353–357. 
(135) Aguilar, R. C., Madhivanan, K., and Ramadesika, S. (2016) Role of Ocrl1 and Inpp5E 
in primary cilia assembly and maintenance: a phosphatidylinositol phosphatase relay 
system? Res. Rep. Biol. 7, 15. 
(136) Mao, Y., Balkin, D. M., Zoncu, R., Erdmann, K. S., Tomasini, L., Hu, F., Jin, M. M., 
Hodsdon, M. E., and De Camilli, P. (2009) A PH domain within OCRL bridges clathrin-
mediated membrane trafficking to phosphoinositide metabolism. EMBO J. 28, 1831–42. 
(137) Lee, K., Kang, H. J., Xia, Y., and Chung, S. J. (2011) Recent Advances in Protein 
Tyrosine Phosphatase Detection Using Chemical Probes. Anticancer. Agents Med. Chem. 
11, 54–63. 
 
247 
(138) Jain, A. N. (2000) Morphological similarity: A 3D molecular similarity method 
correlated with protein-ligand recognition. J. Comput. Aided. Mol. Des. 14, 199–213. 
 
